{{#lst:Section editor transclusions|breast}}
<big>'''Note: these are biomarker-specific regimens, please see the [[breast cancer|main breast cancer page]] for other regimens.'''</big>
{| class="wikitable" style="float:right; margin-right: 5px;"
|-
|<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align="right"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Regimen |limit=10000|format=sum}} [[Tutorial#Regimens|regimens]] on this page</b></font></div>
<div style="background-color: #deebf6; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}"><font size="4"><b>{{#ask: [[-Has subobject::{{FULLPAGENAME}}]] |?Variant |limit=10000|format=sum}} [[Tutorial#Variants|variants]] on this page</b></font></div>
|}
{{TOC limit|limit=3}}
=Guidelines=
==[https://www.asco.org/ ASCO]==
*'''2016:''' Burstein et al. [http://ascopubs.org/doi/full/10.1200/JCO.2015.65.9573 Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: American Society of Clinical Oncology clinical practice guideline update on ovarian suppression] [https://www.ncbi.nlm.nih.gov/pubmed/26884856 PubMed]
*'''2016:''' Rugo et al. [http://ascopubs.org/doi/full/10.1200/JCO.2016.67.1487 Endocrine therapy for hormone receptor-positive metastatic breast cancer: American Society of Clinical Oncology guideline] [https://www.ncbi.nlm.nih.gov/pubmed/27217461 PubMed]
*'''2016:''' Harris et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4933134/ Use of biomarkers to guide decisions on adjuvant systemic therapy for women with early-stage invasive breast cancer: American Society of Clinical Oncology clinical practice guideline]
*'''2015:''' Van Poznak et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5478102/ Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology Clinical practice guideline]
*'''2014:''' Burstein et al. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876310/ Adjuvant endocrine therapy for women with hormone receptor–positive breast cancer: American Society of Clinical Oncology clinical practice guideline focused update]

==[https://www.nccn.org/ NCCN]==
*[https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf NCCN Guidelines - Breast Cancer]


=Neoadjuvant endocrine therapy=
==Anastrozole monotherapy {{#subobject:f8140f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 3-month course {{#subobject:fbebb0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2005.04.005 Smith et al. 2005 (IMPACT)]
| style="background-color:#1a9851" |Phase III (E)
|Anastrozole & Tamoxifen<br> Tamoxifen
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.21872 Cataliotti et al. 2006 (PROACT)]
| style="background-color:#1a9851" |Phase III (E)
|Tamoxifen
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Hormonotherapy====
*[[Anastrozole (Arimidex)]] 1 mg PO once per day

'''12-week course'''
====Subsequent treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]

===Variant #2, 4-month course {{#subobject:84024b|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 33%"|Study
!style="width: 33%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 33%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3107749/ Ellis et al. 2011 (ACOSOG Z1031)]
| style="background-color:#91cf61" |Screening Phase II
|cRR: 69% (95% CI, 60-77)
|-
|}
''Note: ACOSOG Z1031 was randomized but with the intent to select candidates for phase III trials; efficacy comparisons were not made.'' 
====Hormonotherapy====
*[[Anastrozole (Arimidex)]] 1 mg PO once per day

'''16- to 18-week course'''
====Subsequent treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
===References===
# '''IMPACT:''' Smith IE, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer JU, Ashley SE, Francis S, Boeddinghaus I, Walsh G; IMPACT Trialists Group. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 2005 Aug 1;23(22):5108-16. Epub 2005 Jul 5. [http://ascopubs.org/doi/full/10.1200/JCO.2005.04.005 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15998903 PubMed]
# '''PROACT:''' Cataliotti L, Buzdar AU, Noguchi S, Bines J, Takatsuka Y, Petrakova K, Dube P, de Oliveira CT. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: the Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) trial. Cancer. 2006 May 15;106(10):2095-103. [https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.21872 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16598749 PubMed]
# '''ACOSOG Z1031:''' Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, Parker JS, Luo J, DeSchryver K, Allred DC, Esserman LJ, Unzeitig GW, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Watson MA, Leitch M, Hunt K, Olson JA. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. J Clin Oncol. 2011 Jun 10;29(17):2342-9. Epub 2011 May 9. [http://ascopubs.org/doi/full/10.1200/JCO.2010.31.6950 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3107749/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21555689 PubMed]

==Anastrozole & Goserelin {{#subobject:6e3249|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:a131ba|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70373-4/fulltext Masuda et al. 2012 (STAGE)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Goserelin_.26_Tamoxifen|Goserelin & Tamoxifen]]
| style="background-color:#1a9850" |Superior RR
|-
|}
====Hormonotherapy====
*[[Anastrozole (Arimidex)]] 1 mg PO once per day
*[[Goserelin (Zoladex)]] 3.6 mg IM depot once per month

'''24-week course'''
====Subsequent treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]

===References===
# '''STAGE:''' Masuda N, Sagara Y, Kinoshita T, Iwata H, Nakamura S, Yanagita Y, Nishimura R, Iwase H, Kamigaki S, Takei H, Noguchi S. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. Lancet Oncol. 2012 Apr;13(4):345-52. Epub 2012 Jan 20. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70373-4/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22265697 PubMed]

==Goserelin & Tamoxifen {{#subobject:23ef1e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:833f0d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70373-4/fulltext Masuda et al. 2012 (STAGE)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Anastrozole_.26_Goserelin|Anastrozole & Goserelin]]
| style="background-color:#d73027" |Inferior RR
|-
|}
====Hormonotherapy====
*[[Goserelin (Zoladex)]] 3.6 mg IM depot once per month
*[[Tamoxifen (Nolvadex)]] 20 mg PO once per day

'''24-week course'''
====Subsequent treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
===References===
# '''STAGE:''' Masuda N, Sagara Y, Kinoshita T, Iwata H, Nakamura S, Yanagita Y, Nishimura R, Iwase H, Kamigaki S, Takei H, Noguchi S. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. Lancet Oncol. 2012 Apr;13(4):345-52. Epub 2012 Jan 20. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70373-4/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22265697 PubMed]

==Letrozole monotherapy {{#subobject:c68c77|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:c83e5c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2001.19.18.3808 Ellis et al. 2001]
| style="background-color:#1a9851" |Phase III (E)
|Tamoxifen
| style="background-color:#1a9850" |Superior ORR
|-
|[https://academic.oup.com/annonc/article/12/11/1527/160198 Eiermann et al. 2001 (P024)]
| style="background-color:#1a9851" |Phase III (E)
|Tamoxifen
| style="background-color:#1a9850" |Superior ORR
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3107749/ Ellis et al. 2011 (ACOSOG Z1031)]
| style="background-color:#91cf61" |Screening Phase II
| style="background-color:#d3d3d3" |
|cRR: 75% (95% CI, 66-82)
|-
|}
''Note: ACOSOG Z1031 gave a total treatment duration of 16 to 18 weeks, which is approximately 4 months. Also, this trial was randomized but with the intent to select candidates for phase III trials; efficacy comparisons were not made.'' 
====Hormonotherapy====
*[[Letrozole (Femara)]] 2.5 mg PO once per day

'''4-month course'''
====Subsequent treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
===References===
# Ellis MJ, Coop A, Singh B, Mauriac L, Llombert-Cussac A, Jänicke F, Miller WR, Evans DB, Dugan M, Brady C, Quebe-Fehling E, Borgs M. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol. 2001 Sep 15;19(18):3808-16. [http://ascopubs.org/doi/full/10.1200/JCO.2001.19.18.3808 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11559718 PubMed]
# '''P024:''' Eiermann W, Paepke S, Appfelstaedt J, Llombart-Cussac A, Eremin J, Vinholes J, Mauriac L, Ellis M, Lassus M, Chaudri-Ross HA, Dugan M, Borgs M; Letrozole Neo-Adjuvant Breast Cancer Study Group. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol. 2001 Nov;12(11):1527-32. [https://academic.oup.com/annonc/article/12/11/1527/160198 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11822750 PubMed]
# '''ACOSOG Z1031:''' Ellis MJ, Suman VJ, Hoog J, Lin L, Snider J, Prat A, Parker JS, Luo J, DeSchryver K, Allred DC, Esserman LJ, Unzeitig GW, Margenthaler J, Babiera GV, Marcom PK, Guenther JM, Watson MA, Leitch M, Hunt K, Olson JA. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. J Clin Oncol. 2011 Jun 10;29(17):2342-9. Epub 2011 May 9. [http://ascopubs.org/doi/full/10.1200/JCO.2010.31.6950 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3107749/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21555689 PubMed]

=Neoadjuvant response criteria=

==Clinical response rate (cRR)==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
''Although fairly dated, some trials such as [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3107749/ ACOSOG Z1031] make use of the WHO criteria for response to neoadjuvant therapy. Included here primarily for historical purposes.''
===References===
# Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207-14. [https://onlinelibrary.wiley.com/doi/10.1002/1097-0142(19810101)47:1%3C207::AID-CNCR2820470134%3E3.0.CO;2-6/abstract link to original article]  [https://www.ncbi.nlm.nih.gov/pubmed/7459811 PubMed]

==Miller-Payne scoring system==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
*Grade 1: No change or some changes to individual malignant cells, but no reduction in overall cellularity
*Grade 2: Minor loss of tumor cells (up to 30%), but overall cellularity still high 
*Grade 3: An estimated 30 to 90% reduction in the number of tumor cells
*Grade 4: Marked disappearance of tumor cells such that only small clusters or widely dispersed individual cells remain (loss of greater than 90% of tumor cells) 
*Grade 5: No invasive cancer cells identifiable in sections from the site of the tumor (carcinoma ''in situ'' may be present) 
===References===
# Ogston KN, Miller ID, Payne S, Hutcheon AW, Sarkar TK, Smith I, Schofield A, Heys SD. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast. 2003 Oct;12(5):320-7. [http://www.thebreastonline.com/article/S0960-9776(03)00106-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/14659147 PubMed]

==Residual cancer burden (RCB)==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
*The RCB is calculated as follows: RCB = 1.4 (''f<sub>inv</sub>*d<sub>prim</sub>'')<sup>0.17</sup> + [4(1 - 0.75<sup>''LN''</sup>)''d<sub>met</sub>'']<sup>0.17</sup>
**where ''d<sub>prim</sub>'' is derived from the bidimensional diameters of the primary tumor bed in the resected specimen, ''f<sub>inv</sub>'' is the proportion of the primary tumor bed that contains invasive carcinoma, ''LN'' is the number of axillary lymph nodes containing metastatic carcinoma, and ''d<sub>met</sub>'' is the diameter of the largest metastasis in an axillary lymph node.
**The cut-off points are 1.36 and 3.28.
===References===
# Symmans WF, Peintinger F, Hatzis C, Rajan R, Kuerer H, Valero V, Assad L, Poniecka A, Hennessy B, Green M, Buzdar AU, Singletary SE, Hortobagyi GN, Pusztai L. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol. 2007 Oct 1;25(28):4414-22. Epub 2007 Sep 4. [http://ascopubs.org/doi/full/10.1200/JCO.2007.10.6823 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17785706 PubMed]

==Residual disease in breast and nodes (RDBN)==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
*Level 1: pCR in breast and nodes with or without ''in situ'' carcinoma
*Levels 2 to 4: Residual disease, calculated as 0.2 (residual breast tumor size in cm) + index of involved nodes (0 for no positive nodes, 1 for 1 to 4 positive nodes, 2 for 5 to 7 positive nodes, and 3 for 8 positive nodes) + the Scarff–Bloom–Richardson grade (1, 2, or 3). The cut-off points are 3 and 4.3.
===References===
# Chollet P, Abrial C, Durando X, Thivat E, Tacca O, Mouret-Reynier MA, Leheurteur M, Kwiatkowski F, Dauplat J, Penault-Llorca F. A new prognostic classification after primary chemotherapy for breast cancer: residual disease in breast and nodes (RDBN). Cancer J. 2008 Mar-Apr;14(2):128-32. [https://insights.ovid.com/pubmed?pmid=18391619 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18391619 PubMed]

==Sataloff's classification==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
*Breast: 
**T-A: Total or nearly total therapeutic effect 
**T-B: Greater than 50% therapeutic effect
**T-C: Less than 50% therapeutic effect 
**T-D: No therapeutic effect
*Lymph node:
**N-A: Therapeutic effect but no metastasis
**N-B: No metastasis, no therapeutic effect
**N-C: Therapeutic effect but metastasis
**N-D: Metastasis, no therapeutic effect
===References===
# Sataloff DM, Mason BA, Prestipino AJ, Seinige UL, Lieber CP, Baloch Z. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J Am Coll Surg. 1995 Mar;180(3):297-306. [https://www.ncbi.nlm.nih.gov/pubmed/7874340 PubMed]

==Tumor response ratio==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
Calculated as follows: Residual breast disease observed upon pathologic examination divided by the size of the tumor on the pre-neoadjuvant therapy image.
*TRR = 0: pathologic complete response (pCR)
*TRR greater than 0 up to 0.4: strong partial response
*TRR greater than 0.4 up to 1.0: weak partial response (WPR)
*TRR greater than 1.0: tumor growth
===References===
# Miller M, Ottesen RA, Niland JC, Kruper L, Chen SL, Vito C. Tumor response ratio predicts overall survival in breast cancer patients treated with neoadjuvant chemotherapy. Ann Surg Oncol. 2014 Oct;21(10):3317-23. Epub 2014 Jul 25. [https://link.springer.com/article/10.1245%2Fs10434-014-3922-0 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25059788 PubMed]

==ypTNM staging==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
This system is proprietary to the AJCC. Please [https://cancerstaging.org/Pages/default.aspx visit their site] or consult the AJCC Manual for further details.

=Adjuvant endocrine therapy=
==Anastrozole monotherapy {{#subobject:a052f4|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 3-year course {{#subobject:41c2e3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)67059-6/fulltext Jakesz et al. 2005 (ARNO 95)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#ARNO_95|See link]]
| style="background-color:#91cf60" |[[Complex_multipart_regimens#ARNO_95|See link]]
|
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)67059-6/fulltext Jakesz et al. 2005 (ABCSG-8)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#ABCSG-8|See link]]
| style="background-color:#d9ef8b" |[[Complex_multipart_regimens#ABCSG-8|See link]]
|
|-
|[https://academic.oup.com/jnci/article/99/24/1845/2522241 Jakesz et al. 2007 (ABCSG-6a)]
| style="background-color:#1a9851" |Phase III (E)
|No further treatment
| style="background-color:#91cf60" |Seems to have superior RFS
|
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30600-9/fulltext Tjan-Heijnen et al. 2017 (DATA)]
| style="background-color:#1a9851" |Phase III (C)
|6 y of anastrozole
| style="background-color:#fee08b" |Might have inferior DFS
| style="background-color:#1a9851" |Less toxic
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30116-5/fulltext De Placido et al. 2018 (FATA-GIM3)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#FATA-GIM3|See link]]
|[[Complex_multipart_regimens#FATA-GIM3|See link]]
|
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*ABCSG-8, ARNO 95, FATA-GIM3: [[#Tamoxifen_monotherapy|Tamoxifen]] x 2 y
*ABCSG-6a: [[#Tamoxifen_monotherapy|Tamoxifen]] x 5 y versus Aminoglutethemide & Tamoxifen x 5 y
*DATA: [[#Tamoxifen_monotherapy|Tamoxifen]] x 2-3 y
====Hormonotherapy====
*[[Anastrozole (Arimidex)]] 1 mg PO once per day

'''3-year course, for a total of 5 to 8 years of hormonal therapy'''

===Variant #2, 5-year course {{#subobject:b05e8a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
| rowspan="2" |[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(02)09088-8/fulltext Baum et al. 2002 (ATAC)]
| rowspan="2" style="background-color:#1a9851" |Phase III (E)
|1. Anastrozole & Tamoxifen
| style="background-color:#d3d3d3" |Not reported
|-
|2. [[#Tamoxifen_monotherapy|Tamoxifen]]
| style="background-color:#91cf60" |Seems to have superior DFS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3612593/ Goss et al. 2013 (NCIC CTG MA.27)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Exemestane_monotherapy|Exemestane]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2016.69.2871 Smith et al. 2017 (FACE)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Letrozole_monotherapy_2|Letrozole]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30116-5/fulltext De Placido et al. 2018 (FATA-GIM3)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Tamoxifen_monotherapy|Tamoxifen]] x 2 y, then AI x 3 y
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Hormonotherapy====
*[[Anastrozole (Arimidex)]] 1 mg PO once per day

'''5-year course of therapy'''

===Variant #3, 6-year course {{#subobject:ea2190|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30600-9/fulltext Tjan-Heijnen et al. 2017 (DATA)]
| style="background-color:#1a9851" |Phase III (E)
|3 y of anastrozole
| style="background-color:#d9ef8b" |Might have superior DFS
| style="background-color:#ffffbe" |More toxic
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[#Tamoxifen_monotherapy|Tamoxifen]] x 2-3 y
====Hormonotherapy====
*[[Anastrozole (Arimidex)]] 1 mg PO once per day

'''6-year course of therapy'''

===References===
# '''ATAC:''' Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T; ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002 Jun 22;359(9324):2131-9. Erratum in: Lancet 2002 Nov 9;360(9344):1520. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(02)09088-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12090977 PubMed]
## '''Update:''' Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS; ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005 Jan 1-7;365(9453):60-2. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2804%2917666-6/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15639680 PubMed]
## '''Update:''' Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M; Arimidex Tamoxifen Alone or in Combination (ATAC) Trialists' Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008 Jan;9(1):45-53. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2807%2970385-6/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18083636 PubMed]
## '''Update:''' Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF; ATAC/LATTE investigators. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010 Dec;11(12):1135-41. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70257-6/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21087898 PubMed]
# '''ABCSG-8; ARNO 95:''' Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H, Seifert M, Gademann G, Kaufmann M, Wolfgang J; ABCSG and the GABG. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 2005 Aug 6-12;366(9484):455-62. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)67059-6/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16084253 PubMed]
<!-- Presented in part in abstract format at the 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, June 2-6, 2006. -->
## '''Update:''' Kaufmann M, Jonat W, Hilfrich J, Eidtmann H, Gademann G, Zuna I, von Minckwitz G. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. J Clin Oncol. 2007 Jul 1;25(19):2664-70. Epub 2007 Jun 11. [http://jco.ascopubs.org/content/25/19/2664.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17563395 PubMed]
<!-- Presented in poster format at the 46th Annual Meeting of the American Society of Clinical Oncology, June 4-8, 2010, Chicago, IL. -->
## '''Update:''' Dubsky PC, Jakesz R, Mlineritsch B, Pöstlberger S, Samonigg H, Kwasny W, Tausch C, Stöger H, Haider K, Fitzal F, Singer CF, Stierer M, Sevelda P, Luschin-Ebengreuth G, Taucher S, Rudas M, Bartsch R, Steger GG, Greil R, Filipcic L, Gnant M. Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol. 2012 Mar 1;30(7):722-8. Epub 2012 Jan 23. [http://ascopubs.org/doi/full/10.1200/JCO.2011.36.8993 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22271481 PubMed]
# '''ABCSG-6a:''' Jakesz R, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, Mlineritsch B, Tausch C, Stierer M, Hofbauer F, Renner K, Dadak C, Rücklinger E, Samonigg H; Austrian Breast and Colorectal Cancer Study Group. Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst. 2007 Dec 19;99(24):1845-53. Epub 2007 Dec 11. Erratum in: J Natl Cancer Inst. 2008 Feb 6;100(3):226. [https://academic.oup.com/jnci/article/99/24/1845/2522241 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18073378 PubMed]
<!-- Presented at the 33rd Annual San Antonio Breast Cancer Symposium, December 8-12, 2010, San Antonio, TX. -->
# '''NCIC CTG MA.27:''' Goss PE, Ingle JN, Pritchard KI, Ellis MJ, Sledge GW, Budd GT, Rabaglio M, Ansari RH, Johnson DB, Tozer R, D'Souza DP, Chalchal H, Spadafora S, Stearns V, Perez EA, Liedke PE, Lang I, Elliott C, Gelmon KA, Chapman JA, Shepherd LE. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial. J Clin Oncol. 2013 Apr 10;31(11):1398-404. Epub 2013 Jan 28. [http://jco.ascopubs.org/content/31/11/1398.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3612593/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23358971 PubMed]
# '''FACE:''' Smith I, Yardley D, Burris H, De Boer R, Amadori D, McIntyre K, Ejlertsen B, Gnant M, Jonat W, Pritchard KI, Dowsett M, Hart L, Poggio S, Comarella L, Salomon H, Wamil B, O'Shaughnessy J. Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial. J Clin Oncol. 2017 Apr 1;35(10):1041-1048. Epub 2017 Jan 23. [http://ascopubs.org/doi/full/10.1200/JCO.2016.69.2871 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28113032 PubMed]
# '''DATA:''' Tjan-Heijnen VCG, van Hellemond IEG, Peer PGM, Swinkels ACP, Smorenburg CH, van der Sangen MJC, Kroep JR, De Graaf H, Honkoop AH, Erdkamp FLG, van den Berkmortel FWPJ, de Boer M, de Roos WK, Linn SC, Imholz ALT, Seynaeve CM; Dutch Breast Cancer Research Group (BOOG) for the DATA Investigators. Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial. Lancet Oncol. 2017 Nov;18(11):1502-1511. Epub 2017 Oct 12. Erratum in: Lancet Oncol. 2017 Nov;18(11):e642. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30600-9/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29031778 PubMed]
# '''FATA-GIM3:''' De Placido S, Gallo C, De Laurentiis M, Bisagni G, Arpino G, Sarobba MG, Riccardi F, Russo A, Del Mastro L, Cogoni AA, Cognetti F, Gori S, Foglietta J, Frassoldati A, Amoroso D, Laudadio L, Moscetti L, Montemurro F, Verusio C, Bernardo A, Lorusso V, Gravina A, Moretti G, Lauria R, Lai A, Mocerino C, Rizzo S, Nuzzo F, Carlini P, Perrone F; GIM Investigators. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. Lancet Oncol. 2018 Apr;19(4):474-485. Epub 2018 Feb 23. Erratum in: Lancet Oncol. 2018 Apr;19(4):e184. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30116-5/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29482983 PubMed]

==Exemestane monotherapy {{#subobject:62ede3|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 2- to 3-year course {{#subobject:12d72f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa040331 Coombes et al. 2004 (IES)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#Intergroup_Exemestane_Study|See link]]
| style="background-color:#91cf60" |[[Complex_multipart_regimens#Intergroup_Exemestane_Study|See link]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)62312-4/fulltext van de Velde et al. 2011 (TEAM)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#TEAM|See link]]
| style="background-color:#ffffbf" |[[Complex_multipart_regimens#TEAM|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment. The '''IES''' gave a range of 2 to 3 years of therapy. '''TEAM''' gave a range of 2 to 2.5 years of therapy.''
====Preceding treatment====
*[[#Tamoxifen_monotherapy|Tamoxifen]] x 2-3y
====Hormonotherapy====
*[[Exemestane (Aromasin)]] 25 mg PO once per day

'''2 to 3 years, for a total of 5 years of hormonal therapy'''

===Variant #2, 3-year course {{#subobject:4569f0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30116-5/fulltext De Placido et al. 2018 (FATA-GIM3)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#FATA-GIM3|See link]]
|[[Complex_multipart_regimens#FATA-GIM3|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[#Tamoxifen_monotherapy|Tamoxifen]] x 2 y
====Hormonotherapy====
*[[Exemestane (Aromasin)]] 25 mg PO once per day

'''3-year course, for a total of 5 years of hormonal therapy'''

===Variant #3, 5-year course {{#subobject:31f118|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/26/12/1965.long Mamounas et al. 2008 (NSABP B-33)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Placebo|Placebo]]
| style="background-color:#1a9850" |Superior RFS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3612593/ Goss et al. 2013 (NCIC CTG MA.27)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Anastrozole_monotherapy_2|Anastrozole]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30116-5/fulltext De Placido et al. 2018 (FATA-GIM3)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Tamoxifen_monotherapy|Tamoxifen]] x 2 y, then AI x 3 y
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Preceding treatment====
*NSABP B-33: [[#Tamoxifen_monotherapy|Tamoxifen]] x 5 y

====Hormonotherapy====
*[[Exemestane (Aromasin)]] 25 mg PO once per day

'''5-year course of therapy'''

===Variant #4, 5 years, with OFS {{#subobject:818d9f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
| rowspan="2" |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4175521/ Pagani et al. 2014 (TEXT)]
| rowspan="2" style="background-color:#1a9851" |Phase III (E)
|1. [[#Tamoxifen_monotherapy|Tamoxifen]]
| style="background-color:#1a9850" |Superior DFS
|-
|2. [[#Tamoxifen_monotherapy|Tamoxifen & OFS]]
| style="background-color:#1a9850" |Superior DFS
|-
| rowspan="2" |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4175521/ Pagani et al. 2014 (SOFT)]
| rowspan="2" style="background-color:#1a9851" |Phase III (E)
|1. [[#Tamoxifen_monotherapy|Tamoxifen]]
| style="background-color:#1a9850" |Superior DFS
|-
|2. [[#Tamoxifen_monotherapy|Tamoxifen & OFS]]
| style="background-color:#1a9850" |Superior DFS
|-
|}
OFS: '''<u>O</u>'''varian '''<u>F</u>'''unction '''<u>S</u>'''uppression
''These regimens are intended for premenopausal patients. '''Pagani et al. 2014''' report on two trials, but only '''SOFT''' had the tamoxifen only arm.''
====Hormonotherapy====
*[[Exemestane (Aromasin)]] 25 mg PO once per day
*Ovarian function suppression as follows:
**'''TEXT''': [[Triptorelin (Trelstar LA)]] 3.75 mg IM every 28 days
***"[[Endocrine_ablation_surgery#Bilateral_oophorectomy|Bilateral oophorectomy]] or [[External beam radiotherapy|ovarian irradiation]] was allowed after at least 6 months of triptorelin."
**'''SOFT''': Choice of mechanism left to investigators

'''5-year course of therapy'''
===References===
# '''IES:''' Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM, van de Velde C; Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004 Mar 11;350(11):1081-92. [https://www.nejm.org/doi/full/10.1056/NEJMoa040331 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15014181 PubMed]
## '''Update:''' Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, Subar M, Ireland E, Bliss JM; Intergroup Exemestane Study. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007 Feb 17;369(9561):559-70. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2807%2960200-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17307102 PubMed]
## '''Update:''' Bliss JM, Kilburn LS, Coleman RE, Forbes JF, Coates AS, Jones SE, Jassem J, Delozier T, Andersen J, Paridaens R, van de Velde CJ, Lønning PE, Morden J, Reise J, Cisar L, Menschik T, Coombes RC. Disease-related outcomes with long-term follow-up: an updated analysis of the Intergroup Exemestane Study. J Clin Oncol. 2012 Mar 1;30(7):709-17. Epub 2011 Oct 31. [http://ascopubs.org/doi/full/10.1200/JCO.2010.33.7899 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22042946 PubMed] 
<!-- Presented in part in abstract format in the Breast Cancer Research Treatment 100:S22, 2006 (suppl; abstr A40). -->
# '''NSABP B-33:''' Mamounas EP, Jeong JH, Wickerham DL, Smith RE, Ganz PA, Land SR, Eisen A, Fehrenbacher L, Farrar WB, Atkins JN, Pajon ER, Vogel VG, Kroener JF, Hutchins LF, Robidoux A, Hoehn JL, Ingle JN, Geyer CE Jr, Costantino JP, Wolmark N. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. J Clin Oncol. 2008 Apr 20;26(12):1965-71. Epub 2008 Mar 10. [http://jco.ascopubs.org/content/26/12/1965.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18332472 PubMed]
# '''TEAM:''' van de Velde CJ, Rea D, Seynaeve C, Putter H, Hasenburg A, Vannetzel JM, Paridaens R, Markopoulos C, Hozumi Y, Hille ET, Kieback DG, Asmar L, Smeets J, Nortier JW, Hadji P, Bartlett JM, Jones SE. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet. 2011 Jan 22;377(9762):321-31. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)62312-4/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21247627 PubMed]
## '''Update:''' Derks MGM, Blok EJ, Seynaeve C, Nortier JWR, Kranenbarg EM, Liefers GJ, Putter H, Kroep JR, Rea D, Hasenburg A, Markopoulos C, Paridaens R, Smeets JBE, Dirix LY, van de Velde CJH. Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Sep;18(9):1211-1220. Epub 2017 Jul 18. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30419-9/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28732650 PubMed]
<!-- Presented at the 33rd Annual San Antonio Breast Cancer Symposium, December 8-12, 2010, San Antonio, TX. -->
# '''NCIC CTG MA.27:''' Goss PE, Ingle JN, Pritchard KI, Ellis MJ, Sledge GW, Budd GT, Rabaglio M, Ansari RH, Johnson DB, Tozer R, D'Souza DP, Chalchal H, Spadafora S, Stearns V, Perez EA, Liedke PE, Lang I, Elliott C, Gelmon KA, Chapman JA, Shepherd LE. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial. J Clin Oncol. 2013 Apr 10;31(11):1398-404. Epub 2013 Jan 28. [http://jco.ascopubs.org/content/31/11/1398.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3612593/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23358971 PubMed]
# '''TEXT/SOFT:''' Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA; TEXT and SOFT Investigators; International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014 Jul 10;371(2):107-18. Epub 2014 Jun 1. [https://www.nejm.org/doi/full/10.1056/NEJMoa1404037 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4175521/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24881463 PubMed]
# '''FATA-GIM3:''' De Placido S, Gallo C, De Laurentiis M, Bisagni G, Arpino G, Sarobba MG, Riccardi F, Russo A, Del Mastro L, Cogoni AA, Cognetti F, Gori S, Foglietta J, Frassoldati A, Amoroso D, Laudadio L, Moscetti L, Montemurro F, Verusio C, Bernardo A, Lorusso V, Gravina A, Moretti G, Lauria R, Lai A, Mocerino C, Rizzo S, Nuzzo F, Carlini P, Perrone F; GIM Investigators. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. Lancet Oncol. 2018 Apr;19(4):474-485. Epub 2018 Feb 23. Erratum in: Lancet Oncol. 2018 Apr;19(4):e184. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30116-5/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29482983 PubMed]

==Goserelin monotherapy {{#subobject:42a67a|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:eefa6c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2002.05.042 Jonat et al. 2002 (ZEBRA)]
| style="background-color:#1a9851" |Phase III (E)
|[[Breast_cancer#CMF|CMF]]
| style="background-color:#eeee01" |Equivalent DFS
|-
|}
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Hormonotherapy====
*[[Goserelin (Zoladex)]] 3.6 mg IM depot once on day 1

'''28-day cycles for 2 years'''
===References===
# '''ZEBRA:''' Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes JC, de Matteis A, Stewart A, Eiermann W, Szakolczai I, Palmer M, Schumacher M, Geberth M, Lisboa B; Zoladex Early Breast Cancer Research Association Study. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association study. J Clin Oncol. 2002 Dec 15;20(24):4628-35. [http://ascopubs.org/doi/full/10.1200/JCO.2002.05.042 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12488406 PubMed]

==Goserelin & Tamoxifen {{#subobject:23ef1e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:833f0d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2002.09.112 Jakesz et al. 2002 (ABCSG 5)]
| style="background-color:#1a9851" |Phase III (E)
|[[Breast_cancer#CMF|CMF]]
| style="background-color:#91cf60" |Seems to have superior RFS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2005.05.551 Davidson et al. 2005 (ECOG E5188)]
| style="background-color:#1a9851" |Phase III (E)
|Goserelin x 5 y
| style="background-color:#1a9850" |Superior DFS
|-
|}
====Preceding treatment====
*ABCSG 5: [[Surgery#Breast_cancer_surgery|Surgery]]
*ECOG E5188: [[Surgery#Breast_cancer_surgery|Surgery]], then [[Breast_cancer#FAC_2|CAF]] x 6
====Hormonotherapy====
*[[Goserelin (Zoladex)]] 3.6 mg IM depot once per month
**Note: ABCSG 5 stopped goserelin after 3 years
*[[Tamoxifen (Nolvadex)]] 20 mg PO once per day

'''5-year course (see note)'''
===References===
# '''ABCSG 5:''' Jakesz R, Hausmaninger H, Kubista E, Gnant M, Menzel C, Bauernhofer T, Seifert M, Haider K, Mlineritsch B, Steindorfer P, Kwasny W, Fridrik M, Steger G, Wette V, Samonigg H; Austrian Breast and Colorectal Cancer Study Group Trial 5. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer--Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol. 2002 Dec 15;20(24):4621-7. [http://ascopubs.org/doi/full/10.1200/JCO.2002.09.112 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12488405 PubMed]
# '''ECOG E5188:''' Davidson NE, O'Neill AM, Vukov AM, Osborne CK, Martino S, White DR, Abeloff MD. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol. 2005 Sep 1;23(25):5973-82. Epub 2005 Aug 8. [http://ascopubs.org/doi/full/10.1200/JCO.2005.05.551 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16087950 PubMed]

==Letrozole monotherapy {{#subobject:55e6f9|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 2 years of therapy {{#subobject:3d1f97|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa052258 Thürlimann et al. 2005 (BIG 1-98)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#BIG_1-98|See link]]
|[[Complex_multipart_regimens#BIG_1-98|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Hormonotherapy====
*[[Letrozole (Femara)]] 2.5 mg PO once per day

'''2-year course'''
====Subsequent treatment====
*[[#Tamoxifen_monotherapy|Tamoxifen]]

===Variant #2, 2.5 additional years of therapy {{#subobject:34f509|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://academic.oup.com/jnci/article-abstract/110/1/djx134/4093022/Optimal-Duration-of-Extended-Adjuvant-Endocrine Blok et al. 2017 (IDEAL)]
| style="background-color:#1a9851" |Phase III (E)
|Letrozole x 10 y
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment. Continuation of treatment was started within 2 years of the completion of the first 5 years of treatment.''
====Preceding treatment====
*Any endocrine therapy for 5 years
====Hormonotherapy====
*[[Letrozole (Femara)]] 2.5 mg PO once per day

'''2.5-year course, for a total of 7.5 years of hormonal therapy'''

===Variant #3, 3 additional years of therapy {{#subobject:3c3390|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa052258 Thürlimann et al. 2005 (BIG 1-98)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#BIG_1-98|See link]]
|[[Complex_multipart_regimens#BIG_1-98|See link]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30116-5/fulltext De Placido et al. 2018 (FATA-GIM3)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#FATA-GIM3|See link]]
|[[Complex_multipart_regimens#FATA-GIM3|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment.''
====Preceding treatment====
*[[#Tamoxifen_monotherapy|Tamoxifen]] x 2 y
====Hormonotherapy====
*[[Letrozole (Femara)]] 2.5 mg PO once per day

'''3-year course, for a total of 5 years of hormonal therapy'''

===Variant #4, 5 years of therapy {{#subobject:adcf9a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
| rowspan="3" |[https://www.nejm.org/doi/full/10.1056/NEJMoa052258 Thürlimann et al. 2005 (BIG 1-98)]
| rowspan="3" style="background-color:#1a9851" |Phase III (E)
|1. [[#Letrozole_monotherapy_2|Letrozole]], then [[#Tamoxifen_monotherapy|Tamoxifen]]
| style="background-color:#ffffbf" |Seems not superior (*)
|
|-
|2. [[#Tamoxifen_monotherapy|Tamoxifen]]
| style="background-color:#d9ef8b" |Might have superior OS (*)
|
|-
|3. [[#Tamoxifen_monotherapy|Tamoxifen]], then [[#Letrozole_monotherapy_2|Letrozole]]
| style="background-color:#ffffbf" |Seems not superior (*)
|
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024713/ Goss et al. 2016 (NCIC CTG MA.17R)]
| style="background-color:#1a9851" |Phase III (C)
|Letrozole x 10 y
| style="background-color:#d73027" |Inferior DFS
|style="background-color:#eeee01"|No clinical difference in QoL
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2016.69.2871 Smith et al. 2017 (FACE)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Anastrozole_monotherapy_2|Anastrozole]]
| style="background-color:#ffffbf" |Seems not superior
|
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30116-5/fulltext De Placido et al. 2018 (FATA-GIM3)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Tamoxifen_monotherapy|Tamoxifen]] x 2 y, then AI x 3 y
| style="background-color:#ffffbf" |Seems not superior
|
|-
|}
''Efficacy reported for BIG 1-98 is based on the 2011 and 2018 updates.''
====Hormonotherapy====
*[[Letrozole (Femara)]] 2.5 mg PO once per day

'''5-year course of therapy'''

===Variant #5, 5 additional years of therapy {{#subobject:b467cc|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa032312 Goss et al. 2003 (NCIC CTG MA.17)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Placebo|Placebo]]
| style="background-color:#1a9850" |Superior DFS
|style="background-color:#eeee01"|No clinical difference in QoL
|-
|[https://academic.oup.com/annonc/article/27/5/806/2769820 Zdenkowski et al. 2016 (ANZ0501 LATER)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Observation|Observation]]
| style="background-color:#d9ef8b" |Might have superior DFS
|
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024713/ Goss et al. 2016 (NCIC CTG MA.17R)]
| style="background-color:#1a9851" |Phase III (E)
|Letrozole x 5 y
| style="background-color:#1a9850" |Superior DFS
|style="background-color:#eeee01"|No clinical difference in QoL
|-
|[https://academic.oup.com/jnci/article-abstract/110/1/djx134/4093022/Optimal-Duration-of-Extended-Adjuvant-Endocrine Blok et al. 2017 (IDEAL)]
| style="background-color:#1a9851" |Phase III (E)
|Letrozole x 7.5 y
| style="background-color:#ffffbf" |Seems not superior
|
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30715-5/fulltext Colleoni et al. 2017 (SOLE)]
| style="background-color:#1a9851" |Phase III (C)
|Intermittent Letrozole
| style="background-color:#ffffbf" |Seems not superior
|
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30621-1/fulltext Mamounas et al. 2018 (NSABP B-42)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Placebo|Placebo]]
| style="background-color:#d9ef8b" |Might have superior DFS
|
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment. Continuation of treatment was started within 2 years of the completion of the first 5 years of treatment.''
====Preceding treatment====
*NCIC CTG MA.17: Most patients received 5 years of [[#Tamoxifen_monotherapy|tamoxifen]] therapy prior to starting letrozole
*ANZ0501 LATER: At least 4 years of any endocrine therapy
*NCIC CTG MA.17R: Letrozole for 5 years
*IDEAL: Any endocrine therapy for 5 years
====Hormonotherapy====
*[[Letrozole (Femara)]] 2.5 mg PO once per day

'''5 additional years for a total 10-year course of hormonal therapy'''

===References===
# '''NCIC CTG MA.17:''' Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003 Nov 6;349(19):1793-802. Epub 2003 Oct 9. [https://www.nejm.org/doi/full/10.1056/NEJMoa032312 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/14551341 PubMed]
## '''Update:''' Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005 Sep 7;97(17):1262-71. [http://jnci.oxfordjournals.org/content/97/17/1262.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16145047 PubMed]
## '''QoL analysis:''' Whelan TJ, Goss PE, Ingle JN, Pater JL, Tu D, Pritchard K, Liu S, Shepherd LE, Palmer M, Robert NJ, Martino S, Muss HB. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol. 2005 Oct 1;23(28):6931-40. Epub 2005 Sep 12. [http://ascopubs.org/doi/full/10.1200/JCO.2005.11.181 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16157934 PubMed]
## '''Update:''' Muss HB, Tu D, Ingle JN, Martino S, Robert NJ, Pater JL, Whelan TJ, Palmer MJ, Piccart MJ, Shepherd LE, Pritchard KI, He Z, Goss PE. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. J Clin Oncol. 2008 Apr 20;26(12):1956-64. Epub 2008 Mar 10. [http://jco.ascopubs.org/content/26/12/1956.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18332474 PubMed]
## '''Subgroup analysis:''' Goss PE, Ingle JN, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Tu D. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol. 2008 Apr 20;26(12):1948-55. Epub 2008 Mar 10. [http://jco.ascopubs.org/content/26/12/1948.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18332475 PubMed]
## '''Update:''' Jin H, Tu D, Zhao N, Shepherd LE, Goss PE. Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover. J Clin Oncol. 2012 Mar 1;30(7):718-21. Epub 2011 Oct 31. [http://jco.ascopubs.org/content/30/7/718.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3295549/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22042967 PubMed]
# '''BIG 1-98:''' Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A; Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005 Dec 29;353(26):2747-57. Erratum in: N Engl J Med. 2006 May 18;354(20):2200. Wardly, Andrew [corrected to Wardley, Andrew ]. [https://www.nejm.org/doi/full/10.1056/NEJMoa052258 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16382061 PubMed]
## '''Update:''' Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007 Feb 10;25(5):486-92. Epub 2007 Jan 2. [http://jco.ascopubs.org/content/25/5/486.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17200148 PubMed]
## '''Subgroup analysis:''' Rasmussen BB, Regan MM, Lykkesfeldt AE, Dell'Orto P, Del Curto B, Henriksen KL, Mastropasqua MG, Price KN, Méry E, Lacroix-Triki M, Braye S, Altermatt HJ, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Gusterson BA, Thürlimann B, Coates AS, Viale G; BIG 1-98 Collaborative and International Breast Cancer Study Groups. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol. 2008 Jan;9(1):23-8. Epub 2007 Dec 20. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2807%2970386-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18083065 PubMed]
## '''Subgroup analysis:''' Crivellari D, Sun Z, Coates AS, Price KN, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens RJ, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Gladieff L, Rabaglio M, Smith IE, Chirgwin JH, Goldhirsch A. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. J Clin Oncol. 2008 Apr 20;26(12):1972-9. Epub 2008 Mar 10. [http://jco.ascopubs.org/content/26/12/1972.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18332471 PubMed]
## '''Update:''' Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thürlimann B, Paridaens R, Smith I, Mauriac L, Forbes J, Price KN, Regan MM, Gelber RD, Coates AS; BIG 1-98 Collaborative Group. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 2009 Aug 20;361(8):766-76. [https://www.nejm.org/doi/10.1056/NEJMoa0810818 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2921823/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/19692688 PubMed]
## '''Update:''' Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, Smith I, Láng I, Wardley A, Rabaglio M, Price KN, Gelber RD, Coates AS, Thürlimann B; BIG 1-98 Collaborative Group; International Breast Cancer Study Group (IBCSG). Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncol. 2011 Nov;12(12):1101-8. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70270-4/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3235950/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22018631 PubMed]
## '''Update:''' Ruhstaller T, Giobbie-Hurder A, Colleoni M, Jensen MB, Ejlertsen B, de Azambuja E, Neven P, Láng I, Jakobsen EH, Gladieff L, Bonnefoi H, Harvey VJ, Spazzapan S, Tondini C, Del Mastro L, Veyret C, Simoncini E, Gianni L, Rochlitz C, Kralidis E, Zaman K, Jassem J, Piccart-Gebhart M, Di Leo A, Gelber RD, Coates AS, Goldhirsch A, Thürlimann B, Regan MM; members of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group. Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. J Clin Oncol. 2018 Nov 26:JCO1800440. [Epub ahead of print] [http://ascopubs.org/doi/full/10.1200/JCO.18.00440 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/30475668 PubMed]
# '''ANZ0501 LATER:''' Zdenkowski N, Forbes JF, Boyle FM, Kannourakis G, Gill PG, Bayliss E, Saunders C, Della-Fiorentina S, Kling N, Campbell I, Mann GB, Coates AS, Gebski V, Davies L, Thornton R, Reaby L, Cuzick J, Green M; Australia and New Zealand Breast Cancer Trials Group. Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial. Ann Oncol. 2016 May;27(5):806-12. Epub 2016 Feb 9. [https://academic.oup.com/annonc/article/27/5/806/2769820 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26861603 PubMed]
# '''NCIC CTG MA.17R:''' Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, Gelmon K, Whelan T, Strasser-Weippl K, Rubin S, Sturtz K, Wolff AC, Winer E, Hudis C, Stopeck A, Beck JT, Kaur JS, Whelan K, Tu D, Parulekar WR. Extending aromatase-inhibitor adjuvant therapy to 10 Years. N Engl J Med. 2016 Jul 21;375(3):209-19. Epub 2016 Jun 5. [https://www.nejm.org/doi/full/10.1056/NEJMoa1604700 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5024713/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27264120 PubMed]
## '''QoL analysis:''' Lemieux J, Brundage MD, Parulekar WR, Goss PE, Ingle JN, Pritchard KI, Celano P, Muss H, Gralow J, Strasser-Weippl K, Whelan K, Tu D, Whelan TJ. Quality of life from Canadian Cancer Trials Group MA.17R: a randomized trial of extending adjuvant letrozole to 10 years. J Clin Oncol. 2018 Feb 20;36(6):563-571. Epub 2018 Jan 12. [http://ascopubs.org/doi/full/10.1200/JCO.2017.75.7500 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29328860 PubMed]
# '''FACE:''' Smith I, Yardley D, Burris H, De Boer R, Amadori D, McIntyre K, Ejlertsen B, Gnant M, Jonat W, Pritchard KI, Dowsett M, Hart L, Poggio S, Comarella L, Salomon H, Wamil B, O'Shaughnessy J. Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial. J Clin Oncol. 2017 Apr 1;35(10):1041-1048. Epub 2017 Jan 23. [http://ascopubs.org/doi/full/10.1200/JCO.2016.69.2871 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28113032 PubMed]
# '''IDEAL:''' Blok EJ, Kroep JR, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, Putter H, van den Bosch J, Maartense E, van Leeuwen-Stok AE, Liefers GJ, Nortier JWR, Rutgers EJT, van de Velde CJH; IDEAL Study Group. Optimal duration of extended adjuvant endocrine therapy for early breast cancer; results of the IDEAL trial (BOOG 2006-05). J Natl Cancer Inst. 2018 Jan 1;110(1). Epub 2017 Aug 23. [https://academic.oup.com/jnci/article-abstract/110/1/djx134/4093022/Optimal-Duration-of-Extended-Adjuvant-Endocrine link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28922787 PubMed]
# '''SOLE:''' Colleoni M, Luo W, Karlsson P, Chirgwin J, Aebi S, Jerusalem G, Neven P, Hitre E, Graas MP, Simoncini E, Kamby C, Thompson A, Loibl S, Gavilá J, Kuroi K, Marth C, Müller B, O'Reilly S, Di Lauro V, Gombos A, Ruhstaller T, Burstein H, Ribi K, Bernhard J, Viale G, Maibach R, Rabaglio-Poretti M, Gelber RD, Coates AS, Di Leo A, Regan MM, Goldhirsch A; SOLE Investigators. Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018 Jan;19(1):127-138. Epub 2017 Nov 17. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30715-5/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29158011 PubMed]
# '''FATA-GIM3:''' De Placido S, Gallo C, De Laurentiis M, Bisagni G, Arpino G, Sarobba MG, Riccardi F, Russo A, Del Mastro L, Cogoni AA, Cognetti F, Gori S, Foglietta J, Frassoldati A, Amoroso D, Laudadio L, Moscetti L, Montemurro F, Verusio C, Bernardo A, Lorusso V, Gravina A, Moretti G, Lauria R, Lai A, Mocerino C, Rizzo S, Nuzzo F, Carlini P, Perrone F; GIM Investigators. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. Lancet Oncol. 2018 Apr;19(4):474-485. Epub 2018 Feb 23. Erratum in: Lancet Oncol. 2018 Apr;19(4):e184. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30116-5/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29482983 PubMed]
# '''NSABP B-42:''' Mamounas EP, Bandos H, Lembersky BC, Jeong JH, Geyer CE Jr, Rastogi P, Fehrenbacher L, Graham ML, Chia SK, Brufsky AM, Walshe JM, Soori GS, Dakhil SR, Seay TE, Wade JL 3rd, McCarron EC, Paik S, Swain SM, Wickerham DL, Wolmark N. Use of letrozole after aromatase inhibitor-based therapy (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2018 Nov 30. [Epub ahead of print] [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30621-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/30509771 PubMed]

==Leuprolide monotherapy {{#subobject:714c67|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:bf0009|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/25/18/2509.long Schmid et al. 2007 (TABLE)]
| style="background-color:#1a9851" |Phase III (E)
|[[Breast_cancer#CMF|CMF]]
| style="background-color:#1a9850" |Superior OS
|-
|}
====Hormonotherapy====
*[[Leuprolide (Lupron)]] 3-month depot 11.25 mg SC

'''Every 3 months x 2 years'''

===References===
<!-- Presented in part at the 38th Annual Meeting of the American Society of Clinical Oncology, Orlando, FL, May 18-21, 2002; the San Antonio Breast Cancer Symposium, San Antonio, TX, December 3-6, 2003; the 40th Annual Meeting of the American Society of Clinical Oncology, New Orleans, LA, June 5-8, 2004; and the San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-11, 2004. -->
# '''TABLE:''' Schmid P, Untch M, Kossé V, Bondar G, Vassiljev L, Tarutinov V, Lehmann U, Maubach L, Meurer J, Wallwiener D, Possinger K. Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: the TABLE study. J Clin Oncol. 2007 Jun 20;25(18):2509-15. [http://jco.ascopubs.org/content/25/18/2509.long link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17577027 PubMed]

==Observation==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(83)91683-5/abstract Baum et al. 1983 (NATO)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Tamoxifen_monotherapy|Tamoxifen]] x 2 y
| style="background-color:#d73027" |Inferior OS
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(87)90762-8/fulltext Stewart et al. 1987 (Scottish Tamoxifen Trial)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Tamoxifen_monotherapy|Tamoxifen]] x 5 y
| style="background-color:#d73027" |Inferior OS (*)
|-
|[https://www.ejcancer.com/article/S0959-8049(04)00565-9/fulltext Rydén et al. 2005 (SBII:2pre)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Tamoxifen_monotherapy|Tamoxifen]] x 2 y
| style="background-color:#d73027" |Inferior RFS
|-
|[http://jco.ascopubs.org/content/23/33/8313.long Hutchins et al. 2005 (INT-0102)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Tamoxifen_monotherapy|Tamoxifen]] x 5 y
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2005.03.0783 Colleoni et al. 2006 (IBCSG 13-93)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Tamoxifen_monotherapy|Tamoxifen]] x 5 y
| style="background-color:#1a9850" |Superior DFS
|-
|[https://academic.oup.com/annonc/article/27/5/806/2769820 Zdenkowski et al. 2016 (ANZ0501 LATER)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Letrozole_monotherapy_2|Letrozole]] x 5 y
| style="background-color:#fee08b" |Might have inferior DFS
|-
|[http://www.tandfonline.com/doi/full/10.1080/0284186X.2017.1400179 Jensen et al. 2017 (CBC 02)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Tamoxifen_monotherapy|Tamoxifen]] x 2 y
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|}
''No further treatment. Efficacy for the Scottish Tamoxifen Trial is based on the 2001 update.''
====Preceding treatment====
*INT-0102: [[Surgery#Breast_cancer_surgery|Surgery]], then [[Breast_cancer#FAC_2|CAF]] x 6 versus [[Breast_cancer#CMF|CMF]] x 6
*IBCSG 13-93: [[Surgery#Breast_cancer_surgery|Surgery]], then [[Breast_cancer#AC_2|AC]] x 4 or [[Breast_cancer#EC_2|EC]] x 4, then [[Breast_cancer#CMF|CMF]] x 3
*ANZ0501 LATER: At least 4 years of any endocrine therapy
===References===
# '''NATO:''' Baum M, Brinkley DM, Dosset JA, McPherson K, Patterson JS, Rubens RD, Smiddy FG, Stoll BA, Wilson A, Lea JC, Richards D, Ellis SH. Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer: interim analysis at four years by Nolvadex Adjuvant Trial Organisation. Lancet. 1983 Feb 5;1(8319):257-61. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(83)91683-5/abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/6130291 PubMed]
## '''Update:''' Baum M, Brinkley DM, Dosset JA, McPherson K, Patterson JS, Rubens RD, Smiddy FG, Stoll BA, Wilson A, Richards D, Ellis SH. Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer: analysis at six years by Nolvadex Adjuvant Trial Organisation. Lancet. 1985 Apr 13;1(8433):836-40. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(85)92206-8/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/2858709 PubMed]
# '''Scottish Tamoxifen Trial:''' Stewart HJ, Taylor W, Forrest P. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial: report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. Lancet. 1987 Jul 25;2(8552):171-5. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(87)90762-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/2885637 PubMed]
## '''Update:''' Stewart HJ, Forrest AP, Everington D, McDonald CC, Dewar JA, Hawkins RA, Prescott RJ, George WD; The Scottish Cancer Trials Breast Group. Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. Br J Cancer. 1996 Jul;74(2):297-9. [https://www.nature.com/articles/bjc1996356 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074573/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/8688340 PubMed]
## '''Update:''' Stewart HJ, Prescott RJ, Forrest AP. Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. J Natl Cancer Inst. 2001 Mar 21;93(6):456-62. [https://academic.oup.com/jnci/article/93/6/456/2906503 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11259471 PubMed]
# '''SBII:2pre:''' Rydén L, Jönsson PE, Chebil G, Dufmats M, Fernö M, Jirström K, Källström AC, Landberg G, Stål O, Thorstenson S, Nordenskjöld B; South Swedish Breast Cancer Group; South-East Swedish Breast Cancer Group. Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up. Eur J Cancer. 2005 Jan;41(2):256-64. [https://www.ejcancer.com/article/S0959-8049(04)00565-9/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15661551 PubMed]
## '''Update:''' Ekholm M, Bendahl PO, Fernö M, Nordenskjöld B, Stål O, Rydén L. Two years of adjuvant tamoxifen provides a survival benefit compared with no systemic treatment in premenopausal patients with primary breast cancer: Long-term follow-up (> 25 years) of the phase III SBII:2pre trial. J Clin Oncol. 2016 Jul 1;34(19):2232-8. Epub 2016 May 9. [http://jco.ascopubs.org/content/34/19/2232.full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27161974 PubMed]
# '''INT-0102:''' Hutchins LF, Green SJ, Ravdin PM, Lew D, Martino S, Abeloff M, Lyss AP, Allred C, Rivkin SE, Osborne CK. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of intergroup protocol INT-0102. J Clin Oncol. 2005 Nov 20;23(33):8313-21. [http://jco.ascopubs.org/content/23/33/8313.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16293862 PubMed]
# '''IBCSG 13-93:''' Colleoni M, Gelber S, Goldhirsch A, Aebi S, Castiglione-Gertsch M, Price KN, Coates AS, Gelber RD; International Breast Cancer Study Group. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J Clin Oncol. 2006 Mar 20;24(9):1332-41. Epub 2006 Feb 27. [http://ascopubs.org/doi/full/10.1200/JCO.2005.03.0783 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16505417 PubMed]
# '''ANZ0501 LATER:''' Zdenkowski N, Forbes JF, Boyle FM, Kannourakis G, Gill PG, Bayliss E, Saunders C, Della-Fiorentina S, Kling N, Campbell I, Mann GB, Coates AS, Gebski V, Davies L, Thornton R, Reaby L, Cuzick J, Green M; Australia and New Zealand Breast Cancer Trials Group. Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptor-positive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial. Ann Oncol. 2016 May;27(5):806-12. Epub 2016 Feb 9. [https://academic.oup.com/annonc/article/27/5/806/2769820 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26861603 PubMed]
# '''CBC 02:''' Jensen MB, Krarup JF, Palshof T, Mouridsen HT, Ejlertsen B. Two years of tamoxifen or no adjuvant systemic therapy for patients with high-risk breast cancer: long-term follow-up of the Copenhagen Breast Cancer Trial. Acta Oncol. 2018 Jan;57(1):26-30. Epub 2017 Nov 22. [http://www.tandfonline.com/doi/full/10.1080/0284186X.2017.1400179 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29165021 PubMed]

==Placebo==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM198902233200802 Fisher et al. 1989 (NSABP B-14)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Tamoxifen_monotherapy|Tamoxifen]]
| style="background-color:#d73027" |Inferior OS (*)
|-
|[http://jco.ascopubs.org/content/19/4/931.full Fisher et al. 2001 (NSABP B-23)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Tamoxifen_monotherapy|Tamoxifen]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa032312 Goss et al. 2003 (NCIC CTG MA.17)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Letrozole_monotherapy_2|Letrozole]]
| style="background-color:#d73027" |Inferior DFS
|-
|[http://jco.ascopubs.org/content/26/12/1965.long Mamounas et al. 2008 (NSABP B-33)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Exemestane_monotherapy|Exemestane]]
| style="background-color:#d73027" |Inferior RFS
|-
|}
''No active treatment. Used as a comparator arm. Efficacy for NSABP B-14 based on the 2004 update.''
====Preceding treatment====
*NSABP B-14: [[Surgery#Breast_cancer_surgery|Surgery]]
*NSABP B-23: [[Breast_cancer#CMF|CMF]] x 6 versus [[Breast_cancer#AC_2|AC]] x 4
*NCIC CTG MA.17: [[#Tamoxifen_monotherapy|Tamoxifen]] x 5y
*NSABP B-33: [[#Tamoxifen_monotherapy|Tamoxifen]] x 5y

===References===
# '''NSABP B-14:''' Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, Dimitrov NV, Wolmark N, Wickerham DL, Fisher ER, Margolese R, Robidoux A, Shibata H, Terz J, Peterson AHG, Feldman MI, Farrar W, Evans J, Lickley HL, Ketner M. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989 Feb 23;320(8):479-84. [https://www.nejm.org/doi/full/10.1056/NEJM198902233200802 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/2858709 PubMed]
## '''Update:''' Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, Costantino J, Redmond C, Fisher ER, Bowman DM, Deschênes L, Dimitrov NV, Margolese RG, Robidoux A, Shibata H, Terz J, Paterson AH, Feldman MI, Farrar W, Evans J, Lickley HL. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst. 1996 Nov 6;88(21):1529-42. [https://academic.oup.com/jnci/article/88/21/1529/922662 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/8901851 PubMed]
## '''Update:''' Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst. 2001 May 2;93(9):684-90. [https://academic.oup.com/jnci/article/93/9/684/2906559 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11333290 PubMed]
## '''Update:''' Fisher B, Jeong JH, Bryant J, Anderson S, Dignam J, Fisher ER, Wolmark N; National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet. 2004 Sep 4-10;364(9437):858-68. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(04)16981-X/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15351193 PubMed]
## '''Pooled update:''' Taghian AG, Jeong JH, Mamounas EP, Parda DS, Deutsch M, Costantino JP, Wolmark N. Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials. J Clin Oncol. 2006 Aug 20;24(24):3927-32. [http://ascopubs.org/doi/full/10.1200/JCO.2006.06.9054 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16921044 PubMed]
# '''NSABP B-23:''' Fisher B, Anderson S, Tan-Chiu E, Wolmark N, Wickerham DL, Fisher ER, Dimitrov NV, Atkins JN, Abramson N, Merajver S, Romond EH, Kardinal CG, Shibata HR, Margolese RG, Farrar WB. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol. 2001 Feb 15;19(4):931-42. [http://jco.ascopubs.org/content/19/4/931.full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11181655 PubMed]
## '''Pooled update:''' Taghian AG, Jeong JH, Mamounas EP, Parda DS, Deutsch M, Costantino JP, Wolmark N. Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials. J Clin Oncol. 2006 Aug 20;24(24):3927-32. [http://ascopubs.org/doi/full/10.1200/JCO.2006.06.9054 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16921044 PubMed]
# '''NCIC CTG MA.17:''' Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003 Nov 6;349(19):1793-802. Epub 2003 Oct 9. [https://www.nejm.org/doi/full/10.1056/NEJMoa032312 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/14551341 PubMed]
## '''Update:''' Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst. 2005 Sep 7;97(17):1262-71. [http://jnci.oxfordjournals.org/content/97/17/1262.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16145047 PubMed]
## '''QoL analysis:''' Whelan TJ, Goss PE, Ingle JN, Pater JL, Tu D, Pritchard K, Liu S, Shepherd LE, Palmer M, Robert NJ, Martino S, Muss HB. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol. 2005 Oct 1;23(28):6931-40. Epub 2005 Sep 12. [http://ascopubs.org/doi/full/10.1200/JCO.2005.11.181 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16157934 PubMed]
## '''Update:''' Muss HB, Tu D, Ingle JN, Martino S, Robert NJ, Pater JL, Whelan TJ, Palmer MJ, Piccart MJ, Shepherd LE, Pritchard KI, He Z, Goss PE. Efficacy, toxicity, and quality of life in older women with early-stage breast cancer treated with letrozole or placebo after 5 years of tamoxifen: NCIC CTG intergroup trial MA.17. J Clin Oncol. 2008 Apr 20;26(12):1956-64. Epub 2008 Mar 10. [http://jco.ascopubs.org/content/26/12/1956.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18332474 PubMed]
## '''Subgroup analysis:''' Goss PE, Ingle JN, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Tu D. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol. 2008 Apr 20;26(12):1948-55. Epub 2008 Mar 10. [http://jco.ascopubs.org/content/26/12/1948.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18332475 PubMed]
## '''Update:''' Jin H, Tu D, Zhao N, Shepherd LE, Goss PE. Longer-term outcomes of letrozole versus placebo after 5 years of tamoxifen in the NCIC CTG MA.17 trial: analyses adjusting for treatment crossover. J Clin Oncol. 2012 Mar 1;30(7):718-21. Epub 2011 Oct 31. [http://jco.ascopubs.org/content/30/7/718.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3295549/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22042967 PubMed]
<!-- Presented in part in abstract format in the Breast Cancer Research Treatment 100:S22, 2006 (suppl; abstr A40). -->
# '''NSABP B-33:''' Mamounas EP, Jeong JH, Wickerham DL, Smith RE, Ganz PA, Land SR, Eisen A, Fehrenbacher L, Farrar WB, Atkins JN, Pajon ER, Vogel VG, Kroener JF, Hutchins LF, Robidoux A, Hoehn JL, Ingle JN, Geyer CE Jr, Costantino JP, Wolmark N. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. J Clin Oncol. 2008 Apr 20;26(12):1965-71. Epub 2008 Mar 10. [http://jco.ascopubs.org/content/26/12/1965.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18332472 PubMed]

==Tamoxifen monotherapy {{#subobject:2e0ab1|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 1 year {{#subobject:97eecb|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.tandfonline.com/doi/abs/10.3109/02841869209088914 Rydén et al. 1992 (SSBCG II:I)]
|style="background-color:#1a9851" |Phase III (C)
|1. RT<br> 2. Tamoxifen & RT
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1994.12.10.2078 Rivkin et al. 1994 (SWOG S7827)]
|style="background-color:#1a9851" |Phase III (C)
|1. [[Breast_cancer_-_historical#CMFVP|CMFVP]]<br> 2. CMFVPT
| style="background-color:#ffffbf" |Seems not superior
|-
| rowspan="2" |[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(98)09201-0/fulltext Overgaard et al. 1999 (DBCG 82C)]
| rowspan="2" style="background-color:#1a9851" |Phase III (C)
|1. [[Breast_cancer#CMFT|CMFT]]
| style="background-color:#d73027" |Inferior DFS (*)
|-
|2. Tamoxifen & RT
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2001.19.14.3376 Knoop et al. 2001 (DBCG 77C)]
|style="background-color:#1a9851" |Phase III (E)
|Observation
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.tandfonline.com/doi/full/10.1080/02841860802014882 Andersen et al. 2008 (DBCG 89C)]
|style="background-color:#1a9851" |Phase III (C)
|1. Tamoxifen x 2 y<br> 2. TAM/MA
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: efficacy for this arm of DBCG 82C versus CMFT is based on the 2013 update. Knoop et al. 2001 is a retrospective biomarker analysis; we are not aware of another primary publication for DBCG 77C.''
====Preceding treatment====
*[[Surgery#Mastectomy|Mastectomy]]

====Hormonotherapy====
*[[Tamoxifen (Nolvadex)]] 30 mg PO once per day

'''1 year of therapy'''

===Variant #2, 2 years of 20 mg/day {{#subobject:bb9926|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(83)91683-5/abstract Baum et al. 1983 (NATO)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Observation|Observation]]
| style="background-color:#1a9850" |Superior OS
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(88)90521-1/fulltext Bianco et al. 1988 (GUN)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Observation|Observation]]
| style="background-color:#91cf60" |Seems to have superior DFS
|-
|[https://academic.oup.com/jnci/article/88/21/1543/922668 Rutqvist et al. 1996]
| style="background-color:#1a9851" |Phase III (C)
|Tamoxifen x 5 y
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|[https://academic.oup.com/jnci/article/88/24/1834/890202 Baum & Odling-Smee 1996 (CRUK Over 50s)]
| style="background-color:#1a9851" |Phase III (C)
|Tamoxifen x 5 y
| style="background-color:#d73027" |Inferior EFS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.1999.17.6.1701 Jakesz et al. 1999]
| style="background-color:#1a9851" |Phase III (C)
|AV-CMF-TAM
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa040331 Coombes et al. 2004 (IES)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#Intergroup_Exemestane_Study|See link]]
|[[Complex_multipart_regimens#Intergroup_Exemestane_Study|See link]]
|-
|[https://www.ejcancer.com/article/S0959-8049(04)00565-9/fulltext Rydén et al. 2005 (SBII:2pre)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Observation|Observation]]
| style="background-color:#1a9850" |Superior RFS
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa052258 Thürlimann et al. 2005 (BIG 1-98)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#BIG_1-98|See link]]
|[[Complex_multipart_regimens#BIG_1-98|See link]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)67059-6/fulltext Jakesz et al. 2005 (ARNO 95)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#ARNO_95|See link]]
|[[Complex_multipart_regimens#ARNO_95|See link]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)67059-6/fulltext Jakesz et al. 2005 (ABCSG-8)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#ABCSG-8|See link]]
|[[Complex_multipart_regimens#ABCSG-8|See link]]
|-
|[http://www.tandfonline.com/doi/full/10.1080/0284186X.2017.1400179 Jensen et al. 2017 (CBC 02)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Observation|Observation]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30116-5/fulltext De Placido et al. 2018 (FATA-GIM3)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#FATA-GIM3|See link]]
|[[Complex_multipart_regimens#FATA-GIM3|See link]]
|-
|}
''Note: IES gave a range of 2 to 3 years of therapy.''
====Hormonotherapy====
*[[Tamoxifen (Nolvadex)]] 20 mg PO once per day
**In CBC 02, the dose was 10 mg PO TID

'''2-year course'''
====Subsequent treatment====
*IES: [[#Exemestane_monotherapy|Exemestane]]
*BIG 1-98: [[#Letrozole_monotherapy_2|Letrozole]]
*ABCSG-8 & ARNO 95: [[#Anastrozole_monotherapy_2|Anastrozole]] x 3 y
*FATA-GIM3: [[#Anastrozole_monotherapy_2|Anastrozole]] versus [[#Exemestane_monotherapy|Exemestane]] versus [[#Letrozole_monotherapy_2|Letrozole]]

===Variant #3, 2 years of 30 mg/day {{#subobject:ff9926|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1997.15.6.2302 Pritchard et al. 1997]
| style="background-color:#1a9851" |Phase III (C)
|CMFT
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Hormonotherapy====
*[[Tamoxifen (Nolvadex)]] 30 mg PO once per day

'''2-year course'''
===Variant #4, 2 years of 40 mg/d, then 3 years of 20 mg/day {{#subobject:7b8e78|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/jco.2003.01.138 Schmid et al. 2003 (ABCSG-6)]
| style="background-color:#1a9851" |Phase III (C)
|Aminoglutethemide & Tamoxifen
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Hormonotherapy====
*[[Tamoxifen (Nolvadex)]] as follows:
**Years 1 & 2: 40 mg PO once per day
**Years 3 to 5: 20 mg PO once per day

'''5-year course'''

===Variant #5, 3 years of 20 mg/day {{#subobject:7a4c78|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa052258 Thürlimann et al. 2005 (BIG 1-98)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#BIG_1-98|See link]]
|[[Complex_multipart_regimens#BIG_1-98|See link]]
|-
|[https://www.ejcancer.com/article/S0959-8049(06)00908-7/fulltext Morales et al. 2006]
| style="background-color:#1a9851" |Phase III (E)
|[[#Observation|Observation]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)62312-4/fulltext van de Velde et al. 2011 (TEAM)]
| style="background-color:#1a9851" |Phase III (E)
|[[Complex_multipart_regimens#TEAM|See link]]
| style="background-color:#ffffbf" |[[Complex_multipart_regimens#TEAM|See link]]
|-
|}
''Note: this is a component of a sequential treatment protocol; to our knowledge there are no references to support using it as a stand-alone treatment. '''TEAM''' gave a range of 2.5 to 3 years of therapy.''
====Preceding treatment====
*BIG 1-98: [[#Letrozole_monotherapy_2|Letrozole]] x 2y
*Morales et al. 2006: Adjuvant chemotherapy
====Hormonotherapy====
*[[Tamoxifen (Nolvadex)]] 20 mg PO once per day

'''3-year course'''
====Subsequent treatment====
*TEAM: [[#Exemestane_monotherapy|Exemestane]]

===Variant #6, 3 years of 30 mg/day {{#subobject:4f2c78|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2004.02.145 Fargeot et al. 2004 (FASG 08)]
| style="background-color:#1a9851" |Phase III (C)
|Epirubicin & Tamoxifen
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://academic.oup.com/annonc/article/17/1/65/160873 Namer et al. 2006 (FASG 02)]
| style="background-color:#1a9851" |Phase III (C)
|FEC50-Tam
| style="background-color:#d73027" |Inferior DFS
|-
|[https://academic.oup.com/annonc/article/17/1/65/160873 Namer et al. 2006 (FASG 07)]
| style="background-color:#1a9851" |Phase III (C)
|FEC50-Tam
| style="background-color:#d73027" |Inferior DFS
|-
|}
====Hormonotherapy====
*[[Tamoxifen (Nolvadex)]] 30 mg PO once per day

'''3-year course'''

===Variant #7, 5 years {{#subobject:dc8bc3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(87)90762-8/fulltext Stewart et al. 1987 (Scottish Tamoxifen Trial)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Observation|Observation]]
| style="background-color:#1a9850" |Superior OS (*)
|
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM198902233200802 Fisher et al. 1989 (NSABP B-14)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Placebo|Placebo]]
| style="background-color:#1a9850" |Superior OS (*)
|
|-
|rowspan=2|[http://ascopubs.org/doi/abs/10.1200/JCO.1990.8.6.1005 Fisher et al. 1990 (NSABP B-16)]
|rowspan=2 style="background-color:#1a9851" |Phase III (C)
|1. [[Breast_cancer_-_historical#ACT|ACT]]
| style="background-color:#fc8d59" |Seems to have inferior OS
|
|-
|2. [[Breast_cancer_-_historical#PFT|PFT]]
| style="background-color:#fc8d59" |Seems to have inferior DDFS
|
|-
|[https://www.ncbi.nlm.nih.gov/pubmed/7840523 Mustacchi et al. 1994 (GRETA)]
| style="background-color:#1a9851" |Phase III (C)
|Tamoxifen alone (no surgery)
| style="background-color:#ffffbf" |Seems not superior
|
|-
|[https://academic.oup.com/jnci/article/88/21/1543/922668 Rutqvist et al. 1996]
| style="background-color:#1a9851" |Phase III (E)
|Tamoxifen x 2 y
| style="background-color:#91cf60" |Seems to have superior OS
|
|-
|[https://academic.oup.com/jnci/article/88/24/1828/890199 Tormey et al. 1996 (ECOG E4181/E5181)]
| style="background-color:#1a9851" |Phase III (C)
|Tamoxifen indefinitely
| style="background-color:#ffffbf" |Seems not superior
|
|-
|[https://academic.oup.com/jnci/article/88/24/1834/890202 Baum & Odling-Smee 1996 (CRUK Over 50s)]
| style="background-color:#1a9851" |Phase III (E)
|Tamoxifen x 2 y
| style="background-color:#1a9850" |Superior EFS (*)
|
|-
|rowspan=2|[https://academic.oup.com/jnci/article/89/22/1673/2526493 Fisher et al. 1997 (NSABP B-20)]
|rowspan=2 style="background-color:#1a9851" |Phase III (C)
|1. [[Breast_cancer#CMFT|CMFT]]
| style="background-color:#fee08b" |Might have inferior OS (*)
|
|-
|2. MFT
| style="background-color:#d3d3d3" |Not reported (*)
|
|-
|[http://jco.ascopubs.org/content/19/4/931.full Fisher et al. 2001 (NSABP B-23)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Placebo|Placebo]]
| style="background-color:#ffffbf" |Seems not superior
|
|-
| rowspan="2" |[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(02)09088-8/fulltext Baum et al. 2002 (ATAC)]
| rowspan="2" style="background-color:#1a9851" |Phase III (C)
|1. Anastrozole & Tamoxifen
| style="background-color:#ffffbf" |Seems not superior
|
|-
|2. [[#Anastrozole_monotherapy_2|Anastrozole]]
| style="background-color:#fc8d59" |Seems to have inferior DFS
|
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2002.11.101 Fisher et al. 2002 (NSABP B-21)]
|style="background-color:#1a9851" |Phase III (E)
|RT<br> Tamoxifen & RT
| style="background-color:#d73027" |Inferior DFS
|
|-
|[https://onlinelibrary.wiley.com/doi/10.1002/cncr.11396/full Assikis et al. 2003]
| style="background-color:#1a9851" |Phase III (E)
|[[Breast_cancer#FAC|FAC]], then [[Breast_cancer_-_historical#MV|MV]]
| style="background-color:#ffffbf" |Seems not superior
|
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa040331 Coombes et al. 2004 (IES)]
| style="background-color:#1a9851" |Phase III (C)
|Tamoxifen x 2-3y, then [[#Exemestane_monotherapy|Exemestane]] x 2-3y
| style="background-color:#fc8d59" |Seems to have inferior OS (*)
|
|-
|[https://www.nejm.org/doi/10.1056/NEJMoa040595 Fyles et al. 2004]
| style="background-color:#1a9851" |Phase III (*)
|See note
|
|
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa040587 Hughes et al. 2004 (CALGB 9343)]
| style="background-color:#1a9851" |Phase III (*)
|See note
|
|
|-
|[http://jco.ascopubs.org/content/23/33/8313.long Hutchins et al. 2005 (INT-0102)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Observation|Observation]]
| style="background-color:#ffffbf" |Seems not superior
|
|-
| rowspan="3" |[https://www.nejm.org/doi/full/10.1056/NEJMoa052258 Thürlimann et al. 2005 (BIG 1-98)]
| rowspan="3" style="background-color:#1a9851" |Phase III (C)
|1. [[#Letrozole_monotherapy_2|Letrozole]]
| style="background-color:#fee08b" |Might have inferior OS (*)
|
|-
|2. [[#Letrozole_monotherapy_2|Letrozole]] x 2y, then Tamoxifen x 3y
| style="background-color:#d3d3d3" |Not reported
|
|-
|3. Tamoxifen x 2y, then [[#Letrozole_monotherapy_2|Letrozole]] x 3y
| style="background-color:#d3d3d3" |Not reported
|
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)67059-6/fulltext Jakesz et al. 2005 (ARNO 95)]
| style="background-color:#1a9851" |Phase III (C)
|Tamoxifen x 2y, then [[#Anastrozole_monotherapy_2|Anastrozole]] x 3y
| style="background-color:#fc8d59" |Seems to have inferior OS
|
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)67059-6/fulltext Jakesz et al. 2005 (ABCSG-8)]
| style="background-color:#1a9851" |Phase III (C)
|Tamoxifen x 2y, then [[#Anastrozole_monotherapy_2|Anastrozole]] x 3y
| style="background-color:#fee08b" |Might have inferior RFS
|
|-
|[http://jco.ascopubs.org/content/26/12/1965.long Mamounas et al. 2008 (NSABP B-33)]
| style="background-color:#91cf61" |Non-randomized portion of RCT
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140679/ Albain et al. 2009 (SWOG-8814)]
| style="background-color:#1a9851" |Phase III (*)
|[[Complex_multipart_regimens#SWOG-8814|See link]]
|[[Complex_multipart_regimens#SWOG-8814|See link]]
|
|-
|[https://link.springer.com/article/10.1007%2Fs10549-010-0888-x Aihara et al. 2010 (N-SAS BC03)]
| style="background-color:#1a9851" |Phase III (C)
|Tamoxifen x 1-4y, then [[#Anastrozole_monotherapy_2|Anastrozole]] x 1-4y (5y total)
| style="background-color:#ffffbf" |Seems not superior
| style="background-color:#ffffbf" |Similar toxicity
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4947231/ Rao et al. 2010 (ECOG EB193)]
| style="background-color:#1a9851" |Phase III (C)
|Fenretinide & Tamoxifen
| style="background-color:#ffffbf" |Seems not superior
|
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)62312-4/fulltext van de Velde et al. 2011 (TEAM)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Tamoxifen_monotherapy|Tamoxifen]] x 2.5-3y, then [[#Exemestane_monotherapy|Exemestane]] x 2-2.5y
| style="background-color:#ffffbf" |Seems not superior
|
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.33.7006 Pritchard et al. 2011 (NCIC CTG MA.14)]
| style="background-color:#1a9851" |Phase III (C)
|Tamoxifen & Octreotide LAR
| style="background-color:#ffffbf" |Seems not superior
|
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)61963-1/abstract Davies et al. 2013 (ATLAS)]
| style="background-color:#1a9851" |Phase III (C)
|Tamoxifen x 10 years
| style="background-color:#d73027" |Inferior OS
|
|-
| rowspan="2" |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4175521/ Pagani et al. 2014 (SOFT)]
| rowspan="2" style="background-color:#1a9851" |Phase III (C)
|1. [[#Exemestane_monotherapy|Exemestane & OFS]]
| style="background-color:#d73027" |Inferior DFS
|
|-
|2. [[#Tamoxifen_.26_OFS|Tamoxifen & OFS]]
| style="background-color:#fee08b" |Might have inferior DFS (*)
|
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251958/ Tevaarwerk et al. 2014 (ECOG E-3193)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Tamoxifen_.26_OFS|Tamoxifen & OFS]]
| style="background-color:#ffffbf" |Seems not superior
| style="background-color:#1a9850" |Fewer menopausal symptoms
|-
|}
''Note: in Fyles et al. 2004 and CALGB 9343, the randomization was to radiation therapy or no radiation therapy; all patients received 5 years of tamoxifen. Reported efficacy for the Scottish Tamoxifen Trial is based on the 2001 update. Reported efficacy for NSABP B-14 & NSABP B-20 is based on the 2004 update. Efficacy for CRUK Over 50s is based on the 2011 update. Pagani et al. 2014 reports on two trials, but only SOFT had the tamoxifen only arm; efficacy for this arm is as reported in Francis et al. 2015. Reported efficacy for IES is based on the 2011 update. Reported efficacy for BIG 1-98 is based on the 2011 & 2018 updates.''
====Preceding treatment====
*NSABP B-23: [[Breast_cancer#CMF|CMF]] x 6 versus [[Breast_cancer#AC_2|AC]] x 4
*INT-0102: [[Breast_cancer#FAC|CAF]] x 6 versus [[Breast_cancer#CMF|CMF]] x 6
*SWOG-8814: [[Surgery#Breast_cancer_surgery|Surgery]] versus surgery, then [[Breast_cancer#FAC_2|CAF]] x 6
====Hormonotherapy====
*[[Tamoxifen (Nolvadex)]] 20 mg PO once per day
**Some older trials report using 10 mg PO twice per day

'''5 years of therapy'''
====Subsequent treatment====
*NSABP B-33: [[#Exemestane_monotherapy|Exemestane]] versus [[#Placebo|Placebo]]

===Variant #8, 10 years {{#subobject:43a51a|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)61963-1/abstract Davies et al. 2013 (ATLAS)]
| style="background-color:#1a9851" |Phase III (E)
|Tamoxifen x 5 years
| style="background-color:#1a9850" |Superior OS
|-
|}
====Hormonotherapy====
*[[Tamoxifen (Nolvadex)]] 20 mg PO once per day

'''10 years of therapy'''

===References===
# '''NATO:''' Baum M, Brinkley DM, Dosset JA, McPherson K, Patterson JS, Rubens RD, Smiddy FG, Stoll BA, Wilson A, Lea JC, Richards D, Ellis SH. Controlled trial of tamoxifen as adjuvant agent in management of early breast cancer: interim analysis at four years by Nolvadex Adjuvant Trial Organisation. Lancet. 1983 Feb 5;1(8319):257-61. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(83)91683-5/abstract link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/6130291 PubMed]
## '''Update:''' Baum M, Brinkley DM, Dosset JA, McPherson K, Patterson JS, Rubens RD, Smiddy FG, Stoll BA, Wilson A, Richards D, Ellis SH. Controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer: analysis at six years by Nolvadex Adjuvant Trial Organisation. Lancet. 1985 Apr 13;1(8433):836-40. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(85)92206-8/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/2858709 PubMed]
# '''Scottish Tamoxifen Trial:''' Stewart HJ, Taylor W, Forrest P. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish Trial: report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. Lancet. 1987 Jul 25;2(8552):171-5. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(87)90762-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/2885637 PubMed]
## '''Update:''' Stewart HJ, Forrest AP, Everington D, McDonald CC, Dewar JA, Hawkins RA, Prescott RJ, George WD; The Scottish Cancer Trials Breast Group. Randomised comparison of 5 years of adjuvant tamoxifen with continuous therapy for operable breast cancer. Br J Cancer. 1996 Jul;74(2):297-9. [https://www.nature.com/articles/bjc1996356 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2074573/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/8688340 PubMed]
## '''Update:''' Stewart HJ, Prescott RJ, Forrest AP. Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. J Natl Cancer Inst. 2001 Mar 21;93(6):456-62. [https://academic.oup.com/jnci/article/93/6/456/2906503 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11259471 PubMed]
# '''GUN:''' Bianco AR, De Placido S, Gallo C, Pagliarulo C, Marinelli A, Petrella G, D'Istria M, Delrio G. Adjuvant therapy with tamoxifen in operable breast cancer: 10 year results of the Naples (GUN) study. Lancet. 1988 Nov 12;2(8620):1095-9. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(88)90521-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/2903322 PubMed]
# '''NSABP B-14:''' Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, Dimitrov NV, Wolmark N, Wickerham DL, Fisher ER, Margolese R, Robidoux A, Shibata H, Terz J, Peterson AHG, Feldman MI, Farrar W, Evans J, Lickley HL, Ketner M. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med. 1989 Feb 23;320(8):479-84. [https://www.nejm.org/doi/full/10.1056/NEJM198902233200802 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/2858709 PubMed]
## '''Update:''' Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, Costantino J, Redmond C, Fisher ER, Bowman DM, Deschênes L, Dimitrov NV, Margolese RG, Robidoux A, Shibata H, Terz J, Paterson AH, Feldman MI, Farrar W, Evans J, Lickley HL. Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst. 1996 Nov 6;88(21):1529-42. [https://academic.oup.com/jnci/article/88/21/1529/922662 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/8901851 PubMed]
## '''Update:''' Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst. 2001 May 2;93(9):684-90. [https://academic.oup.com/jnci/article/93/9/684/2906559 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11333290 PubMed]
## '''Update:''' Fisher B, Jeong JH, Bryant J, Anderson S, Dignam J, Fisher ER, Wolmark N; National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet. 2004 Sep 4-10;364(9437):858-68. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(04)16981-X/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15351193 PubMed]
## '''Pooled update:''' Taghian AG, Jeong JH, Mamounas EP, Parda DS, Deutsch M, Costantino JP, Wolmark N. Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials. J Clin Oncol. 2006 Aug 20;24(24):3927-32. [http://ascopubs.org/doi/full/10.1200/JCO.2006.06.9054 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16921044 PubMed]
# '''NSABP B-16:''' Fisher B, Redmond C, Legault-Poisson S, Dimitrov NV, Brown AM, Wickerham DL, Wolmark N, Margolese RG, Bowman D, Glass AG, Kardinal CG, Robidoux A, Jochimsen P, Cronin W, Deutsch M, Fisher ER, Myers DB, Hoehn JL. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol. 1990 Jun;8(6):1005-18. [http://ascopubs.org/doi/abs/10.1200/JCO.1990.8.6.1005 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/2189950 PubMed]
## '''Pooled update:''' Taghian A, Jeong JH, Mamounas E, Anderson S, Bryant J, Deutsch M, Wolmark N. Patterns of locoregional failure in patients with operable breast cancer treated by mastectomy and adjuvant chemotherapy with or without tamoxifen and without radiotherapy: results from five National Surgical Adjuvant Breast and Bowel Project randomized clinical trials. J Clin Oncol. 2004 Nov 1;22(21):4247-54. Epub 2004 Sep 27. [http://ascopubs.org/doi/full/10.1200/JCO.2004.01.042 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15452182 PubMed]
# '''SSBCG II:I:''' Rydén S, Fernö M, Möller T, Aspegren K, Bergljung L, Killander D, Landberg T. Long-term effects of adjuvant tamoxifen and/or radiotherapy: the South Sweden Breast Cancer Trial. Acta Oncol. 1992;31(2):271-4. [https://www.tandfonline.com/doi/abs/10.3109/02841869209088914 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/1622645 PubMed]
## '''Update:''' Killander F, Anderson H, Rydén S, Möller T, Aspegren K, Ceberg J, Danewid C, Malmström P. Radiotherapy and tamoxifen after mastectomy in postmenopausal women -- 20 year follow-up of the South Sweden Breast Cancer Group randomised trial SSBCG II:I. Eur J Cancer. 2007 Sep;43(14):2100-8. Epub 2007 Jul 17. [https://www.ejcancer.com/article/S0959-8049(07)00439-X/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17644330 PubMed]
# '''GRETA:''' Mustacchi G, Milani S, Pluchinotta A, De Matteis A, Rubagotti A, Perrota A; Group for Research on Endocrine Therapy in the Elderly. Tamoxifen or surgery plus tamoxifen as primary treatment for elderly patients with operable breast cancer: the GRETA trial. Anticancer Res. 1994 Sep-Oct;14(5B):2197-200. [https://www.ncbi.nlm.nih.gov/pubmed/7840523 PubMed]
## '''Update:''' Mustacchi G, Ceccherini R, Milani S, Pluchinotta A, De Matteis A, Maiorino L, Farris A, Scanni A, Sasso F; Italian Cooperative Group GRETA. Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: long-term results of the phase III randomized controlled multicenter GRETA trial. Ann Oncol. 2003 Mar;14(3):414-20. [https://academic.oup.com/annonc/article/14/3/414/211377 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12598347 PubMed]
# '''SWOG S7827:''' Rivkin SE, Green S, Metch B, Cruz AB, Abeloff MD, Jewell WR, Costanzi JJ, Farrar WB, Minton JP, Osborne CK. Adjuvant CMFVP versus tamoxifen versus concurrent CMFVP and tamoxifen for postmenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study. J Clin Oncol. 1994 Oct;12(10):2078-85. [http://ascopubs.org/doi/abs/10.1200/JCO.1994.12.10.2078 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/7931477 PubMed]
# Rutqvist LE, Hatschek T, Rydén S, Bergh J, Bengtsson NO, Carstenssen J, Nordenskjöld B, Wallgren A; Swedish Breast Cancer Cooperative Group. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst. 1996 Nov 6;88(21):1543-9. [https://academic.oup.com/jnci/article/88/21/1543/922668 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/8901852 PubMed]
# '''ECOG E4181/E5181:''' Tormey DC, Gray R, Falkson HC; Eastern Cooperative Oncology Group. Postchemotherapy adjuvant tamoxifen therapy beyond five years in patients with lymph node-positive breast cancer. J Natl Cancer Inst. 1996 Dec 18;88(24):1828-33. [https://academic.oup.com/jnci/article/88/24/1828/890199 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8961972 PubMed]
# '''CRUK Over 50s:''' Baum M, Odling-Smee W; Current Trials working Party of the Cancer Research Campaign Breast Cancer Trials Group. Preliminary results from the cancer research campaign trial evaluating tamoxifen duration in women aged fifty years or older with breast cancer. J Natl Cancer Inst. 1996 Dec 18;88(24):1834-9. Erratum in: J Natl Cancer Inst 1997 Apr 16;89(8):590. [https://academic.oup.com/jnci/article/88/24/1834/890202 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8961973 PubMed]
## '''Update:''' Hackshaw A, Roughton M, Forsyth S, Monson K, Reczko K, Sainsbury R, Baum M. Long-term benefits of 5 years of tamoxifen: 10-year follow-up of a large randomized trial in women at least 50 years of age with early breast cancer. J Clin Oncol. 2011 May 1;29(13):1657-63. Epub 2011 Mar 21. [http://ascopubs.org/doi/full/10.1200/JCO.2010.32.2933 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21422412 PubMed]
# Pritchard KI, Paterson AH, Fine S, Paul NA, Zee B, Shepherd LE, Abu-Zahra H, Ragaz J, Knowling M, Levine MN, Verma S, Perrault D, Walde PL, Bramwell VH, Poljicak M, Boyd N, Warr D, Norris BD, Bowman D, Armitage GR, Weizel H, Buckman RA; NCIC CTG Breast Cancer Site Group. Randomized trial of cyclophosphamide, methotrexate, and fluorouracil chemotherapy added to tamoxifen as adjuvant therapy in postmenopausal women with node-positive estrogen and/or progesterone receptor-positive breast cancer: a report of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1997 Jun;15(6):2302-11. [http://ascopubs.org/doi/abs/10.1200/JCO.1997.15.6.2302 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/9196144 PubMed]
# '''NSABP B-20:''' Fisher B, Dignam J, Wolmark N, DeCillis A, Emir B, Wickerham DL, Bryant J, Dimitrov NV, Abramson N, Atkins JN, Shibata H, Deschenes L, Margolese RG. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst. 1997 Nov 19;89(22):1673-82. [https://academic.oup.com/jnci/article/89/22/1673/2526493 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9390536 PubMed]
## '''Update:''' Fisher B, Jeong JH, Bryant J, Anderson S, Dignam J, Fisher ER, Wolmark N; National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Treatment of lymph-node-negative, oestrogen-receptor-positive breast cancer: long-term findings from National Surgical Adjuvant Breast and Bowel Project randomised clinical trials. Lancet. 2004 Sep 4-10;364(9437):858-68. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(04)16981-X/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15351193 PubMed]
## '''Pooled update:''' Taghian AG, Jeong JH, Mamounas EP, Parda DS, Deutsch M, Costantino JP, Wolmark N. Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials. J Clin Oncol. 2006 Aug 20;24(24):3927-32. [http://ascopubs.org/doi/full/10.1200/JCO.2006.06.9054 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16921044 PubMed]
# '''DBCG 82C:''' Overgaard M, Jensen MB, Overgaard J, Hansen PS, Rose C, Andersson M, Kamby C, Kjaer M, Gadeberg CC, Rasmussen BB, Blichert-Toft M, Mouridsen HT. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet. 1999 May 15;353(9165):1641-8. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(98)09201-0/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10335782 PubMed]
## '''Update:''' Ejlertsen B, Jensen MB, Elversang J, Rasmussen BB, Andersson M, Andersen J, Nielsen DL, Cold S, Mouridsen HT. One year of adjuvant tamoxifen compared with chemotherapy and tamoxifen in postmenopausal patients with stage II breast cancer. Eur J Cancer. 2013 Sep;49(14):2986-94. Epub 2013 Jun 8. [https://www.ejcancer.com/article/S0959-8049(13)00383-3/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23756360 PubMed]
# Jakesz R, Hausmaninger H, Haider K, Kubista E, Samonigg H, Gnant M, Manfreda D, Tschurtschenthaler G, Kolb R, Stierer M, Fridrik M, Mlineritsch B, Steindorfer P, Mittlböck M, Steger G; ABCSG. Randomized trial of low-dose chemotherapy added to tamoxifen in patients with receptor-positive and lymph node-positive breast cancer. J Clin Oncol. 1999 Jun;17(6):1701-9. [http://ascopubs.org/doi/full/10.1200/JCO.1999.17.6.1701 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/10561206 PubMed]
# '''NSABP B-23:''' Fisher B, Anderson S, Tan-Chiu E, Wolmark N, Wickerham DL, Fisher ER, Dimitrov NV, Atkins JN, Abramson N, Merajver S, Romond EH, Kardinal CG, Shibata HR, Margolese RG, Farrar WB. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol. 2001 Feb 15;19(4):931-42. [http://jco.ascopubs.org/content/19/4/931.full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11181655 PubMed]
## '''Pooled update:''' Taghian AG, Jeong JH, Mamounas EP, Parda DS, Deutsch M, Costantino JP, Wolmark N. Low locoregional recurrence rate among node-negative breast cancer patients with tumors 5 cm or larger treated by mastectomy, with or without adjuvant systemic therapy and without radiotherapy: results from five national surgical adjuvant breast and bowel project randomized clinical trials. J Clin Oncol. 2006 Aug 20;24(24):3927-32. [http://ascopubs.org/doi/full/10.1200/JCO.2006.06.9054 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16921044 PubMed]
# '''DBCG 77C:''' Knoop AS, Bentzen SM, Nielsen MM, Rasmussen BB, Rose C. Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J Clin Oncol. 2001 Jul 15;19(14):3376-84. [http://ascopubs.org/doi/full/10.1200/JCO.2001.19.14.3376 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11454885 PubMed]
# '''ATAC:''' Baum M, Budzar AU, Cuzick J, Forbes J, Houghton JH, Klijn JG, Sahmoud T; ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002 Jun 22;359(9324):2131-9. Erratum in: Lancet 2002 Nov 9;360(9344):1520. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(02)09088-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12090977 PubMed]
## '''Update:''' Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes JF, Hoctin-Boes G, Houghton J, Locker GY, Tobias JS; ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005 Jan 1-7;365(9453):60-2. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2804%2917666-6/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15639680 PubMed]
## '''Update:''' Forbes JF, Cuzick J, Buzdar A, Howell A, Tobias JS, Baum M; Arimidex Tamoxifen Alone or in Combination (ATAC) Trialists' Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008 Jan;9(1):45-53. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2807%2970385-6/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18083636 PubMed]
## '''Update:''' Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF; ATAC/LATTE investigators. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010 Dec;11(12):1135-41. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(10)70257-6/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21087898 PubMed]
# '''NSABP B-21:''' Fisher B, Bryant J, Dignam JJ, Wickerham DL, Mamounas EP, Fisher ER, Margolese RG, Nesbitt L, Paik S, Pisansky TM, Wolmark N; National Surgical Adjuvant Breast and Bowel Project. Tamoxifen, radiation therapy, or both for prevention of ipsilateral breast tumor recurrence after lumpectomy in women with invasive breast cancers of one centimeter or less. J Clin Oncol. 2002 Oct 15;20(20):4141-9. [http://ascopubs.org/doi/full/10.1200/JCO.2002.11.101 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12377957 PubMed]
# '''ABCSG-6:''' Schmid M, Jakesz R, Samonigg H, Kubista E, Gnant M, Menzel C, Seifert M, Haider K, Taucher S, Mlineritsch B, Steindorfer P, Kwasny W, Stierer M, Tausch C, Fridrik M, Wette V, Steger G, Hausmaninger H; ABCSG. Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian breast and colorectal cancer study group trial 6. J Clin Oncol. 2003 Mar 15;21(6):984-90. [http://ascopubs.org/doi/full/10.1200/jco.2003.01.138 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12637461 PubMed]
# Assikis V, Buzdar A, Yang Y, Smith T, Theriault R, Booser D, Valero V, Walters R, Singletary E, Ames F, Hortobagyi G. A phase III trial of sequential adjuvant chemotherapy for operable breast carcinoma: final analysis with 10-year follow-up. Cancer. 2003 Jun 1;97(11):2716-23. [https://onlinelibrary.wiley.com/doi/10.1002/cncr.11396/full link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12767083 PubMed]
# '''IES:''' Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, Jones SE, Alvarez I, Bertelli G, Ortmann O, Coates AS, Bajetta E, Dodwell D, Coleman RE, Fallowfield LJ, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Stewart A, Stuart N, Snowdon CF, Carpentieri M, Massimini G, Bliss JM, van de Velde C; Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med. 2004 Mar 11;350(11):1081-92. [https://www.nejm.org/doi/full/10.1056/NEJMoa040331 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15014181 PubMed]
## '''Update:''' Coombes RC, Kilburn LS, Snowdon CF, Paridaens R, Coleman RE, Jones SE, Jassem J, Van de Velde CJ, Delozier T, Alvarez I, Del Mastro L, Ortmann O, Diedrich K, Coates AS, Bajetta E, Holmberg SB, Dodwell D, Mickiewicz E, Andersen J, Lønning PE, Cocconi G, Forbes J, Castiglione M, Stuart N, Stewart A, Fallowfield LJ, Bertelli G, Hall E, Bogle RG, Carpentieri M, Colajori E, Subar M, Ireland E, Bliss JM; Intergroup Exemestane Study. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007 Feb 17;369(9561):559-70. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2807%2960200-1/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17307102 PubMed]
## '''Update:''' Bliss JM, Kilburn LS, Coleman RE, Forbes JF, Coates AS, Jones SE, Jassem J, Delozier T, Andersen J, Paridaens R, van de Velde CJ, Lønning PE, Morden J, Reise J, Cisar L, Menschik T, Coombes RC. Disease-related outcomes with long-term follow-up: an updated analysis of the Intergroup Exemestane Study. J Clin Oncol. 2012 Mar 1;30(7):709-17. Epub 2011 Oct 31. [http://ascopubs.org/doi/full/10.1200/JCO.2010.33.7899 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22042946 PubMed] 
# Fyles AW, McCready DR, Manchul LA, Trudeau ME, Merante P, Pintilie M, Weir LM, Olivotto IA. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med. 2004 Sep 2;351(10):963-70. [https://www.nejm.org/doi/10.1056/NEJMoa040595 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15342804 PubMed]
# '''CALGB 9343:''' Hughes KS, Schnaper LA, Berry D, Cirrincione C, McCormick B, Shank B, Wheeler J, Champion LA, Smith TJ, Smith BL, Shapiro C, Muss HB, Winer E, Hudis C, Wood W, Sugarbaker D, Henderson IC, Norton L; Cancer and Leukemia Group B; Radiation Therapy Oncology Group; Eastern Cooperative Oncology Group. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004 Sep 2;351(10):971-7. [https://www.nejm.org/doi/full/10.1056/NEJMoa040587 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15342805 PubMed]
## '''Update:''' Hughes KS, Schnaper LA, Bellon JR, Cirrincione CT, Berry DA, McCormick B, Muss HB, Smith BL, Hudis CA, Winer EP, Wood WC. Lumpectomy plus tamoxifen with or without irradiation in women age 70 years or older with early breast cancer: long-term follow-up of CALGB 9343. J Clin Oncol. 2013 Jul 1;31(19):2382-7. Epub 2013 May 20. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3691356/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23690420 PubMed]
# '''FASG 08:''' Fargeot P, Bonneterre J, Roché H, Lortholary A, Campone M, Van Praagh I, Monnier A, Namer M, Schraub S, Barats JC, Guastalla JP, Goudier MJ, Chapelle-Marcillac I. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial. J Clin Oncol. 2004 Dec 1;22(23):4622-30. Epub 2004 Oct 25. Erratum in: J Clin Oncol. 2005 Jan 1;23(1):248. [http://ascopubs.org/doi/full/10.1200/JCO.2004.02.145 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15505276 PubMed]
# Rydén L, Jönsson PE, Chebil G, Dufmats M, Fernö M, Jirström K, Källström AC, Landberg G, Stål O, Thorstenson S, Nordenskjöld B; South Swedish Breast Cancer Group; South-East Swedish Breast Cancer Group. Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up. Eur J Cancer. 2005 Jan;41(2):256-64. [https://www.ejcancer.com/article/S0959-8049(04)00565-9/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/15661551 PubMed]
## '''Update:''' Ekholm M, Bendahl PO, Fernö M, Nordenskjöld B, Stål O, Rydén L. Two years of adjuvant tamoxifen provides a survival benefit compared with no systemic treatment in premenopausal patients with primary breast cancer: Long-term follow-up (> 25 years) of the phase III SBII:2pre trial. J Clin Oncol. 2016 Jul 1;34(19):2232-8. Epub 2016 May 9. [http://jco.ascopubs.org/content/34/19/2232.full link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/27161974 PubMed]
# '''Review:''' Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005 May 14-20;365(9472):1687-717. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2805%2966544-0/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15894097 PubMed]
# '''ABCSG-8; ARNO 95:''' Jakesz R, Jonat W, Gnant M, Mittlboeck M, Greil R, Tausch C, Hilfrich J, Kwasny W, Menzel C, Samonigg H, Seifert M, Gademann G, Kaufmann M, Wolfgang J; ABCSG and the GABG. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet. 2005 Aug 6-12;366(9484):455-62. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)67059-6/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16084253 PubMed]
<!-- Presented in part in abstract format at the 42nd Annual Meeting of the American Society of Clinical Oncology, Atlanta, GA, June 2-6, 2006. -->
## '''Update:''' Kaufmann M, Jonat W, Hilfrich J, Eidtmann H, Gademann G, Zuna I, von Minckwitz G. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. J Clin Oncol. 2007 Jul 1;25(19):2664-70. Epub 2007 Jun 11. [http://jco.ascopubs.org/content/25/19/2664.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17563395 PubMed]
<!-- Presented in poster format at the 46th Annual Meeting of the American Society of Clinical Oncology, June 4-8, 2010, Chicago, IL. -->
## '''Update:''' Dubsky PC, Jakesz R, Mlineritsch B, Pöstlberger S, Samonigg H, Kwasny W, Tausch C, Stöger H, Haider K, Fitzal F, Singer CF, Stierer M, Sevelda P, Luschin-Ebengreuth G, Taucher S, Rudas M, Bartsch R, Steger GG, Greil R, Filipcic L, Gnant M. Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group. J Clin Oncol. 2012 Mar 1;30(7):722-8. Epub 2012 Jan 23. [http://ascopubs.org/doi/full/10.1200/JCO.2011.36.8993 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/22271481 PubMed]
# '''INT-0102:''' Hutchins LF, Green SJ, Ravdin PM, Lew D, Martino S, Abeloff M, Lyss AP, Allred C, Rivkin SE, Osborne CK. Randomized, controlled trial of cyclophosphamide, methotrexate, and fluorouracil versus cyclophosphamide, doxorubicin, and fluorouracil with and without tamoxifen for high-risk, node-negative breast cancer: treatment results of Intergroup Protocol INT-0102. J Clin Oncol. 2005 Nov 20;23(33):8313-21. [http://jco.ascopubs.org/content/23/33/8313.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16293862 PubMed]
# '''IBCSG 13-93:''' Colleoni M, Gelber S, Goldhirsch A, Aebi S, Castiglione-Gertsch M, Price KN, Coates AS, Gelber RD; International Breast Cancer Study Group. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J Clin Oncol. 2006 Mar 20;24(9):1332-41. Epub 2006 Feb 27. [http://ascopubs.org/doi/full/10.1200/JCO.2005.03.0783 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/16505417 PubMed]
# '''BIG 1-98:''' Thürlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Rabaglio M, Smith I, Wardley A, Price KN, Goldhirsch A; Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005 Dec 29;353(26):2747-57. Erratum in: N Engl J Med. 2006 May 18;354(20):2200. Wardly, Andrew [corrected to Wardley, Andrew ]. [https://www.nejm.org/doi/full/10.1056/NEJMoa052258 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/16382061 PubMed]
## '''Update:''' Coates AS, Keshaviah A, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens R, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Smith I, Chirgwin J, Nogaret JM, Pienkowski T, Wardley A, Jakobsen EH, Price KN, Goldhirsch A. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol. 2007 Feb 10;25(5):486-92. Epub 2007 Jan 2. [http://jco.ascopubs.org/content/25/5/486.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/17200148 PubMed]
## '''Subgroup analysis:''' Rasmussen BB, Regan MM, Lykkesfeldt AE, Dell'Orto P, Del Curto B, Henriksen KL, Mastropasqua MG, Price KN, Méry E, Lacroix-Triki M, Braye S, Altermatt HJ, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Gusterson BA, Thürlimann B, Coates AS, Viale G; BIG 1-98 Collaborative and International Breast Cancer Study Groups. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol. 2008 Jan;9(1):23-8. Epub 2007 Dec 20. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2807%2970386-8/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18083065 PubMed]
## '''Subgroup analysis:''' Crivellari D, Sun Z, Coates AS, Price KN, Thürlimann B, Mouridsen H, Mauriac L, Forbes JF, Paridaens RJ, Castiglione-Gertsch M, Gelber RD, Colleoni M, Láng I, Del Mastro L, Gladieff L, Rabaglio M, Smith IE, Chirgwin JH, Goldhirsch A. Letrozole compared with tamoxifen for elderly patients with endocrine-responsive early breast cancer: the BIG 1-98 trial. J Clin Oncol. 2008 Apr 20;26(12):1972-9. Epub 2008 Mar 10. [http://jco.ascopubs.org/content/26/12/1972.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18332471 PubMed]
## '''Update:''' Mouridsen H, Giobbie-Hurder A, Goldhirsch A, Thürlimann B, Paridaens R, Smith I, Mauriac L, Forbes J, Price KN, Regan MM, Gelber RD, Coates AS; BIG 1-98 Collaborative Group. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 2009 Aug 20;361(8):766-76. [https://www.nejm.org/doi/10.1056/NEJMoa0810818 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2921823/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/19692688 PubMed]
## '''Update:''' Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, Smith I, Láng I, Wardley A, Rabaglio M, Price KN, Gelber RD, Coates AS, Thürlimann B; BIG 1-98 Collaborative Group; International Breast Cancer Study Group (IBCSG). Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up. Lancet Oncol. 2011 Nov;12(12):1101-8. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70270-4/abstract link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3235950/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22018631 PubMed]
## '''Update:''' Ruhstaller T, Giobbie-Hurder A, Colleoni M, Jensen MB, Ejlertsen B, de Azambuja E, Neven P, Láng I, Jakobsen EH, Gladieff L, Bonnefoi H, Harvey VJ, Spazzapan S, Tondini C, Del Mastro L, Veyret C, Simoncini E, Gianni L, Rochlitz C, Kralidis E, Zaman K, Jassem J, Piccart-Gebhart M, Di Leo A, Gelber RD, Coates AS, Goldhirsch A, Thürlimann B, Regan MM; members of the BIG 1-98 Collaborative Group and the International Breast Cancer Study Group. Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial. J Clin Oncol. 2018 Nov 26:JCO1800440. [Epub ahead of print] [http://ascopubs.org/doi/full/10.1200/JCO.18.00440 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/30475668 PubMed]
# '''FASG 02; FASG 07:''' Namer M, Fargeot P, Roché H, Campone M, Kerbrat P, Romestaing P, Monnier A, Luporsi E, Montcuquet P, Bonneterre J; French Adjuvant Study Group. Improved disease-free survival with epirubicin-based chemoendocrine adjuvant therapy compared with tamoxifen alone in one to three node-positive, estrogen-receptor-positive, postmenopausal breast cancer patients: results of French Adjuvant Study Group 02 and 07 trials. Ann Oncol. 2006 Jan;17(1):65-73. [https://academic.oup.com/annonc/article/17/1/65/160873 link to original article] '''contains article''' [https://www.ncbi.nlm.nih.gov/pubmed/16361531 PubMed]
# Morales L, Canney P, Dyczka J, Rutgers E, Coleman R, Cufer T, Welnicka-Jaskiewicz M, Nortier J, Bogaerts J, Therasse P, Paridaens R; European Organisation for Research and Treatment of Cancer Breast Group; Scottish Breast Cancer Trials Group. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group. Eur J Cancer. 2007 Jan;43(2):331-40. Epub 2006 Nov 28. [https://www.ejcancer.com/article/S0959-8049(06)00908-7/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17134892 PubMed]
# '''DBCG 89C:''' Andersen J, Kamby C, Ejlertsen B, Cold S, Ewertz M, Jacobsen EH, Philip P, Møller KA, Jensen D, Møller S. Tamoxifen for one year versus two years versus 6 months of Tamoxifen and 6 months of megestrol acetate: a randomized comparison in postmenopausal patients with high-risk breast cancer (DBCG 89C). Acta Oncol. 2008;47(4):718-24. [https://www.tandfonline.com/doi/full/10.1080/02841860802014882 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18465340 PubMed]
<!-- Presented in part in abstract format in the Breast Cancer Research Treatment 100:S22, 2006 (suppl; abstr A40). -->
# '''NSABP B-33:''' Mamounas EP, Jeong JH, Wickerham DL, Smith RE, Ganz PA, Land SR, Eisen A, Fehrenbacher L, Farrar WB, Atkins JN, Pajon ER, Vogel VG, Kroener JF, Hutchins LF, Robidoux A, Hoehn JL, Ingle JN, Geyer CE Jr, Costantino JP, Wolmark N. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. J Clin Oncol. 2008 Apr 20;26(12):1965-71. Epub 2008 Mar 10. [http://jco.ascopubs.org/content/26/12/1965.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18332472 PubMed]
# '''SWOG-8814:''' Albain KS, Barlow WE, Ravdin PM, Farrar WB, Burton GV, Ketchel SJ, Cobau CD, Levine EG, Ingle JN, Pritchard KI, Lichter AS, Schneider DJ, Abeloff MD, Henderson IC, Muss HB, Green SJ, Lew D, Livingston RB, Martino S, Osborne CK; Breast Cancer Intergroup of North America. Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009 Dec 19;374(9707):2055-2063. Epub 2009 Dec 10. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)61523-3/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3140679/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20004966 PubMed]
# '''N-SAS BC03:''' Aihara T, Takatsuka Y, Ohsumi S, Aogi K, Hozumi Y, Imoto S, Mukai H, Iwata H, Watanabe T, Shimizu C, Nakagami K, Tamura M, Ito T, Masuda N, Ogino N, Hisamatsu K, Mitsuyama S, Abe H, Tanaka S, Yamaguchi T, Ohashi Y. Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study. Breast Cancer Res Treat. 2010 Jun;121(2):379-87. [https://link.springer.com/article/10.1007%2Fs10549-010-0888-x link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20390343 PubMed]
# '''ECOG EB193:''' Rao RD, Cobleigh MA, Gray R, Graham ML 2nd, Norton L, Martino S, Budd GT, Ingle JN, Wood WC. Phase III double-blind, placebo-controlled, prospective randomized trial of adjuvant tamoxifen vs tamoxifen and fenretinide in postmenopausal women with positive receptors (EB193): an intergroup trial coordinated by the Eastern Cooperative Oncology Group. Med Oncol. 2011 Dec;28 Suppl 1:S39-47. Epub 2010 Sep 28. [https://link.springer.com/article/10.1007%2Fs12032-010-9682-1 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4947231/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/20878269 PubMed]
# '''TEAM:''' van de Velde CJ, Rea D, Seynaeve C, Putter H, Hasenburg A, Vannetzel JM, Paridaens R, Markopoulos C, Hozumi Y, Hille ET, Kieback DG, Asmar L, Smeets J, Nortier JW, Hadji P, Bartlett JM, Jones SE. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet. 2011 Jan 22;377(9762):321-31. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)62312-4/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/21247627 PubMed]
## '''Update:''' Derks MGM, Blok EJ, Seynaeve C, Nortier JWR, Kranenbarg EM, Liefers GJ, Putter H, Kroep JR, Rea D, Hasenburg A, Markopoulos C, Paridaens R, Smeets JBE, Dirix LY, van de Velde CJH. Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2017 Sep;18(9):1211-1220. Epub 2017 Jul 18. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30419-9/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/28732650 PubMed]
# '''NCIC CTG MA.14:''' Pritchard KI, Shepherd LE, Chapman JA, Norris BD, Cantin J, Goss PE, Dent SF, Walde D, Vandenberg TA, Findlay B, O'Reilly SE, Wilson CF, Han L, Piura E, Whelan TJ, Pollak MN. Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14. J Clin Oncol. 2011 Oct 10;29(29):3869-76. Epub 2011 Sep 12. [http://ascopubs.org/doi/full/10.1200/JCO.2010.33.7006 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/21911723 PubMed]
## '''Update:''' Chapman JA, Costantino JP, Dong B, Margolese RG, Pritchard KI, Shepherd LE, Gelmon KA, Wolmark N, Pollak MN. Octreotide LAR and tamoxifen versus tamoxifen in phase III randomize early breast cancer trials: NCIC CTG MA.14 and NSABP B-29. Breast Cancer Res Treat. 2015 Sep;153(2):353-60. Epub 2015 Aug 15. [http://link.springer.com/article/10.1007%2Fs10549-015-3547-4 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4681581/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/26276354 PubMed]
# '''ATLAS:''' Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, Abraham M, Medeiros Alencar VH, Badran A, Bonfill X, Bradbury J, Clarke M, Collins R, Davis SR, Delmestri A, Forbes JF, Haddad P, Hou MF, Inbar M, Khaled H, Kielanowska J, Kwan WH, Mathew BS, Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet. 2013 Mar 9;381(9869):805-16. Erratum in: Lancet. 2013 Mar 9;381(9869):804. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(12)61963-1/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3596060/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/23219286 PubMed]
# '''TEXT/SOFT:''' Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA; TEXT and SOFT Investigators; International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014 Jul 10;371(2):107-18. Epub 2014 Jun 1. [https://www.nejm.org/doi/full/10.1056/NEJMoa1404037 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4175521/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24881463 PubMed]
## '''Update:''' Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, Bonnefoi HR, Climent MA, Da Prada GA, Burstein HJ, Martino S, Davidson NE, Geyer CE Jr, Walley BA, Coleman R, Kerbrat P, Buchholz S, Ingle JN, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Colleoni M, Viale G, Coates AS, Goldhirsch A, Gelber RD; SOFT Investigators; International Breast Cancer Study Group. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015 Jan 29;372(5):436-46. Epub 2014 Dec 11. [https://www.nejm.org/doi/full/10.1056/NEJMoa1412379 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4341825/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25495490 PubMed]
# '''ECOG E-3193:''' Tevaarwerk AJ, Wang M, Zhao F, Fetting JH, Cella D, Wagner LI, Martino S, Ingle JN, Sparano JA, Solin LJ, Wood WC, Robert NJ. Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2014 Dec 10;32(35):3948-58. Epub 2014 Oct 27. [http://ascopubs.org/doi/full/10.1200/JCO.2014.55.6993 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251958/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25349302 PubMed]
# '''CBC 02:''' Jensen MB, Krarup JF, Palshof T, Mouridsen HT, Ejlertsen B. Two years of tamoxifen or no adjuvant systemic therapy for patients with high-risk breast cancer: long-term follow-up of the Copenhagen Breast Cancer Trial. Acta Oncol. 2018 Jan;57(1):26-30. Epub 2017 Nov 22. [http://www.tandfonline.com/doi/full/10.1080/0284186X.2017.1400179 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29165021 PubMed]
# '''FATA-GIM3:''' De Placido S, Gallo C, De Laurentiis M, Bisagni G, Arpino G, Sarobba MG, Riccardi F, Russo A, Del Mastro L, Cogoni AA, Cognetti F, Gori S, Foglietta J, Frassoldati A, Amoroso D, Laudadio L, Moscetti L, Montemurro F, Verusio C, Bernardo A, Lorusso V, Gravina A, Moretti G, Lauria R, Lai A, Mocerino C, Rizzo S, Nuzzo F, Carlini P, Perrone F; GIM Investigators. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial. Lancet Oncol. 2018 Apr;19(4):474-485. Epub 2018 Feb 23. Erratum in: Lancet Oncol. 2018 Apr;19(4):e184. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30116-5/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29482983 PubMed]

==Tamoxifen & OFS {{#subobject:97a16d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
Tamoxifen & OFS: Tamoxifen & OFS: '''<u>O</u>'''varian '''<u>F</u>'''unction '''<u>S</u>'''uppression
===Variant #1, 3 years {{#subobject:de0411|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/10.1056/NEJMoa0806285 Gnant et al. 2009 (ABCSG-12)]
| style="background-color:#1a9851" |Phase III (C)
|Tamoxifen, OFS, Zoledronic acid
| style="background-color:#d73027" |Inferior DFS
|-
|}
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Hormonotherapy====
*[[Tamoxifen (Nolvadex)]] 20 mg PO once per day
====Supportive medications====
*[[Goserelin (Zoladex)]] 3.6 mg SC once every 28 days

'''3-year course'''

===Variant #2, 5 years {{#subobject:4656a6|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 20%"|Study
!style="width: 20%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 20%"|Comparator
!style="width: 20%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
!style="width: 20%"|[[Levels_of_Evidence#Toxicity|Toxicity]]
|-
| rowspan="2" |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4175521/ Pagani et al. 2014 (TEXT)]
| rowspan="2" style="background-color:#1a9851" |Phase III (E)
|1. [[#Exemestane_monotherapy|Exemestane & OFS]]
| style="background-color:#d73027" |Inferior DFS
|
|-
|2. [[#Tamoxifen_monotherapy|Tamoxifen]]
| style="background-color:#d9ef8b" |Might have superior DFS (*)
|
|-
| rowspan="2" |[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4175521/ Pagani et al. 2014 (SOFT)]
| rowspan="2" style="background-color:#1a9851" |Phase III (E)
|1. [[#Exemestane_monotherapy|Exemestane & OFS]]
| style="background-color:#d73027" |Inferior DFS
|
|-
|2. [[#Tamoxifen_monotherapy|Tamoxifen]]
| style="background-color:#d9ef8b" |Might have superior DFS (*)
|
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251958/ Tevaarwerk et al. 2014 (ECOG E-3193)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Tamoxifen_monotherapy|Tamoxifen]]
| style="background-color:#ffffbf" |Seems not superior
| style="background-color:#d73027" |More menopausal symptoms
|-
|}
''These regimens are intended for premenopausal patients. Pagani et al. 2014 reports on two trials, but only '''SOFT''' had the tamoxifen only arm; efficacy for this arm is as reported in Francis et al. 2015.''
====Hormonotherapy====
*[[Tamoxifen (Nolvadex)]] 20 mg PO once per day
====Supportive medications====
*Ovarian function suppression as follows:
**'''TEXT''': [[Triptorelin (Trelstar LA)]] 3.75 mg IM every 28 days
***"[[Endocrine_ablation_surgery#Bilateral_oophorectomy|Bilateral oophorectomy]] or [[External beam radiotherapy|ovarian irradiation]] was allowed after at least 6 months of triptorelin."
**'''SOFT''': Choice of mechanism left to investigators

'''5 years of therapy'''

===References===
# '''ABCSG-12:''' Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C, Jakesz R, Seifert M, Hubalek M, Bjelic-Radisic V, Samonigg H, Tausch C, Eidtmann H, Steger G, Kwasny W, Dubsky P, Fridrik M, Fitzal F, Stierer M, Rücklinger E, Marth C, Greil R; ABCSG-12 Trial Investigators. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009 Feb 12;360(7):679-91. Erratum in: N Engl J Med. 2009 May 28;360(22):2379. [https://www.nejm.org/doi/10.1056/NEJMoa0806285 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19213681 PubMed]
## '''Update:''' Gnant M, Mlineritsch B, Stoeger H, Luschin-Ebengreuth G, Heck D, Menzel C, Jakesz R, Seifert M, Hubalek M, Pristauz G, Bauernhofer T, Eidtmann H, Eiermann W, Steger G, Kwasny W, Dubsky P, Hochreiner G, Forsthuber EP, Fesl C, Greil R; Austrian Breast and Colorectal Cancer Study Group. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol. 2011 Jul;12(7):631-41. Epub 2011 Jun 5. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(11)70122-X/fulltext linkt o original article] [https://www.ncbi.nlm.nih.gov/pubmed/21641868 PubMed]
# '''TEXT/SOFT:''' Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Bernhard J, Luo W, Ribi K, Viale G, Coates AS, Gelber RD, Goldhirsch A, Francis PA; TEXT and SOFT Investigators; International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014 Jul 10;371(2):107-18. Epub 2014 Jun 1. [https://www.nejm.org/doi/full/10.1056/NEJMoa1404037 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4175521/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24881463 PubMed]
## '''Update:''' Francis PA, Regan MM, Fleming GF, Láng I, Ciruelos E, Bellet M, Bonnefoi HR, Climent MA, Da Prada GA, Burstein HJ, Martino S, Davidson NE, Geyer CE Jr, Walley BA, Coleman R, Kerbrat P, Buchholz S, Ingle JN, Winer EP, Rabaglio-Poretti M, Maibach R, Ruepp B, Giobbie-Hurder A, Price KN, Colleoni M, Viale G, Coates AS, Goldhirsch A, Gelber RD; SOFT Investigators; International Breast Cancer Study Group. Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015 Jan 29;372(5):436-46. Epub 2014 Dec 11. [https://www.nejm.org/doi/full/10.1056/NEJMoa1412379 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4341825/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25495490 PubMed]
# '''ECOG E-3193:''' Tevaarwerk AJ, Wang M, Zhao F, Fetting JH, Cella D, Wagner LI, Martino S, Ingle JN, Sparano JA, Solin LJ, Wood WC, Robert NJ. Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2014 Dec 10;32(35):3948-58. Epub 2014 Oct 27. [http://ascopubs.org/doi/full/10.1200/JCO.2014.55.6993 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251958/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/25349302 PubMed]

==Toremifene monotherapy {{#subobject:4feb63|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:b872bf|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://link.springer.com/article/10.1007%2Fs12282-012-0394-6 Kimura et al. 2012]
| style="background-color:#1a9851" |Phase III (E)
|[[#Tamoxifen_monotherapy|Tamoxifen]]
| style="background-color:#eeee01" |Non-inferior OS
|-
|}
====Preceding treatment====
*[[Surgery#Breast_cancer_surgery|Surgery]]
====Hormonotherapy====
*[[Toremifene (Fareston)]] 40 mg PO once per day

'''2-year course'''
===References===
# Kimura M, Tominaga T, Kimijima I, Takatsuka Y, Takashima S, Nomura Y, Kasumi F, Yamaguchi A, Masuda N, Noguchi S, Eshima N. Phase III randomized trial of toremifene versus tamoxifen for Japanese postmenopausal patients with early breast cancer. Breast Cancer. 2014 May;21(3):275-83. Epub 2012 Sep 12. [https://link.springer.com/article/10.1007%2Fs12282-012-0394-6 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22968626 PubMed]

=Metastatic disease, first-line endocrine therapy=
==Abemaciclib & Anastrozole {{#subobject:213a4e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:c0e636|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2017.75.6155 Goetz et al. 2017 (MONARCH 3)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Anastrozole_monotherapy_3|Anastrozole]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
====Chemohormonotherapy====
*[[Abemaciclib (Verzenio)]] 150 mg PO twice per day
*[[Anastrozole (Arimidex)]] 1 mg PO once per day

'''28-day cycles'''

===References===
# '''MONARCH 3:''' Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, Park IH, Trédan O, Chen SC, Manso L, Freedman OC, Garnica Jaliffe G, Forrester T, Frenzel M, Barriga S, Smith IC, Bourayou N, Di Leo A. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017 Nov 10;35(32):3638-3646. Epub 2017 Oct 2. [http://ascopubs.org/doi/full/10.1200/JCO.2017.75.6155 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28968163 PubMed]

==Abemaciclib & Letrozole {{#subobject:cb27ef|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:e434e3|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2017.75.6155 Goetz et al. 2017 (MONARCH 3)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Letrozole_monotherapy_3|Letrozole]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
====Chemohormonotherapy====
*[[Abemaciclib (Verzenio)]] 150 mg PO twice per day
*[[Letrozole (Femara)]] 2.5 mg PO once per day

'''28-day cycles'''

===References===
# '''MONARCH 3:''' Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, Park IH, Trédan O, Chen SC, Manso L, Freedman OC, Garnica Jaliffe G, Forrester T, Frenzel M, Barriga S, Smith IC, Bourayou N, Di Leo A. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017 Nov 10;35(32):3638-3646. Epub 2017 Oct 2. [http://ascopubs.org/doi/full/10.1200/JCO.2017.75.6155 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28968163 PubMed]

==Anastrozole monotherapy {{#subobject:796bb|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:bd033c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2000.18.22.3748 Bonneterre et al. 2000 (TARGET)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Tamoxifen_monotherapy_2|Tamoxifen]]
| style="background-color:#eeee01" |Equivalent TTP
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2000.18.22.3758 Nabholtz et al. 2000 (Arimidex Study Group)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Tamoxifen_monotherapy_2|Tamoxifen]]
| style="background-color:#1a9850" |Superior TTP
|-
|[https://insights.ovid.com/pubmed?pmid=12796608 Milla-Santos et al. 2003]
| style="background-color:#1a9851" |Phase III (E)
|[[#Tamoxifen_monotherapy_2|Tamoxifen]]
| style="background-color:#1a9850" |Superior OS
|-
|[http://ascopubs.org/doi/10.1200/JCO.2008.20.6847 Kaufman et al. 2009 (TAnDEM)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Anastrozole_.26_Trastuzumab|Anastrozole & Trastuzumab]]
| style="background-color:#d73027" |Inferior PFS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2011.38.1095 Bergh et al. 2012 (FACT)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Anastrozole_.26_Fulvestrant|Anastrozole & Fulvestrant]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3951300/ Mehta et al. 2012 (SWOG S0226)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Anastrozole_.26_Fulvestrant|Anastrozole & Fulvestrant]]
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3669502/ Iwata et al. 2013]
| style="background-color:#1a9851" |Phase III (C)
|[[#Exemestane_monotherapy_2|Exemestane]]
| style="background-color:#ffffbf" |Inconclusive whether non-inferior
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)32389-3/fulltext Robertson et al. 2016 (FALCON)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Fulvestrant_monotherapy|Fulvestrant]]
| style="background-color:#fc8d59" |Seems to have inferior PFS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2017.75.6155 Goetz et al. 2017 (MONARCH 3)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Abemaciclib_.26_Anastrozole|Abemaciclib & Anastrozole]]
| style="background-color:#d73027" |Inferior PFS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30292-4/fulltext Tripathy et al. 2018 (MONALEESA-7)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Anastrozole_.26_Ribociclib|Anastrozole & Ribociclib]]
| style="background-color:#d73027" |Inferior PFS
|-
|}
''Note: TAnDEM enrolled patients who were HER2+ and ER/PR-positive.''
====Hormonotherapy====
*[[Anastrozole (Arimidex)]] 1 mg PO once per day
====Supportive medications====
*For premenopausal patients:
**'''MONALEESA-7:''' [[Goserelin (Zoladex)]] 3.6 mg SC once every 28 days

'''Continued indefinitely'''

===References===
# '''TARGET:''' Bonneterre J, Thürlimann B, Robertson JF, Krzakowski M, Mauriac L, Koralewski P, Vergote I, Webster A, Steinberg M, von Euler M. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol. 2000 Nov 15;18(22):3748-57. Erratum in: J Clin Oncol. 2012 Jan 20;30(3):343. [http://ascopubs.org/doi/full/10.1200/JCO.2000.18.22.3748 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11078487 PubMed]
# '''Arimidex Study Group:''' Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A, von Euler M. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial; Arimidex Study Group. J Clin Oncol. 2000 Nov 15;18(22):3758-67. [http://ascopubs.org/doi/full/10.1200/JCO.2000.18.22.3758 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11078488 PubMed]
# Milla-Santos A, Milla L, Portella J, Rallo L, Pons M, Rodes E, Casanovas J, Puig-Gali M. Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study. Am J Clin Oncol. 2003 Jun;26(3):317-22. [https://insights.ovid.com/pubmed?pmid=12796608 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12796608 PubMed]
# '''TAnDEM:''' Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Feyereislova A, Révil C, Jones A. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol. 2009 Nov 20;27(33):5529-37. Epub 2009 Sep 28. [http://ascopubs.org/doi/10.1200/JCO.2008.20.6847 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19786670 PubMed]
# '''FACT:''' Bergh J, Jönsson PE, Lidbrink EK, Trudeau M, Eiermann W, Brattström D, Lindemann JP, Wiklund F, Henriksson R. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol. 2012 Jun 1;30(16):1919-25. Epub 2012 Feb 27. [http://ascopubs.org/doi/full/10.1200/JCO.2011.38.1095 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22370325 PubMed]
# '''SWOG S0226:''' Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Lew DL, Hayes DF, Gralow JR, Livingston RB, Hortobagyi GN. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med. 2012 Aug 2;367(5):435-44. [https://www.nejm.org/doi/full/10.1056/NEJMoa1201622 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3951300/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22853014 PubMed]
# Iwata H, Masuda N, Ohno S, Rai Y, Sato Y, Ohsumi S, Hashigaki S, Nishizawa Y, Hiraoka M, Morimoto T, Sasano H, Saeki T, Noguchi S. A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer. Breast Cancer Res Treat. 2013 Jun;139(2):441-51. Epub 2013 May 30. [https://link.springer.com/article/10.1007%2Fs10549-013-2573-3 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3669502/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23715630 PubMed]
# '''FALCON:''' Robertson JF, Bondarenko IM, Trishkina E, Dvorkin M, Panasci L, Manikhas A, Shparyk Y, Cardona-Huerta S, Cheung KL, Philco-Salas MJ, Ruiz-Borrego M, Shao Z, Noguchi S, Rowbottom J, Stuart M, Grinsted LM, Fazal M, Ellis MJ. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2016 Dec 17;388(10063):2997-3005. Epub 2016 Nov 28. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)32389-3/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27908454 PubMed]
# '''MONARCH-3:''' Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, Park IH, Trédan O, Chen SC, Manso L, Freedman OC, Garnica Jaliffe G, Forrester T, Frenzel M, Barriga S, Smith IC, Bourayou N, Di Leo A. MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017 Nov 10;35(32):3638-3646. Epub 2017 Oct 2. [http://ascopubs.org/doi/full/10.1200/JCO.2017.75.6155 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28968163 PubMed]
<!-- # '''Abstract:''' Tripathy D, Sohn J, Im S-A, Colleoni M, Franke F, Bardia A, Harbeck N, Hurvitz S, Chow L, Lee KS, Campos-Gomez S, Villanueva Vazquez R, Jung KH, Carlson G, Hughes G, Diaz-Padilla I, Germa C, Hirawat S, Lu Y-S. First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial. 2017 Dec SABCS Abstract 828 [http://www.abstracts2view.com/sabcs/view.php?nu=SABCS17L_828 link to abstract] '''contains protocol''' -->
# '''MONALEESA-7:''' Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, Hurvitz SA, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva Vazquez R, Jung KH, Babu KG, Wheatley-Price P, De Laurentiis M, Im YH, Kuemmel S, El-Saghir N, Liu MC, Carlson G, Hughes G, Diaz-Padilla I, Germa C, Hirawat S, Lu YS. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018 Jul;19(7):904-915. Epub 2018 May 24. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30292-4/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29804902 PubMed]

==Anastrozole & Fulvestrant {{#subobject:c3bc6e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:7ef8ed|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2011.38.1095 Bergh et al. 2012 (FACT)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Anastrozole_monotherapy_3|Anastrozole]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3951300/ Mehta et al. 2012 (SWOG S0226)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Anastrozole_monotherapy_3|Anastrozole]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|}
====Hormonotherapy====
*[[Anastrozole (Arimidex)]] 1 mg PO once per day
*[[Fulvestrant (Faslodex)]] 500 mg IM once on day 1, then 250 mg IM once per day on days 14 & 28, then 250 mg IM once every four weeks
**Patients in '''SWOG S0226''' who progressed while on therapy were allowed to receive a higher dose, 500 mg IM once every four weeks

'''28-day cycles'''

===References===
# '''FACT:''' Bergh J, Jönsson PE, Lidbrink EK, Trudeau M, Eiermann W, Brattström D, Lindemann JP, Wiklund F, Henriksson R. FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol. 2012 Jun 1;30(16):1919-25. Epub 2012 Feb 27. [http://ascopubs.org/doi/full/10.1200/JCO.2011.38.1095 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22370325 PubMed]
# '''SWOG S0226:''' Mehta RS, Barlow WE, Albain KS, Vandenberg TA, Dakhil SR, Tirumali NR, Lew DL, Hayes DF, Gralow JR, Livingston RB, Hortobagyi GN. Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med. 2012 Aug 2;367(5):435-44. [https://www.nejm.org/doi/full/10.1056/NEJMoa1201622 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3951300/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/22853014 PubMed]

==Anastrozole & Ribociclib {{#subobject:443971|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:d9afb9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30292-4/fulltext Tripathy et al. 2018 (MONALEESA-7)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Anastrozole_monotherapy_3|Anastrozole]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
====Chemohormonotherapy====
*[[Anastrozole (Arimidex)]] 1 mg PO once per day
*[[Ribociclib (Kisqali)]] 600 mg PO once per day on days 1 to 21
====Supportive medications====
*[[Goserelin (Zoladex)]] 3.6 mg SC once every 28 days

'''28-day cycles'''

===References===
<!-- # '''Abstract:''' Tripathy D, Sohn J, Im S-A, Colleoni M, Franke F, Bardia A, Harbeck N, Hurvitz S, Chow L, Lee KS, Campos-Gomez S, Villanueva Vazquez R, Jung KH, Carlson G, Hughes G, Diaz-Padilla I, Germa C, Hirawat S, Lu Y-S. First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial. 2017 Dec SABCS Abstract 828 [http://www.abstracts2view.com/sabcs/view.php?nu=SABCS17L_828 link to abstract] '''contains protocol''' -->
# '''MONALEESA-7:''' Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, Hurvitz SA, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva Vazquez R, Jung KH, Babu KG, Wheatley-Price P, De Laurentiis M, Im YH, Kuemmel S, El-Saghir N, Liu MC, Carlson G, Hughes G, Diaz-Padilla I, Germa C, Hirawat S, Lu YS. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018 Jul;19(7):904-915. Epub 2018 May 24. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30292-4/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29804902 PubMed]

==Exemestane monotherapy {{#subobject:d17b4d|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:babfaa|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2652082/ Paridaens et al. 2008]
| style="background-color:#1a9851" |Phase III (E)
|[[#Tamoxifen_monotherapy_2|Tamoxifen]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3669502/ Iwata et al. 2013]
| style="background-color:#1a9851" |Phase III (C)
|[[#Anastrozole_monotherapy_3|Anastrozole]]
| style="background-color:#ffffbf" |Inconclusive whether non-inferior
|-
|}
====Hormonotherapy====
*[[Exemestane (Aromasin)]] 25 mg PO once per day

'''Continued indefinitely'''

===References===
# Paridaens RJ, Dirix LY, Beex LV, Nooij M, Cameron DA, Cufer T, Piccart MJ, Bogaerts J, Therasse P. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol. 2008 Oct 20;26(30):4883-90. Epub 2008 Sep 15. [http://ascopubs.org/doi/full/10.1200/JCO.2007.14.4659 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2652082/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18794551 PubMed]
# Iwata H, Masuda N, Ohno S, Rai Y, Sato Y, Ohsumi S, Hashigaki S, Nishizawa Y, Hiraoka M, Morimoto T, Sasano H, Saeki T, Noguchi S. A randomized, double-blind, controlled study of exemestane versus anastrozole for the first-line treatment of postmenopausal Japanese women with hormone-receptor-positive advanced breast cancer. Breast Cancer Res Treat. 2013 Jun;139(2):441-51. Epub 2013 May 30. [https://link.springer.com/article/10.1007%2Fs10549-013-2573-3 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3669502/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23715630 PubMed]

==Fulvestrant monotherapy {{#subobject:da9e37|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 250 mg {{#subobject:addae5|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2014.57.2388 Martín et al. 2015 (LEA)]
| style="background-color:#1a9851" |Phase III (C)
|Fulvestrant & Bevacizumab
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Hormonotherapy====
*[[Fulvestrant (Faslodex)]] 250 mg IM once on day 1

'''28-day cycles'''

===Variant #2, 500 mg {{#subobject:e6f584|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/22/9/1605.long Howell et al. 2004]
| style="background-color:#1a9851" |Phase III (E)
|[[#Tamoxifen_monotherapy_2|Tamoxifen]]
| style="background-color:#fee08b" |Might have inferior TTP
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2018.78.9909 Slamon et al. 2018 (MONALEESA-3)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Fulvestrant_.26_Ribociclib|Fulvestrant & Ribociclib]]
| style="background-color:#d73027" |Inferior PFS
|-
|}
====Hormonotherapy====
*[[Fulvestrant (Faslodex)]] as follows:
**Cycle 1: 500 mg IM once per day on days 1 & 15
**Cycle 2 onwards: 500 mg IM once on day 1

'''28-day cycles'''

===References===
# Howell A, Robertson JF, Abram P, Lichinitser MR, Elledge R, Bajetta E, Watanabe T, Morris C, Webster A, Dimery I, Osborne CK. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol. 2004 May 1;22(9):1605-13. [http://jco.ascopubs.org/content/22/9/1605.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15117982 PubMed]
# '''LEA:''' Martín M, Loibl S, von Minckwitz G, Morales S, Martinez N, Guerrero A, Anton A, Aktas B, Schoenegg W, Muñoz M, Garcia-Saenz JÁ, Gil M, Ramos M, Margeli M, Carrasco E, Liedtke C, Wachsmann G, Mehta K, de la Haba-Rodríguez J. Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study. J Clin Oncol. 2015 Mar 20;33(9):1045-52. Epub 2015 Feb 17. [http://ascopubs.org/doi/full/10.1200/JCO.2014.57.2388 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25691671 PubMed]
# '''MONALEESA-3:''' Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martín M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Pivot X, Vidam G, Wang Y, Rodriguez Lorenc K, Miller M, Taran T, Jerusalem G. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018 Aug 20;36(24):2465-2472. Epub 2018 Jun 3. [http://ascopubs.org/doi/full/10.1200/JCO.2018.78.9909 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29860922 PubMed]

==Fulvestrant & Ribociclib {{#subobject:f6031e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:310fb1|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2018.78.9909 Slamon et al. 2018 (MONALEESA-3)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Fulvestrant_monotherapy|Fulvestrant]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
====Chemohormonotherapy====
*[[Fulvestrant (Faslodex)]] as follows:
**Cycle 1: 500 mg IM once per day on days 1 & 15
**Cycle 2 onwards: 500 mg IM once on day 1
*[[Ribociclib (Kisqali)]] 600 mg PO once per day on days 1 to 21

'''28-day cycles'''

===References===
# '''MONALEESA-3:''' Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martín M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Pivot X, Vidam G, Wang Y, Rodriguez Lorenc K, Miller M, Taran T, Jerusalem G. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018 Aug 20;36(24):2465-2472. Epub 2018 Jun 3. [http://ascopubs.org/doi/full/10.1200/JCO.2018.78.9909 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29860922 PubMed]

==Goserelin & Tamoxifen {{#subobject:46ef1e|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:644f0d|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ejcancer.com/article/0959-8049(94)00415-2/pdf Jonat et al. 1995]
| style="background-color:#1a9851" |Phase III (E)
|Goserelin
| style="background-color:#91cf60" |Seems to have superior TTP
|-
|}
====Hormonotherapy====
*[[Goserelin (Zoladex)]]
*[[Tamoxifen (Nolvadex)]]

===References===
# Jonat W, Kaufmann M, Blamey RW, Howell A, Collins JP, Coates A, Eiermann W, Jänicke F, Njordenskold B, Forbes JF, Kolvenbag GJCM. A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer. Eur J Cancer. 1995;31A(2):137-42. [https://www.ejcancer.com/article/0959-8049(94)00415-2/pdf link to original article] [PubMed https://www.ncbi.nlm.nih.gov/pubmed/7718316]

==Letrozole monotherapy {{#subobject:75d541|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:d7ef99|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/10.1200/JCO.2001.19.10.2596 Mouridsen et al. 2001 (ILBCG)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Tamoxifen_monotherapy_2|Tamoxifen]]
| style="background-color:#1a9850" |Superior TTP
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2006.09.5455 Goss et al. 2007]
|style="background-color:#1a9851"|Phase III (C)
|Atamestane & Toremifene
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/10.1200/JCO.2009.23.3734 Johnston et al. 2009 (EGF30008)]
|style="background-color:#1a9851"|Phase III (C)
|[[#Lapatinib_.26_Letrozole|Lapatinib & Letrozole]]
| style="background-color:#fc8d59" |Seems to have inferior PFS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3532391/ Wolff et al. 2012 (HORIZON)]
| style="background-color:#1a9851" |Phase III (C)
|Letrozole & Temsirolimus
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2814%2971159-3/abstract Finn et al. 2015 (PALOMA-1/TRIO-18)]
| style="background-color:#1a9851" |Randomized Phase II (C)
|[[#Letrozole_.26_Palbociclib|Letrozole & Palbociclib]]
| style="background-color:#d73027" |Inferior PFS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2014.57.2388 Martín et al. 2015 (LEA)]
| style="background-color:#1a9851" |Phase III (C)
|Letrozole & Bevacizumab
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5012690/ Dickler et al. 2016 (CALGB 40503)]
| style="background-color:#1a9851" |Phase III (C)
|Letrozole & Bevacizumab
| style="background-color:#fc8d59" |Seems to have inferior PFS
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1609709 Hortobagyi et al. 2016 (MONALEESA-2)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Letrozole_.26_Ribociclib|Letrozole & Ribociclib]]
| style="background-color:#d73027" |Inferior PFS
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1607303 Finn et al. 2016 (PALOMA-2)]
| style="background-color:#1a9851" |Randomized Phase II (C)
|[[#Letrozole_.26_Palbociclib|Letrozole & Palbociclib]]
| style="background-color:#d73027" |Inferior PFS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2017.75.6155 Goetz et al. 2017 (MONARCH 3)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Abemaciclib_.26_Letrozole|Abemaciclib & Letrozole]]
| style="background-color:#d73027" |Inferior PFS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30292-4/fulltext Tripathy et al. 2018 (MONALEESA-7)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Letrozole_.26_Ribociclib|Letrozole & Ribociclib]]
| style="background-color:#d73027" |Inferior PFS
|-
|}
''Note: EGF30008 enrolled patients who were HER2+ and ER/PR-positive.''
====Hormonotherapy====
*[[Letrozole (Femara)]] 2.5 mg PO once per day
====Supportive medications====
*For premenopausal patients:
**'''MONALEESA-7:''' [[Goserelin (Zoladex)]] 3.6 mg SC once every 28 days

'''Continued indefinitely'''

===References===
# '''ILBCG:''' Mouridsen H, Gershanovich M, Sun Y, Pérez-Carrión R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jänicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Lassus M, Verbeek JA, Staffler B, Chaudri-Ross HA, Dugan M. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol. 2001 May 15;19(10):2596-606. Erratum in: J Clin Oncol 2001 Jul 1;19(13):3302. [http://ascopubs.org/doi/10.1200/JCO.2001.19.10.2596 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11352951 PubMed]
## '''Update:''' Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jaenicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Chaudri-Ross H, Lang R, Wyld P, Bhatnagar A. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol. 2003 Jun 1;21(11):2101-9. [http://ascopubs.org/doi/full/10.1200/JCO.2003.04.194 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12775735 PubMed]
# Goss P, Bondarenko IN, Manikhas GN, Pendergrass KB, Miller WH Jr, Langecker P, Blanchett D. Phase III, double-blind, controlled trial of atamestane plus toremifene compared with letrozole in postmenopausal women with advanced receptor-positive breast cancer. J Clin Oncol. 2007 Nov 1;25(31):4961-6. [http://ascopubs.org/doi/full/10.1200/JCO.2006.09.5455 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17971594 PubMed]
# '''EGF30008:''' Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O'Rourke L, Oliva C, Stein S, Pegram M. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2009 Nov 20;27(33):5538-46. Epub 2009 Sep 28. [http://ascopubs.org/doi/10.1200/JCO.2009.23.3734 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19786658 PubMed]
# '''HORIZON:''' Wolff AC, Lazar AA, Bondarenko I, Garin AM, Brincat S, Chow L, Sun Y, Neskovic-Konstantinovic Z, Guimaraes RC, Fumoleau P, Chan A, Hachemi S, Strahs A, Cincotta M, Berkenblit A, Krygowski M, Kang LL, Moore L, Hayes DF. Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol. 2013 Jan 10;31(2):195-202. Epub 2012 Dec 10. [http://ascopubs.org/doi/full/10.1200/JCO.2011.38.3331 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3532391/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23233719 PubMed]
# '''PALOMA-1/TRIO-18:''' Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, Shparyk Y, Thummala AR, Voytko NL, Fowst C, Huang X, Kim ST, Randolph S, Slamon DJ. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015 Jan;16(1):25-35. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2814%2971159-3/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25524798 PubMed]
# '''LEA:''' Martín M, Loibl S, von Minckwitz G, Morales S, Martinez N, Guerrero A, Anton A, Aktas B, Schoenegg W, Muñoz M, Garcia-Saenz JÁ, Gil M, Ramos M, Margeli M, Carrasco E, Liedtke C, Wachsmann G, Mehta K, de la Haba-Rodríguez J. Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer: the letrozole/fulvestrant and avastin (LEA) study. J Clin Oncol. 2015 Mar 20;33(9):1045-52. Epub 2015 Feb 17. [http://ascopubs.org/doi/full/10.1200/JCO.2014.57.2388 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25691671 PubMed]
<!-- Presented in part at the 51st Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 29-June 2, 2015. -->
# '''CALGB 40503:''' Dickler MN, Barry WT, Cirrincione CT, Ellis MJ, Moynahan ME, Innocenti F, Hurria A, Rugo HS, Lake DE, Hahn O, Schneider BP, Tripathy D, Carey LA, Winer EP, Hudis CA. Phase III trial evaluating letrozole as first-line endocrine therapy with or without bevacizumab for the treatment of postmenopausal women with hormone receptor-positive advanced-stage breast cancer: CALGB 40503 (Alliance). J Clin Oncol. 2016 Aug 1;34(22):2602-9. Epub 2016 May 2. [http://jco.ascopubs.org/content/34/22/2602.full link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5012690/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/27138575 PubMed]
# '''MONALEESA-2:''' Hortobagyi GN, Stemmer SM, Burris HA 3rd, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, André F, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Petrakova K, Hart LL, Villanueva C, Chan A, Jakobsen E, Nusch A, Burdaeva O, Grischke EM, Alba E, Wist E, Marschner N, Favret AM, Yardley D, Bachelot T, Tseng LM, Blau S, Xuan F, Souami F, Miller M, Germa C, Hirawat S, O'Shaughnessy J. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016 Nov 3;375(18):1738-1748. Epub 2016 Oct 7.[https://www.nejm.org/doi/full/10.1056/NEJMoa1609709 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27717303 PubMed]
## '''Subgroup analysis:''' Sonke GS, Hart LL, Campone M, Erdkamp F, Janni W, Verma S, Villanueva C, Jakobsen E, Alba E, Wist E, Favret AM, Bachelot T, Hegg R, Wheatley-Price P, Souami F, Sutradhar S, Miller M, Germa C, Burris HA. Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial. Breast Cancer Res Treat. 2018 Feb;167(3):659-669. Epub 2017 Oct 22. [https://link.springer.com/article/10.1007%2Fs10549-017-4523-y link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5807486/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/29058175 PubMed]
## '''Update:''' Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, Blackwell KL, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Mondal S, Su F, Miller M, Elmeliegy M, Germa C, O'Shaughnessy J. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018 Jul 1;29(7):1541-1547. [https://academic.oup.com/annonc/article/29/7/1541/4989216 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29718092 PubMed]
# '''PALOMA-2:''' Finn RS, Martín M, Rugo HS, Jones S, Im SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, Gauthier E, Lu DR, Randolph S, Diéras V, Slamon DJ. Palbociclib and letrozole in advanced breast cancer. N Engl J Med. 2016 Nov 17;375(20):1925-1936. [https://www.nejm.org/doi/full/10.1056/NEJMoa1607303 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27959613 PubMed]
# '''MONARCH 3:''' Goetz MP, Toi M, Campone M, Sohn J, Paluch-Shimon S, Huober J, Park IH, Trédan O, Chen SC, Manso L, Freedman OC, Garnica Jaliffe G, Forrester T, Frenzel M, Barriga S, Smith IC, Bourayou N, Di Leo A. MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol. 2017 Nov 10;35(32):3638-3646. Epub 2017 Oct 2. [http://ascopubs.org/doi/full/10.1200/JCO.2017.75.6155 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28968163 PubMed]
<!-- # '''Abstract:''' Tripathy D, Sohn J, Im S-A, Colleoni M, Franke F, Bardia A, Harbeck N, Hurvitz S, Chow L, Lee KS, Campos-Gomez S, Villanueva Vazquez R, Jung KH, Carlson G, Hughes G, Diaz-Padilla I, Germa C, Hirawat S, Lu Y-S. First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial. 2017 Dec SABCS Abstract 828 [http://www.abstracts2view.com/sabcs/view.php?nu=SABCS17L_828 link to abstract] '''contains protocol''' -->
# '''MONALEESA-7:''' Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, Hurvitz SA, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva Vazquez R, Jung KH, Babu KG, Wheatley-Price P, De Laurentiis M, Im YH, Kuemmel S, El-Saghir N, Liu MC, Carlson G, Hughes G, Diaz-Padilla I, Germa C, Hirawat S, Lu YS. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018 Jul;19(7):904-915. Epub 2018 May 24. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30292-4/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29804902 PubMed]

==Letrozole & Palbociclib {{#subobject:da6f2|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:d4d90|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2814%2971159-3/abstract Finn et al. 2015 (PALOMA-1/TRIO-18)]
| style="background-color:#1a9851" |Randomized Phase II (E)
|[[#Letrozole_monotherapy_3|Letrozole]]
| style="background-color:#1a9850" |Superior PFS
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1607303 Finn et al. 2016 (PALOMA-2)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Letrozole_monotherapy_3|Letrozole]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
====Chemohormonotherapy====
*[[Letrozole (Femara)]] 2.5 mg PO once per day
*[[Palbociclib (Ibrance)]] 125 mg PO once per day on days 1 to 21

'''28-day cycles'''

===References===
# '''PALOMA-1/TRIO-18:''' Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel R, Pinter T, Schmidt M, Shparyk Y, Thummala AR, Voytko NL, Fowst C, Huang X, Kim ST, Randolph S, Slamon DJ. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. Lancet Oncol. 2015 Jan;16(1):25-35. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045%2814%2971159-3/abstract link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25524798 PubMed]
# '''PALOMA-2:''' Finn RS, Martín M, Rugo HS, Jones S, Im SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, Gauthier E, Lu DR, Randolph S, Diéras V, Slamon DJ. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016 Nov 17;375(20):1925-1936. [https://www.nejm.org/doi/full/10.1056/NEJMoa1607303 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27959613 PubMed]

==Letrozole & Ribociclib {{#subobject:b27d88|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:66fc2e|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1609709 Hortobagyi et al. 2016 (MONALEESA-2)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Letrozole_monotherapy_3|Letrozole]]
| style="background-color:#1a9850" |Superior PFS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30292-4/fulltext Tripathy et al. 2018 (MONALEESA-7)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Letrozole_monotherapy_3|Letrozole]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
====Chemohormonotherapy====
*[[Letrozole (Femara)]] 2.5 mg PO once per day
*[[Ribociclib (Kisqali)]] 600 mg PO once per day on days 1 to 21
====Supportive medications====
*For premenopausal patients:
**'''MONALEESA-7:''' [[Goserelin (Zoladex)]] 3.6 mg SC once every 28 days

'''28-day cycles'''

===References===
# '''MONALEESA-2:''' Hortobagyi GN, Stemmer SM, Burris HA 3rd, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Blackwell KL, André F, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Petrakova K, Hart LL, Villanueva C, Chan A, Jakobsen E, Nusch A, Burdaeva O, Grischke EM, Alba E, Wist E, Marschner N, Favret AM, Yardley D, Bachelot T, Tseng LM, Blau S, Xuan F, Souami F, Miller M, Germa C, Hirawat S, O'Shaughnessy J. Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med. 2016 Nov 3;375(18):1738-1748. Epub 2016 Oct 7. [https://www.nejm.org/doi/full/10.1056/NEJMoa1609709 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27717303 PubMed]
## '''Subgroup analysis:''' Sonke GS, Hart LL, Campone M, Erdkamp F, Janni W, Verma S, Villanueva C, Jakobsen E, Alba E, Wist E, Favret AM, Bachelot T, Hegg R, Wheatley-Price P, Souami F, Sutradhar S, Miller M, Germa C, Burris HA. Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial. Breast Cancer Res Treat. 2018 Feb;167(3):659-669. Epub 2017 Oct 22. [https://link.springer.com/article/10.1007%2Fs10549-017-4523-y link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5807486/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/29058175 PubMed]
## '''Update:''' Hortobagyi GN, Stemmer SM, Burris HA, Yap YS, Sonke GS, Paluch-Shimon S, Campone M, Petrakova K, Blackwell KL, Winer EP, Janni W, Verma S, Conte P, Arteaga CL, Cameron DA, Mondal S, Su F, Miller M, Elmeliegy M, Germa C, O'Shaughnessy J. Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol. 2018 Jul 1;29(7):1541-1547. [https://academic.oup.com/annonc/article/29/7/1541/4989216 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29718092 PubMed]
<!-- # '''Abstract:''' Tripathy D, Sohn J, Im S-A, Colleoni M, Franke F, Bardia A, Harbeck N, Hurvitz S, Chow L, Lee KS, Campos-Gomez S, Villanueva Vazquez R, Jung KH, Carlson G, Hughes G, Diaz-Padilla I, Germa C, Hirawat S, Lu Y-S. First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial. 2017 Dec SABCS Abstract 828 [http://www.abstracts2view.com/sabcs/view.php?nu=SABCS17L_828 link to abstract] '''contains protocol''' -->
# '''MONALEESA-7:''' Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, Hurvitz SA, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva Vazquez R, Jung KH, Babu KG, Wheatley-Price P, De Laurentiis M, Im YH, Kuemmel S, El-Saghir N, Liu MC, Carlson G, Hughes G, Diaz-Padilla I, Germa C, Hirawat S, Lu YS. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018 Jul;19(7):904-915. Epub 2018 May 24. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30292-4/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29804902 PubMed]

==Ribociclib & Tamoxifen {{#subobject:93f428|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:e86701|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30292-4/fulltext Tripathy et al. 2018 (MONALEESA-7)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Tamoxifen_monotherapy_2|Tamoxifen]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
====Chemohormonotherapy====
*[[Tamoxifen (Nolvadex)]] 20 mg PO once per day
*[[Ribociclib (Kisqali)]] 600 mg PO once per day on days 1 to 21
====Supportive medications====
*[[Goserelin (Zoladex)]] 3.6 mg SC once on day 1

'''28-day cycles'''

===References===
<!-- # '''Abstract:''' Tripathy D, Sohn J, Im S-A, Colleoni M, Franke F, Bardia A, Harbeck N, Hurvitz S, Chow L, Lee KS, Campos-Gomez S, Villanueva Vazquez R, Jung KH, Carlson G, Hughes G, Diaz-Padilla I, Germa C, Hirawat S, Lu Y-S. First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial. 2017 Dec SABCS Abstract 828 [http://www.abstracts2view.com/sabcs/view.php?nu=SABCS17L_828 link to abstract] '''contains protocol''' -->
# '''MONALEESA-7:''' Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, Hurvitz SA, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva Vazquez R, Jung KH, Babu KG, Wheatley-Price P, De Laurentiis M, Im YH, Kuemmel S, El-Saghir N, Liu MC, Carlson G, Hughes G, Diaz-Padilla I, Germa C, Hirawat S, Lu YS. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018 Jul;19(7):904-915. Epub 2018 May 24. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30292-4/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29804902 PubMed]

==Tamoxifen monotherapy {{#subobject:dffabd|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 20 mg/day {{#subobject:497965|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJM198101013040104 Ingle et al. 1981]
| style="background-color:#1a9851" |Phase III (E)
|[[Breast_cancer_-_historical#DES_monotherapy|DES]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1976875/ Bratherton et al. 1984]
| style="background-color:#1a9851" |Phase III (C)
|Tamoxifen 40 mg/d
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1986.4.6.958 Ingle et al. 1986]
| style="background-color:#1a9851" |Phase III (C)
|Aminoglutethemide, Hydrocortisone, Tamoxifen
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(88)91478-X/fulltext Gazet et al. 1988]
| style="background-color:#1a9851" |Phase III (E)
|Surgery
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1988.6.5.825 Ingle et al. 1988]
| style="background-color:#1a9851" |Phase III (C)
|Fluoxymesterone & Tamoxifen
| style="background-color:#fc8d59" |Seems to have inferior TTP (*)
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1988.6.7.1098 Muss et al. 1988]
| style="background-color:#1a9851" |Phase III (C)
|[[Breast_cancer_-_historical#Megestrol_acetate_monotherapy|Megestrol acetate]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246832/ Rubens et al. 1988]
| style="background-color:#1a9851" |Phase III (C)
|Tamoxifen & Prednisolone
| style="background-color:#fc8d59" |Seems to have inferior OS
|-
|[https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(19910701)68:1%3C34::AID-CNCR2820680107%3E3.0.CO;2-Q Ingle et al. 1991]
| style="background-color:#1a9851" |Phase III (C)
|Tamoxifen & Prednisolone
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://academic.oup.com/annonc/article-abstract/4/9/735/170824 Castiglione-Gertsch et al. 1993]
| style="background-color:#1a9851" |Phase III (C)
|[[Breast_cancer_-_historical#Megestrol_acetate_monotherapy|Megestrol acetate]]
| style="background-color:#fee08b" |Might have inferior TTP
|-
|[http://ascopubs.org/doi/abs/10.1200/JCO.1994.12.10.2071 Borner et al. 1994 (SAKK 23/82)]
| style="background-color:#1a9851" |Phase III (E)
|Observation
| style="background-color:#d9ef8b" |Might have superior DFS (*)
|-
| rowspan="2" |[http://jco.ascopubs.org/content/13/10/2556.long Hayes et al. 1995]
| rowspan="2" style="background-color:#1a9851" |Phase III (C)
|1. [[#Toremifene_monotherapy|Toremifene 60 mg per day]]
| style="background-color:#ffffbf" |Seems not superior
|-
|2. Toremifene 200 mg per day
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://academic.oup.com/annonc/article/7/5/471/153004 Thürlimann et al. 1996 (SAKK 20/88)]
| style="background-color:#1a9851" |Phase III (C)
|Fadrozole
| style="background-color:#d9ef8b" |Might have superior TTTF
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2000.18.22.3748 Bonneterre et al. 2000 (TARGET)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Anastrozole_monotherapy_3|Anastrozole]]
| style="background-color:#eeee01" |Equivalent TTP
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2000.18.22.3758 Nabholtz et al. 2000 (Arimidex Study Group)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Anastrozole_monotherapy_3|Anastrozole]]
| style="background-color:#d73027" |Inferior TTP
|-
|[http://ascopubs.org/doi/10.1200/JCO.2001.19.10.2596 Mouridsen et al. 2001 (ILBCG)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Letrozole_monotherapy_3|Letrozole]]
| style="background-color:#d73027" |Inferior TTP
|-
|[https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.10239 Bajetta et al. 2002]
| style="background-color:#1a9851" |Phase III (C)
|Octreotide LAR & Tamoxifen
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://link.springer.com/article/10.1023/A:1015229630260 Buzdar et al. 2002]
| style="background-color:#1a9851" |Phase III (C)
|Droloxifene
| style="background-color:#1a9850" |Superior TTP
|-
|[http://jco.ascopubs.org/content/22/9/1605.long Howell et al. 2004]
| style="background-color:#1a9851" |Phase III (C)
|[[#Fulvestrant_monotherapy|Fulvestrant]]
| style="background-color:#d9ef8b" |Might have superior TTP
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2006.09.5992 Deshmane et al. 2007]
| style="background-color:#1a9851" |Phase III (C)
|Arzoxifene
| style="background-color:#1a9850" |Superior PFS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2652082/ Paridaens et al. 2008]
| style="background-color:#1a9851" |Phase III (C)
|[[#Exemestane_monotherapy_2|Exemestane]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30292-4/fulltext Tripathy et al. 2018 (MONALEESA-7)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Ribociclib_.26_Tamoxifen|Ribociclib & Tamoxifen]]
| style="background-color:#d73027" |Inferior PFS
|-
|}
''Note: patients in Gazet et al. 1988 had resectable disease but did not undergo surgery in this arm. Reported efficacy for Ingle et al. 1988 is based on the 1991 update. Patients in SAKK 23/82 had isolated locoregional recurrence; reported efficacy is based on the 2003 update.''
====Hormonotherapy====
*[[Tamoxifen (Nolvadex)]] 20 mg PO once per day
**Some earlier trials used 10 mg PO twice per day instead

====Supportive medications====
*For premenopausal patients:
**MONALEESA-7: [[Goserelin (Zoladex)]] 3.6 mg SC once every 28 days

'''Continued indefinitely'''

===Variant #2, 30 mg/day {{#subobject:de3bbg|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://link.springer.com/article/10.1007/BF01812683 Gundersen et al. 1990]
| style="background-color:#1a9851" |Phase III (C)
|Tamoxifen/MPA
| style="background-color:#fc8d59" |Seems to have inferior ORR
|-
|}
====Hormonotherapy====
*[[Tamoxifen (Nolvadex)]] 30 mg PO once per day

'''Continued indefinitely'''

===Variant #3, 40 mg/day {{#subobject:de3aaf|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.ncbi.nlm.nih.gov/pubmed/191185 Morgan et al. 1976]
| style="background-color:#91cf61" |Non-randomized
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://annals.org/aim/fullarticle/691616/tamoxifen-antiestrogen-therapy-advanced-breast-cancer Kiang et al. 1977]
| style="background-color:#91cf61" |Non-randomized
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1976875/ Bratherton et al. 1984]
| style="background-color:#1a9851" |Phase III (E)
|Tamoxifen 20 mg/d
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(19860701)58:1%3C7::AID-CNCR2820580103%3E3.0.CO;2-%23 van Veelen et al. 1986]
| style="background-color:#1a9851" |Phase III (E)
|[[Breast_cancer_-_historical#Medroxyprogesterone_acetate_monotherapy|MPA]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://ascopubs.org/doi/pdf/10.1200/JCO.1986.4.9.1326 Buchanan et al. 1986]
| style="background-color:#1a9851" |Phase III (E)
|Oophorectomy
| style="background-color:#d9ef8b" |Might have superior PFS
|-
|[https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(19871115)60:10%3C2376::AID-CNCR2820601005%3E3.0.CO;2-N Kellokumpu-Lehtinen et al. 1987]
| style="background-color:#1a9851" |Phase III (C)
|Nandrolone
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://academic.oup.com/annonc/article-abstract/4/9/741/170864 Gill et al. 1993]
| style="background-color:#1a9851" |Phase III (C)
|1. [[Breast_cancer_-_historical#Megestrol_acetate_monotherapy|Megestrol acetate]]<br> 2. Megestrol acetate & Tamoxifen
| style="background-color:#ffffbf" |Seems not superior
|-
| rowspan="2" |[http://www.springerlink.com/content/pg25l5346057212u/ Gershanovich et al. 1997]
| rowspan="2" style="background-color:#1a9851" |Phase III (C)
|1. [[#Toremifene_monotherapy|Toremifene 60 mg per day]]
| style="background-color:#ffffbf" |Seems not superior
|-
|2. Toremifene 240 mg per day
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2223944/ Pyrhönen et al. 1997]
| style="background-color:#1a9851" |Phase III (C)
|[[#Toremifene_monotherapy|Toremifene 60 mg per day]]
| style="background-color:#91cf60" |Seems to have superior TTP
|-
|[https://www.ejcancer.com/article/S0959-8049(06)00765-9/fulltext Beex et al. 2006 (EORTC 10863)]
| style="background-color:#1a9851" |Phase III (C)
|1. Intermittent Tamoxifen<br> 2. Intermittent Tamoxifen/MPA
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Hormonotherapy====
*[[Tamoxifen (Nolvadex)]] 40 mg PO once per day
**Some earlier trials used 20 mg PO twice per day instead

'''Continued indefinitely'''

===References===
# Morgan LR Jr, Schein PS, Woolley PV, Hoth D, Macdonald J, Lippman M, Posey LE, Beazley RW. Therapeutic use of tamoxifen in advanced breast cancer: correlation with biochemical parameters. Cancer Treat Rep. 1976 Oct;60(10):1437-43. [https://www.ncbi.nlm.nih.gov/pubmed/191185 PubMed]
# Kiang DT, Kennedy BJ. Tamoxifen (antiestrogen) therapy in advanced breast cancer. Ann Intern Med. 1977 Dec;87(6):687-90. [http://annals.org/aim/fullarticle/691616/tamoxifen-antiestrogen-therapy-advanced-breast-cancer link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/931204 PubMed]
# Ingle JN, Ahmann DL, Green SJ, Edmonson JH, Bisel HF, Kvols LK, Nichols WC, Creagan ET, Hahn RG, Rubin J, Frytak S. Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med. 1981 Jan 1;304(1):16-21. [https://www.nejm.org/doi/full/10.1056/NEJM198101013040104 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/7001242 PubMed]
# Bratherton DG, Brown CH, Buchanan R, Hall V, Kingsley Pillers EM, Wheeler TK, Williams CJ. A comparison of two doses of tamoxifen (Nolvadex) in postmenopausal women with advanced breast cancer: 10 mg bd versus 20 mg bd. Br J Cancer. 1984 Aug;50(2):199-205. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1976875/ link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/6380554 PubMed]
# Ingle JN, Green SJ, Ahmann DL, Long HJ, Edmonson JH, Rubin J, Chang MN, Creagan ET. Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer. J Clin Oncol. 1986 Jun;4(6):958-64. [http://ascopubs.org/doi/abs/10.1200/JCO.1986.4.6.958 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/3519885 PubMed]
# van Veelen H, Willemse PH, Tjabbes T, Schweitzer MJ, Sleijfer DT. Oral high-dose medroxyprogesterone acetate versus tamoxifen: a randomized crossover trial in postmenopausal patients with advanced breast cancer. Cancer. 1986 Jul 1;58(1):7-13. [https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(19860701)58:1%3C7::AID-CNCR2820580103%3E3.0.CO;2-%23 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/2939943 PubMed]
# Buchanan RB, Blamey RW, Durrant KR, Howell A, Paterson AG, Preece PE, Smith DC, Williams CJ, Wilson RG. A randomized comparison of tamoxifen with surgical oophorectomy in premenopausal patients with advanced breast cancer. J Clin Oncol. 1986 Sep;4(9):1326-30. [http://ascopubs.org/doi/abs/10.1200/JCO.1986.4.9.1326 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/3528402 PubMed]
# Kellokumpu-Lehtinen P, Huovinen R, Johansson R. Hormonal treatment of advanced breast cancer: a randomized trial of tamoxifen versus nandrolone decanoate. Cancer. 1987 Nov 15;60(10):2376-81. [https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(19871115)60:10%3C2376::AID-CNCR2820601005%3E3.0.CO;2-N link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/3664426 PubMed]
# Gazet JC, Markopoulos C, Ford HT, Coombes RC, Bland JM, Dixon RC. Prospective randomised trial of tamoxifen versus surgery in elderly patients with breast cancer. Lancet. 1988 Mar 26;1(8587):679-81. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(88)91478-X/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/2895214 PubMed]
# Ingle JN, Twito DI, Schaid DJ, Cullinan SA, Krook JE, Mailliard JA, Marschke RF, Long HJ, Gerstner JG, Windschitl HE, Everson LK, Pfeifle DM. Randomized clinical trial of tamoxifen alone or combined with fluoxymesterone in postmenopausal women with metastatic breast cancer. J Clin Oncol. 1988 May;6(5):825-31. [http://ascopubs.org/doi/abs/10.1200/JCO.1988.6.5.825 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/3284975 PubMed]
## '''Update:''' Ingle JN, Twito DI, Schaid DJ, Cullinan SA, Krook JE, Mailliard JA, Tschetter LK, Long HJ, Gerstner JG, Windschitl HE, Levitt R, Pfeifle DM. Combination hormonal therapy with tamoxifen plus fluoxymesterone versus tamoxifen alone in postmenopausal women with metastatic breast cancer: an updated analysis. Cancer. 1991 Feb 15;67(4):886-91. [https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(19910215)67:4%3C886::AID-CNCR2820670405%3E3.0.CO;2-O link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/1991261 PubMed]
# Muss HB, Wells HB, Paschold EH, Black WR, Cooper MR, Capizzi RL, Christian R, Cruz JM, Jackson DV, Powell BL, Richards F, White DR, Zekan PJ, Spurr CL, Pope E, Case D, Morgan TM. Megestrol acetate versus tamoxifen in advanced breast cancer: 5-year analysis--a phase III trial of the Piedmont Oncology Association. J Clin Oncol. 1988 Jul;6(7):1098-106. [http://ascopubs.org/doi/abs/10.1200/JCO.1988.6.7.1098 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/3292710 PubMed]
# Rubens RD, Tinson CL, Coleman RE, Knight RK, Tong D, Winter PJ, North WR. Prednisolone improves the response to primary endocrine treatment for advanced breast cancer. Br J Cancer. 1988 Nov;58(5):626-30. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2246832/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/3219274 PubMed]
# Gundersen S, Kvinnsland S, Lundgren S, Klepp O, Lund E, Børmer O, Høst H. Cyclical use of tamoxifen and high-dose medroxyprogesterone acetate in advanced estrogen receptor positive breast cancer. Breast Cancer Res Treat. 1990 Nov;17(1):45-50. [https://link.springer.com/article/10.1007/BF01812683 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/2151369 PubMed]
# Ingle JN, Mailliard JA, Schaid DJ, Krook JE, Gesme DH Jr, Windschitl HE, Pfeifle DM, Etzell PS, Gerstner JG, Long HJ, Foley JF, Loprinzi CL, Dalton RJ. A double-blind trial of tamoxifen plus prednisolone versus tamoxifen plus placebo in postmenopausal women with metastatic breast cancer: a collaborative trial of the North Central Cancer Treatment Group and Mayo Clinic. Cancer. 1991 Jul 1;68(1):34-9. [https://onlinelibrary.wiley.com/doi/abs/10.1002/1097-0142(19910701)68:1%3C34::AID-CNCR2820680107%3E3.0.CO;2-Q link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/2049750 PubMed]
# Castiglione-Gertsch M, Pampallona S, Varini M, Cavalli F, Brunner K, Senn HJ, Goldhirsch A, Metzger U. Primary endocrine therapy for advanced breast cancer: to start with tamoxifen or with medroxyprogesterone acetate?. Ann Oncol. 1993 Nov;4(9):735-40. [https://academic.oup.com/annonc/article-abstract/4/9/735/170824 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8280653 PubMed]
# Gill PG, Gebski V, Snyder R, Burns I, Levi J, Byrne M, Coates A. Randomized comparison of the effects of tamoxifen, megestrol acetate, or tamoxifen plus megestrol acetate on treatment response and survival in patients with metastatic breast cancer. Ann Oncol. 1993 Nov;4(9):741-4. [https://academic.oup.com/annonc/article-abstract/4/9/741/170864 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8280654 PubMed]
# '''SAKK 23/82:''' Borner M, Bacchi M, Goldhirsch A, Greiner R, Harder F, Castiglione M, Jungi WF, Thürlimann B, Cavalli F, Obrecht JP, Leyvraz S, Alberto P, Adam H, Varini M, Loehnert T, Senn HJ, Metzger U, Brunner K; Swiss Group for Clinical Cancer Research. First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. J Clin Oncol. 1994 Oct;12(10):2071-7. [http://ascopubs.org/doi/abs/10.1200/JCO.1994.12.10.2071 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/7931476 PubMed]
## '''Update:''' Waeber M, Castiglione-Gertsch M, Dietrich D, Thürlimann B, Goldhirsch A, Brunner KW, Borner MM; Swiss Group for Clinical Cancer Research (SAKK). Adjuvant therapy after excision and radiation of isolated postmastectomy locoregional breast cancer recurrence: definitive results of a phase III randomized trial (SAKK 23/82) comparing tamoxifen with observation. Ann Oncol. 2003 Aug;14(8):1215-21. [https://academic.oup.com/annonc/article/14/8/1215/170810 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12881382 PubMed]
# Hayes DF, Van Zyl JA, Hacking A, Goedhals L, Bezwoda WR, Mailliard JA, Jones SE, Vogel CL, Berris RF, Shemano I, Schoenfelder J. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol. 1995 Oct;13(10):2556-66. [http://jco.ascopubs.org/content/13/10/2556.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/7595707 PubMed]
# '''SAKK 20/88:''' Thürlimann B, Beretta K, Bacchi M, Castiglione-Gertsch M, Goldhirsch A, Jungi WF, Cavalli F, Senn HJ, Fey M, Löhnert T. First-line fadrozole HCI (CGS 16949A) versus tamoxifen in postmenopausal women with advanced breast cancer: prospective randomised trial of the Swiss Group for Clinical Cancer Research SAKK 20/88. Ann Oncol. 1996 Jul;7(5):471-9. [https://academic.oup.com/annonc/article/7/5/471/153004 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8839901 PubMed] 
# Gershanovich M, Garin A, Baltina D, Kurvet A, Kangas L, Ellmén J; Eastern European Study Group. A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Breast Cancer Res Treat. 1997 Sep;45(3):251-62. [http://www.springerlink.com/content/pg25l5346057212u/ link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/9386869 PubMed]
# Pyrhönen S, Valavaara R, Modig H, Pawlicki M, Pienkowski T, Gundersen S, Bauer J, Westman G, Lundgren S, Blanco G, Mella O, Nilsson I, Hietanen T, Hindy I, Vuorinen J, Hajba A. Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'Nordic' phase III study. Br J Cancer. 1997;76(2):270-7. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2223944/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/9231932 PubMed]
# '''TARGET:''' Bonneterre J, Thürlimann B, Robertson JF, Krzakowski M, Mauriac L, Koralewski P, Vergote I, Webster A, Steinberg M, von Euler M. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol. 2000 Nov 15;18(22):3748-57. Erratum in: J Clin Oncol. 2012 Jan 20;30(3):343. [http://ascopubs.org/doi/full/10.1200/JCO.2000.18.22.3748 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11078487 PubMed]
# '''Arimidex Study Group:''' Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A, von Euler M; Arimidex Study Group. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. J Clin Oncol. 2000 Nov 15;18(22):3758-67. [http://ascopubs.org/doi/full/10.1200/JCO.2000.18.22.3758 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/11078488 PubMed]
# '''ILBCG:''' Mouridsen H, Gershanovich M, Sun Y, Pérez-Carrión R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jänicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Lassus M, Verbeek JA, Staffler B, Chaudri-Ross HA, Dugan M. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol. 2001 May 15;19(10):2596-606. Erratum in: J Clin Oncol 2001 Jul 1;19(13):3302. [http://ascopubs.org/doi/10.1200/JCO.2001.19.10.2596 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11352951 PubMed]
## '''Update:''' Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, Apffelstaedt J, Smith R, Sleeboom HP, Jaenicke F, Pluzanska A, Dank M, Becquart D, Bapsy PP, Salminen E, Snyder R, Chaudri-Ross H, Lang R, Wyld P, Bhatnagar A. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol. 2003 Jun 1;21(11):2101-9. [http://ascopubs.org/doi/full/10.1200/JCO.2003.04.194 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12775735 PubMed]
# Bajetta E, Procopio G, Ferrari L, Martinetti A, Zilembo N, Catena L, Alú M, Della TS, Alberti D, Buzzoni R. A randomized, multicenter prospective trial assessing long-acting release octreotide pamoate plus tamoxifen as a first line therapy for advanced breast carcinoma. Cancer. 2002 Jan 15;94(2):299-304. [https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.10239 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11900215 PubMed]
# Buzdar A, Hayes D, El-Khoudary A, Yan S, Lønning P, Lichinitser M, Gopal R, Falkson G, Pritchard K, Lipton A, Wolter K, Lee A, Fly K, Chew R, Alderdice M, Burke K, Eisenber P; Droloxifene 301 Study Group. Phase III randomized trial of droloxifene and tamoxifen as first-line endocrine treatment of ER/PgR-positive advanced breast cancer. Breast Cancer Res Treat. 2002 May;73(2):161-75. [https://link.springer.com/article/10.1023/A:1015229630260 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12088118 PubMed]
# Howell A, Robertson JF, Abram P, Lichinitser MR, Elledge R, Bajetta E, Watanabe T, Morris C, Webster A, Dimery I, Osborne CK. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial. J Clin Oncol. 2004 May 1;22(9):1605-13. [http://jco.ascopubs.org/content/22/9/1605.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15117982 PubMed]
# '''EORTC 10863:''' Beex L, Rose C, Mouridsen H, Jassem J, Nooij M, Estape J, Paridaens R, Piccart M, Gorlia T, Lardenoije S, Baila L. Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: an EORTC phase III study (10863). Eur J Cancer. 2006 Dec;42(18):3178-85. Epub 2006 Oct 12. [https://www.ejcancer.com/article/S0959-8049(06)00765-9/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17045796 PubMed]
# Deshmane V, Krishnamurthy S, Melemed AS, Peterson P, Buzdar AU. Phase III double-blind trial of arzoxifene compared with tamoxifen for locally advanced or metastatic breast cancer. J Clin Oncol. 2007 Nov 1;25(31):4967-73. [http://ascopubs.org/doi/full/10.1200/JCO.2006.09.5992 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17971595 PubMed]
# Paridaens RJ, Dirix LY, Beex LV, Nooij M, Cameron DA, Cufer T, Piccart MJ, Bogaerts J, Therasse P. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol. 2008 Oct 20;26(30):4883-90. Epub 2008 Sep 15. [http://ascopubs.org/doi/full/10.1200/JCO.2007.14.4659 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2652082/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/18794551 PubMed]
<!-- Presented in part at the 33rd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-12, 2010, and 2011 European Multidisciplinary Cancer Congress, Stockholm, Sweden, September 23-27, 2011. -->
<!-- # '''Abstract:''' Tripathy D, Sohn J, Im S-A, Colleoni M, Franke F, Bardia A, Harbeck N, Hurvitz S, Chow L, Lee KS, Campos-Gomez S, Villanueva Vazquez R, Jung KH, Carlson G, Hughes G, Diaz-Padilla I, Germa C, Hirawat S, Lu Y-S. First-line ribociclib vs placebo with goserelin and tamoxifen or a non-steroidal aromatase inhibitor in premenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer: Results from the randomized phase III MONALEESA-7 trial. 2017 Dec SABCS Abstract 828 [http://www.abstracts2view.com/sabcs/view.php?nu=SABCS17L_828 link to abstract] '''contains protocol''' -->
# '''MONALEESA-7:''' Tripathy D, Im SA, Colleoni M, Franke F, Bardia A, Harbeck N, Hurvitz SA, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva Vazquez R, Jung KH, Babu KG, Wheatley-Price P, De Laurentiis M, Im YH, Kuemmel S, El-Saghir N, Liu MC, Carlson G, Hughes G, Diaz-Padilla I, Germa C, Hirawat S, Lu YS. Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol. 2018 Jul;19(7):904-915. Epub 2018 May 24. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(18)30292-4/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29804902 PubMed]

==Toremifene monotherapy {{#subobject:eeba1|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:32e0dd|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
| rowspan="2" |[http://jco.ascopubs.org/content/13/10/2556.long Hayes et al. 1995]
| rowspan="2" style="background-color:#1a9851" |Phase III (E)
|1. [[#Tamoxifen_monotherapy_2|Tamoxifen]]
| style="background-color:#ffffbf" |Seems not superior
|-
|2. Toremifene 200 mg per day
| style="background-color:#ffffbf" |Seems not superior
|-
| rowspan="2" |[http://www.springerlink.com/content/pg25l5346057212u/ Gershanovich et al. 1997]
| rowspan="2" style="background-color:#1a9851" |Phase III (E)
|1. [[#Tamoxifen_monotherapy_2|Tamoxifen 40 mg per day]]
| style="background-color:#ffffbf" |Seems not superior
|-
|2. Toremifene 240 mg per day
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2223944/ Pyrhönen et al. 1997]
| style="background-color:#1a9851" |Phase III (E)
|[[#Tamoxifen_monotherapy_2|Tamoxifen 40 mg per day]]
| style="background-color:#fc8d59" |Seems to have inferior TTP
|-
|[https://link.springer.com/article/10.1023/A:1006440802709 Milla-Santos et al. 2001]
| style="background-color:#1a9851" |Phase III (E)
|[[#Tamoxifen_monotherapy_2|Tamoxifen 40 mg per day]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Hormonotherapy====
*[[Toremifene (Fareston)]] 60 mg PO once per day

'''Continued indefinitely'''
===References===
# Hayes DF, Van Zyl JA, Hacking A, Goedhals L, Bezwoda WR, Mailliard JA, Jones SE, Vogel CL, Berris RF, Shemano I, Schoenfelder J. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol. 1995 Oct;13(10):2556-66. [http://jco.ascopubs.org/content/13/10/2556.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/7595707 PubMed]
# Gershanovich M, Garin A, Baltina D, Kurvet A, Kangas L, Ellmén J; Eastern European Study Group. A phase III comparison of two toremifene doses to tamoxifen in postmenopausal women with advanced breast cancer. Breast Cancer Res Treat. 1997 Sep;45(3):251-62. [http://www.springerlink.com/content/pg25l5346057212u/ link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/9386869 PubMed]
# Pyrhönen S, Valavaara R, Modig H, Pawlicki M, Pienkowski T, Gundersen S, Bauer J, Westman G, Lundgren S, Blanco G, Mella O, Nilsson I, Hietanen T, Hindy I, Vuorinen J, Hajba A. Comparison of toremifene and tamoxifen in post-menopausal patients with advanced breast cancer: a randomized double-blind, the 'Nordic' phase III study. Br J Cancer. 1997;76(2):270-7. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2223944/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/9231932 PubMed]
# Milla-Santos A, Milla L, Rallo L, Solano V. Phase III randomized trial of toremifene vs tamoxifen in hormonodependant advanced breast cancer. Breast Cancer Res Treat. 2001 Jan;65(2):119-24. [https://link.springer.com/article/10.1023/A:1006440802709 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11261827 PubMed]

=Metastatic disease, first-line endocrine therapy, HER2 co-expressing=
==Anastrozole & Trastuzumab {{#subobject:8077ad|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:e6f8f0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/10.1200/JCO.2008.20.6847 Kaufman et al. 2009 (TAnDEM)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Anastrozole_monotherapy_3|Anastrozole]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
====Chemohormonotherapy====
*[[Anastrozole (Arimidex)]] 1 mg PO once per day
*[[Trastuzumab (Herceptin)]] 4 mg/kg IV once on day 1, then 2 mg/kg IV once per week

'''Continued indefinitely'''

===References===
# '''TAnDEM:''' Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, Tjulandin S, Jahn M, Lehle M, Feyereislova A, Révil C, Jones A. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol. 2009 Nov 20;27(33):5529-37. Epub 2009 Sep 28. [http://ascopubs.org/doi/10.1200/JCO.2008.20.6847 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19786670 PubMed]

==Lapatinib & Letrozole {{#subobject:5fba83|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:879969|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/10.1200/JCO.2009.23.3734 Johnston et al. 2009 (EGF30008)]
|style="background-color:#1a9851"|Phase III (E)
|[[#Letrozole_monotherapy_3|Letrozole]]
| style="background-color:#91cf60" |Seems to have superior PFS
|-
|}
====Chemohormonotherapy====
*[[Lapatinib (Tykerb)]] 1500 mg PO once per day
*[[Letrozole (Femara)]] 2.5 mg PO once per day

'''Continued indefinitely'''

===References===
# '''EGF30008:''' Johnston S, Pippen J Jr, Pivot X, Lichinitser M, Sadeghi S, Dieras V, Gomez HL, Romieu G, Manikhas A, Kennedy MJ, Press MF, Maltzman J, Florance A, O'Rourke L, Oliva C, Stein S, Pegram M. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2009 Nov 20;27(33):5538-46. Epub 2009 Sep 28. [http://ascopubs.org/doi/10.1200/JCO.2009.23.3734 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/19786658 PubMed]

==Lapatinib, Letrozole, Trastuzumab {{#subobject:ee0dbc|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:251384|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[http://ascopubs.org/doi/full/10.1200/JCO.2017.74.7824 Johnston et al. 2017 (ALTERNATIVE)]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|1. [[#Lapatinib_.26_Letrozole|Lapatinib & Letrozole]]
| style="background-color:#d3d3d3" |Not reported
|-
|2. Letrozole & Trastuzumab
| style="background-color:#1a9850" |Superior PFS
|-
|}
====Chemohormonotherapy====
*[[Lapatinib (Tykerb)]] 1000 mg PO once per day
*[[Letrozole (Femara)]] 2.5 mg PO once per day
*[[Trastuzumab (Herceptin)]] as follows:
**Cycle 1: 8 mg/kg IV once on day 1
**Cycle 2 onwards: 6 mg/kg IV once on day 1

'''21-day cycles'''

===References===
# '''ALTERNATIVE:''' Johnston SRD, Hegg R, Im SA, Park IH, Burdaeva O, Kurteva G, Press MF, Tjulandin S, Iwata H, Simon SD, Kenny S, Sarp S, Izquierdo MA, Williams LS, Gradishar WJ. Phase III, Randomized Study of Dual Human Epidermal Growth Factor Receptor 2 (HER2) Blockade With Lapatinib Plus Trastuzumab in Combination With an Aromatase Inhibitor in Postmenopausal Women With HER2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: ALTERNATIVE. J Clin Oncol. 2018 Mar 10;36(8):741-748. Epub 2017 Dec 15. [http://ascopubs.org/doi/full/10.1200/JCO.2017.74.7824 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29244528 PubMed]

=Metastatic disease, subsequent lines of endocrine therapy=

==Abemaciclib & Fulvestrant {{#subobject:9cf796|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:35ec78|Variant=1}}===
{| class="wikitable" style="color:white; background-color:#404040"
|<small>'''FDA-recommended dose'''</small>
|-
|}
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2017.73.7585 Sledge et al. 2017 (MONARCH 2)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Fulvestrant_monotherapy_2|Fulvestrant]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
====Chemohormonotherapy====
*[[Abemaciclib (Verzenio)]] 150 mg PO twice per day
*[[Fulvestrant (Faslodex)]] as follows:
**Cycle 1: 500 mg IM once per day on days 1 & 15
**Cycle 2 onwards: 500 mg IM once on day 1

'''28-day cycles'''

===References===
# '''MONARCH 2:''' Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Frenzel M, Lin Y, Barriga S, Smith IC, Bourayou N, Llombart-Cussac A. MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017 Sep 1;35(25):2875-2884. Epub 2017 Jun 3. [http://ascopubs.org/doi/full/10.1200/JCO.2017.73.7585 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28580882 PubMed]

==Anastrozole monotherapy {{#subobject:327095|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:62abc2|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan = 2|[https://www.ejcancer.com/article/0959-8049(95)00014-3/pdf Jonat et al. 1996]
|rowspan=2 style="background-color:#1a9851" |Phase III (E)
|Anastrozole 10 mg/d
| style="background-color:#d3d3d3" |Not reported
|-
|[[Breast_cancer_-_historical#Megestrol_acetate_monotherapy|Megestrol acetate]]
| style="background-color:#91cf60" |Seems to have superior OS (*)
|-
|rowspan = 2|[https://onlinelibrary.wiley.com/doi/full/10.1002/%28SICI%291097-0142%2819970215%2979%3A4%3C730%3A%3AAID-CNCR10%3E3.0.CO%3B2-0 Buzdar et al. 1997]
|rowspan=2 style="background-color:#1a9851" |Phase III (E)
|Anastrozole 10 mg/d
| style="background-color:#d3d3d3" |Not reported
|-
|[[Breast_cancer_-_historical#Megestrol_acetate_monotherapy|Megestrol acetate]]
| style="background-color:#91cf60" |Seems to have superior OS (*)
|-
|[http://ascopubs.org/doi/10.1200/JCO.2002.10.058 Osborne et al. 2002 (Trial 0021)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Fulvestrant_monotherapy_2|Fulvestrant]] 250 mg
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://jco.ascopubs.org/content/20/16/3396.long Howell et al. 2002 (Trial 0020)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Fulvestrant_monotherapy_2|Fulvestrant]] 250 mg
| style="background-color:#eeee01" |Seems to have non-inferior TTP
|-
|[https://link.springer.com/article/10.1007%2Fs00280-010-1483-x Xu et al. 2010]
| style="background-color:#1a9851" |Phase III (C)
|[[#Fulvestrant_monotherapy_2|Fulvestrant]] 250 mg
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)32389-3/fulltext Robertson et al. 2016 (FALCON)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Fulvestrant_monotherapy_2|Fulvestrant]] 500 mg
| style="background-color:#fc8d59" |Seems to have inferior PFS
|-
|}
''Note: reported efficacy for Jonat et al. 1996 and Buzdar et al. 1997 is based on the 1998 pooled update.''
====Hormonotherapy====
*[[Anastrozole (Arimidex)]] 1 mg PO once per day

'''Continued indefinitely'''

===References===
# Jonat W, Howell A, Blomqvist C, Eiermann W, Winblad G, Tyrrell C, Mauriac L, Roche H, Lundgren S, Hellmund R, Azab M. A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer. Eur J Cancer. 1996 Mar;32A(3):404-12. [https://www.ejcancer.com/article/0959-8049(95)00014-3/pdf link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/8814682 PubMed]
## '''Pooled update:''' Buzdar AU, Jonat W, Howell A, Jones SE, Blomqvist CP, Vogel CL, Eiermann W, Wolter JM, Steinberg M, Webster A, Lee D; Arimidex Study Group. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Cancer. 1998 Sep 15;83(6):1142-52. Erratum in: Cancer 1999 Feb 15;85(4):1010. [https://onlinelibrary.wiley.com/doi/full/10.1002/%28SICI%291097-0142%2819980915%2983%3A6%3C1142%3A%3AAID-CNCR13%3E3.0.CO%3B2-5 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/9740079 PubMed]
# Buzdar AU, Jones SE, Vogel CL, Wolter J, Plourde P, Webster A; Arimidex Study Group. A phase III trial comparing anastrozole (1 and 10 milligrams), a potent and selective aromatase inhibitor, with megestrol acetate in postmenopausal women with advanced breast carcinoma. Cancer. 1997 Feb 15;79(4):730-9. [https://onlinelibrary.wiley.com/doi/full/10.1002/%28SICI%291097-0142%2819970215%2979%3A4%3C730%3A%3AAID-CNCR10%3E3.0.CO%3B2-0 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/9024711 PubMed]
## '''Pooled update:''' Buzdar AU, Jonat W, Howell A, Jones SE, Blomqvist CP, Vogel CL, Eiermann W, Wolter JM, Steinberg M, Webster A, Lee D; Arimidex Study Group. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Cancer. 1998 Sep 15;83(6):1142-52. Erratum in: Cancer 1999 Feb 15;85(4):1010. [https://onlinelibrary.wiley.com/doi/full/10.1002/%28SICI%291097-0142%2819980915%2983%3A6%3C1142%3A%3AAID-CNCR13%3E3.0.CO%3B2-5 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/9740079 PubMed]
# '''Trial 0021:''' Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R, Buzdar A. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol. 2002 Aug 15;20(16):3386-95. [http://ascopubs.org/doi/10.1200/JCO.2002.10.058 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12177098 PubMed]
## '''Pooled update:''' Howell A, Pippen J, Elledge RM, Mauriac L, Vergote I, Jones SE, Come SE, Osborne CK, Robertson JF. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer. 2005 Jul 15;104(2):236-9. [https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.21163 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15937908 PubMed]
# '''Trial 0020:''' Howell A, Robertson JF, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, Vergote I, Erikstein B, Webster A, Morris C. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol. 2002 Aug 15;20(16):3396-403. [http://jco.ascopubs.org/content/20/16/3396.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12177099 PubMed]
## '''Pooled update:''' Howell A, Pippen J, Elledge RM, Mauriac L, Vergote I, Jones SE, Come SE, Osborne CK, Robertson JF. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer. 2005 Jul 15;104(2):236-9. [https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.21163 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15937908 PubMed]
# Xu B, Jiang Z, Shao Z, Wang J, Feng J, Song S, Chen Z, Gu K, Yu S, Zhang Y, Wang C, Zhang F, Yang J. Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial. Cancer Chemother Pharmacol. 2011 Jan;67(1):223-30. Epub 2010 Oct 12. [https://link.springer.com/article/10.1007%2Fs00280-010-1483-x link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/20938664 PubMed]
# '''FALCON:''' Robertson JF, Bondarenko IM, Trishkina E, Dvorkin M, Panasci L, Manikhas A, Shparyk Y, Cardona-Huerta S, Cheung KL, Philco-Salas MJ, Ruiz-Borrego M, Shao Z, Noguchi S, Rowbottom J, Stuart M, Grinsted LM, Fazal M, Ellis MJ. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2016 Dec 17;388(10063):2997-3005. Epub 2016 Nov 28. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)32389-3/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27908454 PubMed]

==Anastrozole & Fulvestrant {{#subobject:ae2512|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:967cf8|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70322-X/fulltext Johnston et al. 2013 (SoFEA)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Fulvestrant_monotherapy_2|Fulvestrant]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Hormonotherapy====
*[[Anastrozole (Arimidex)]] 1 mg PO once per day
*[[Fulvestrant (Faslodex)]] 500 mg IM once on day 1, then 250 mg IM once per day on days 14 & 28, then 250 mg IM once every four weeks

'''28-day cycles'''

===References===
# '''SoFEA:''' Johnston SR, Kilburn LS, Ellis P, Dodwell D, Cameron D, Hayward L, Im YH, Braybrooke JP, Brunt AM, Cheung KL, Jyothirmayi R, Robinson A, Wardley AM, Wheatley D, Howell A, Coombes G, Sergenson N, Sin HJ, Folkerd E, Dowsett M, Bliss JM; SoFEA investigators. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncol. 2013 Sep;14(10):989-98. Epub 2013 Jul 29. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70322-X/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23902874 PubMed]

==Everolimus & Exemestane {{#subobject:c6aadc|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:fdbaa3|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1109653 Baselga et al. 2011 (BOLERO-2)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Exemestane_monotherapy_3|Exemestane]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
====Chemohormonotherapy====
*[[Everolimus (Afinitor)]] 10 mg PO once per day
*[[Exemestane (Aromasin)]] 25 mg PO once per day

'''Continued indefinitely'''

===References===
# '''BOLERO-2:''' Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012 Feb 9;366(6):520-9. Epub 2011 Dec 7. [https://www.nejm.org/doi/full/10.1056/NEJMoa1109653 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22149876 PubMed]
## '''Update:''' Yardley DA, Noguchi S, Pritchard KI, Burris HA 3rd, Baselga J, Gnant M, Hortobagyi GN, Campone M, Pistilli B, Piccart M, Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Feng W, Cahana A, Taran T, Lebwohl D, Rugo HS. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther. 2013 Oct;30(10):870-84. Erratum in: Adv Ther. 2014 Sep;31(9):1008-9. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898123/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24158787 PubMed]
## '''Update:''' Piccart M, Hortobagyi GN, Campone M, Pritchard KI, Lebrun F, Ito Y, Noguchi S, Perez A, Rugo HS, Deleu I, Burris HA 3rd, Provencher L, Neven P, Gnant M, Shtivelband M, Wu C, Fan J, Feng W, Taran T, Baselga J. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Ann Oncol. 2014 Dec;25(12):2357-62. Epub 2014 Sep 17. [https://academic.oup.com/annonc/article/25/12/2357/299656 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25231953 PubMed]

==Everolimus & Tamoxifen {{#subobject:2abaa9|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:dd6395|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2011.39.0708 Bachelot et al. 2012 (TAMRAD)]
| style="background-color:#1a9851" |Randomized Phase II (E)
|[[#Tamoxifen_monotherapy_2|Tamoxifen]]
| style="background-color:#1a9850" |Superior OS
|-
|}
====Chemohormonotherapy====
*[[Everolimus (Afinitor)]] 10 mg PO once per day
*[[Tamoxifen (Nolvadex)]] 20 mg PO once per day

'''Continued indefinitely'''

===References===
<!-- Presented in part at the 33rd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-12, 2010, and 2011 European Multidisciplinary Cancer Congress, Stockholm, Sweden, September 23-27, 2011. -->
# '''TAMRAD:''' Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, Abadie-Lacourtoisie S, Eymard JC, Debled M, Spaëth D, Legouffe E, Allouache D, El Kouri C, Pujade-Lauraine E. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: A GINECO study. J Clin Oncol. 2012 Aug 1;30(22):2718-24. Epub 2012 May 7. [http://ascopubs.org/doi/full/10.1200/JCO.2011.39.0708 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22565002 PubMed]

==Exemestane monotherapy {{#subobject:a3d882|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}

===Regimen {{#subobject:49119f|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2000.18.7.1399 Kaufmann et al. 2000]
| style="background-color:#1a9851" |Phase III (E)
|[[Breast_cancer_-_historical#Megestrol_acetate_monotherapy|Megestrol acetate]]
| style="background-color:#91cf60" |Seems to have superior OS
|-
|[http://jco.ascopubs.org/content/26/10/1664.long Chia et al. 2008 (EFECT)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Fulvestrant_monotherapy_2|Fulvestrant]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1109653 Baselga et al. 2011 (BOLERO-2)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Everolimus_.26_Exemestane|Everolimus & Exemestane]]
| style="background-color:#d73027" |Inferior PFS
|-
|}
====Hormonotherapy====
*[[Exemestane (Aromasin)]] 25 mg PO once per day

'''Continued indefinitely'''

===References===
# Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Zilembo N, Dugardyn JL, Nasurdi C, Mennel RG, Cervek J, Fowst C, Polli A, di Salle E, Arkhipov A, Piscitelli G, Miller LL, Massimini G; The Exemestane Study Group. Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. J Clin Oncol. 2000 Apr;18(7):1399-411. [http://ascopubs.org/doi/full/10.1200/JCO.2000.18.7.1399 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/10735887 PubMed]
<!-- Presented in part at the 29th Annual San Antonio Breast Cancer Symposium December 14-17, 2006, San Antonio, Texas. -->
# '''EFECT:''' Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, Fein L, Romieu G, Buzdar A, Robertson JF, Brufsky A, Possinger K, Rennie P, Sapunar F, Lowe E, Piccart M. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol. 2008 Apr 1;26(10):1664-70. Epub 2008 Mar 3. [http://jco.ascopubs.org/content/26/10/1664.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18316794 PubMed]
# '''BOLERO-2:''' Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D, Hortobagyi GN. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2012 Feb 9;366(6):520-9. Epub 2011 Dec 7. [https://www.nejm.org/doi/full/10.1056/NEJMoa1109653 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22149876 PubMed]
## '''Update:''' Yardley DA, Noguchi S, Pritchard KI, Burris HA 3rd, Baselga J, Gnant M, Hortobagyi GN, Campone M, Pistilli B, Piccart M, Melichar B, Petrakova K, Arena FP, Erdkamp F, Harb WA, Feng W, Cahana A, Taran T, Lebwohl D, Rugo HS. Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther. 2013 Oct;30(10):870-84. Erratum in: Adv Ther. 2014 Sep;31(9):1008-9. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898123/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24158787 PubMed]
## '''Update:''' Piccart M, Hortobagyi GN, Campone M, Pritchard KI, Lebrun F, Ito Y, Noguchi S, Perez A, Rugo HS, Deleu I, Burris HA 3rd, Provencher L, Neven P, Gnant M, Shtivelband M, Wu C, Fan J, Feng W, Taran T, Baselga J. Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2. Ann Oncol. 2014 Dec;25(12):2357-62. Epub 2014 Sep 17. [https://academic.oup.com/annonc/article/25/12/2357/299656 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/25231953 PubMed]

==Fulvestrant monotherapy {{#subobject:c91702|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Variant #1, 250 mg {{#subobject:2dbfb0|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140673695911561/fulltext Howell et al. 1995]
| style="background-color:#ffffbe" |Phase I/II, <20 pts
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://ascopubs.org/doi/10.1200/JCO.2002.10.058 Osborne et al. 2002 (Trial 0021)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Anastrozole_monotherapy_4|Anastrozole]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[http://jco.ascopubs.org/content/20/16/3396.long Howell et al. 2002 (Trial 0020)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Anastrozole_monotherapy_4|Anastrozole]]
| style="background-color:#eeee01" |Seems to have non-inferior TTP
|-
|[https://academic.oup.com/annonc/article/18/1/64/282842 Perey et al. 2006 (SAKK 21/00)]
| style="background-color:#91cf61" |Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.28.8415 Di Leo et al. 2010 (CONFIRM)]
| style="background-color:#1a9851" |Phase III (C)
|Fulvestrant 500 mg
| style="background-color:#fc8d59" |Seems to have inferior OS (*)
|-
|[https://link.springer.com/article/10.1007%2Fs00280-010-1483-x Xu et al. 2010]
| style="background-color:#1a9851" |Phase III (E)
|[[#Anastrozole_monotherapy_4|Anastrozole]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: reported efficacy for CONFIRM is based on the 2013 update.''
====Hormonotherapy====
*[[Fulvestrant (Faslodex)]] 250 mg IM once on day 1

'''28-day cycles'''

===Variant #2, 250 mg, with loading dose {{#subobject:37d8e9|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://jco.ascopubs.org/content/26/10/1664.long Chia et al. 2008 (EFECT)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Exemestane_monotherapy_3|Exemestane]]
| style="background-color:#ffffbf" |Seems not superior
|-
|rowspan=2|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70322-X/fulltext Johnston et al. 2013 (SoFEA)]
|rowspan=2 style="background-color:#1a9851" |Phase III (E)
|1. [[#Exemestane_monotherapy_3|Exemestane]]
| style="background-color:#ffffbf" |Seems not superior
|-
|2. [[#Anastrozole_.26_Fulvestrant|Anastrozole & Fulvestrant]]
| style="background-color:#ffffbf" |Seems not superior
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251959/ Burstein et al. 2014 (CALGB 40302)]
| style="background-color:#1a9851" |Phase III (C)
|Fulvestrant & Lapatinib
| style="background-color:#ffffbf" |Seems not superior
|-
|}
''Note: EFECT states that the 2nd dose of cycle 1 is to be given on day 14, but also notes in the abstract that the first day of the cycle is day 0. Based on other published fulvestrant schedules, we note the second dose as on day 15.''
====Hormonotherapy====
*[[Fulvestrant (Faslodex)]] as follows:
**Cycle 1: 500 mg IM once on day 1, then 250 mg IM once on day 15
**Cycle 2 onwards: 250 mg IM once on day 1

'''28-day cycles'''

===Variant #3, 500 mg {{#subobject:bd033c|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2010.28.8415 Di Leo et al. 2010 (CONFIRM)]
| style="background-color:#1a9851" |Phase III (E)
|Fulvestrant 250 mg
| style="background-color:#91cf60" |Seems to have superior OS (*)
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1505270 Turner et al. 2015 (PALOMA-3)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Fulvestrant_.26_Palbociclib|Fulvestrant & Palbociclib]]
| style="background-color:#d73027" |Inferior PFS
|-
|[https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)32389-3/fulltext Robertson et al. 2016 (FALCON)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Anastrozole_monotherapy_3|Anastrozole]]
| style="background-color:#91cf60" |Seems to have superior PFS
|-
|[https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549667/ Baselga et al. 2017 (BELLE-2)]
| style="background-color:#1a9851" |Phase III (C)
|Buparlisib & Fulvestrant
| style="background-color:#d73027" |Inferior PFS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2017.73.7585 Sledge et al. 2017 (MONARCH 2)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Abemaciclib_.26_Fulvestrant|Abemaciclib & Fulvestrant]]
| style="background-color:#d73027" |Inferior PFS
|-
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30688-5/fulltext Di Leo et al. 2017 (BELLE-3)]
| style="background-color:#1a9851" |Phase III (C)
|Buparlisib & Fulvestrant
| style="background-color:#d73027" |Inferior PFS
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2018.78.9909 Slamon et al. 2018 (MONALEESA-3)]
| style="background-color:#1a9851" |Phase III (C)
|[[#Fulvestrant_.26_Ribociclib_2|Fulvestrant & Ribociclib]]
| style="background-color:#d73027" |Inferior PFS
|-
|}
''Note: while this regimen was inferior in '''BELLE-2''' and '''BELLE-3''', the authors note that "no further studies [of this combination] are being pursued because of the toxicity associated with [the experimental arm]." Reported efficacy for CONFIRM is based on the 2013 update.''
====Hormonotherapy====
*[[Fulvestrant (Faslodex)]] as follows:
**Cycle 1: 500 mg IM once per day on days 1 & 15
**Cycle 2 onwards: 500 mg IM once on day 1

'''28-day cycles'''

===References===
# Howell A, DeFriend D, Robertson J, Blamey R, Walton P. Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet. 1995 Jan 7;345(8941):29-30. [https://www.thelancet.com/journals/lancet/article/PIIS0140673695911561/fulltext link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/7799704 PubMed]
# '''Trial 0021:''' Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, Dimery I, Webster A, Morris C, Elledge R, Buzdar A. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol. 2002 Aug 15;20(16):3386-95. [http://ascopubs.org/doi/10.1200/JCO.2002.10.058 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/12177098 PubMed]
## '''Pooled update:''' Howell A, Pippen J, Elledge RM, Mauriac L, Vergote I, Jones SE, Come SE, Osborne CK, Robertson JF. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer. 2005 Jul 15;104(2):236-9. [https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.21163 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15937908 PubMed]
# '''Trial 0020:''' Howell A, Robertson JF, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, Vergote I, Erikstein B, Webster A, Morris C. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol. 2002 Aug 15;20(16):3396-403. [http://jco.ascopubs.org/content/20/16/3396.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/12177099 PubMed]
## '''Pooled update:''' Howell A, Pippen J, Elledge RM, Mauriac L, Vergote I, Jones SE, Come SE, Osborne CK, Robertson JF. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma: a prospectively planned combined survival analysis of two multicenter trials. Cancer. 2005 Jul 15;104(2):236-9. [https://onlinelibrary.wiley.com/doi/full/10.1002/cncr.21163 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/15937908 PubMed]
# '''SAKK 21/00:''' Perey L, Paridaens R, Hawle H, Zaman K, Nolé F, Wildiers H, Fiche M, Dietrich D, Clément P, Köberle D, Goldhirsch A, Thürlimann B. Clinical benefit of fulvestrant in postmenopausal women with advanced breast cancer and primary or acquired resistance to aromatase inhibitors: final results of phase II Swiss Group for Clinical Cancer Research Trial (SAKK 21/00). Ann Oncol. 2007 Jan;18(1):64-9. Epub 2006 Oct 9. [https://academic.oup.com/annonc/article/18/1/64/282842 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/17030543 PubMed]
<!-- Presented in part at the 29th Annual San Antonio Breast Cancer Symposium December 14-17, 2006, San Antonio, Texas. -->
# '''EFECT:''' Chia S, Gradishar W, Mauriac L, Bines J, Amant F, Federico M, Fein L, Romieu G, Buzdar A, Robertson JF, Brufsky A, Possinger K, Rennie P, Sapunar F, Lowe E, Piccart M. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol. 2008 Apr 1;26(10):1664-70. Epub 2008 Mar 3. [http://jco.ascopubs.org/content/26/10/1664.long link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/18316794 PubMed]
# '''CONFIRM:''' Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Garnett S, Lindemann JP, Sapunar F, Martín M. Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol. 2010 Oct 20;28(30):4594-600. Epub 2010 Sep 20. Erratum in: J Clin Oncol. 2011 Jun 1;29(16):2293. [http://ascopubs.org/doi/full/10.1200/JCO.2010.28.8415 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/20855825 PubMed]
## '''Update:''' Di Leo A, Jerusalem G, Petruzelka L, Torres R, Bondarenko IN, Khasanov R, Verhoeven D, Pedrini JL, Smirnova I, Lichinitser MR, Pendergrass K, Malorni L, Garnett S, Rukazenkov Y, Martin M. Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst. 2014 Jan;106(1):djt337. Epub 2013 Dec 7. [https://academic.oup.com/jnci/article/106/1/djt337/2517856 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3906991/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/24317176 PubMed]
# Xu B, Jiang Z, Shao Z, Wang J, Feng J, Song S, Chen Z, Gu K, Yu S, Zhang Y, Wang C, Zhang F, Yang J. Fulvestrant 250 mg versus anastrozole for Chinese patients with advanced breast cancer: results of a multicentre, double-blind, randomised phase III trial. Cancer Chemother Pharmacol. 2011 Jan;67(1):223-30. Epub 2010 Oct 12. [https://link.springer.com/article/10.1007%2Fs00280-010-1483-x link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/20938664 PubMed]
# '''SoFEA:''' Johnston SR, Kilburn LS, Ellis P, Dodwell D, Cameron D, Hayward L, Im YH, Braybrooke JP, Brunt AM, Cheung KL, Jyothirmayi R, Robinson A, Wardley AM, Wheatley D, Howell A, Coombes G, Sergenson N, Sin HJ, Folkerd E, Dowsett M, Bliss JM; SoFEA investigators. Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncol. 2013 Sep;14(10):989-98. Epub 2013 Jul 29. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70322-X/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/23902874 PubMed]
# '''CALGB 40302:''' Burstein HJ, Cirrincione CT, Barry WT, Chew HK, Tolaney SM, Lake DE, Ma C, Blackwell KL, Winer EP, Hudis CA. Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance). J Clin Oncol. 2014 Dec 10;32(35):3959-66. Epub 2014 Oct 27. [http://ascopubs.org/doi/full/10.1200/JCO.2014.56.7941 link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4251959/ link to PMC article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/25348000 PubMed]
# '''PALOMA-3:''' Turner NC, Ro J, André F, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Huang Bartlett C, Zhang K, Giorgetti C, Randolph S, Koehler M, Cristofanilli M; PALOMA3 Study Group. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015 Jul 16;373(3):209-19. Epub 2015 Jun 1. [https://www.nejm.org/doi/full/10.1056/NEJMoa1505270 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26030518 PubMed]
## '''Update:''' Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Zhang K, Theall KP, Jiang Y, Bartlett CH, Koehler M, Slamon D. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016 Apr;17(4):425-39. Epub 2016 Mar 3. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00613-0/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26947331 PubMed]
## '''Subgroup analysis:''' Loibl S, Turner NC, Ro J, Cristofanilli M, Iwata H, Im SA, Masuda N, Loi S, André F, Harbeck N, Verma S, Folkerd E, Puyana Theall K, Hoffman J, Zhang K, Bartlett CH, Dowsett M. Palbociclib combined with fulvestrant in premenopausal women with advanced breast cancer and prior progression on endocrine therapy: PALOMA-3 results. Oncologist. 2017 Sep;22(9):1028-1038. Epub 2017 Jun 26. [http://theoncologist.alphamedpress.org/content/22/9/1028.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5599195/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28652278 PubMed]
## '''Update:''' Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, André F, Puyana Theall K, Huang X, Giorgetti C, Huang Bartlett C, Cristofanilli M. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018 Nov 15;379(20):1926-1936. Epub 2018 Oct 20. [https://www.nejm.org/doi/full/10.1056/NEJMoa1810527 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/30345905 PubMed]
# '''FALCON:''' Robertson JF, Bondarenko IM, Trishkina E, Dvorkin M, Panasci L, Manikhas A, Shparyk Y, Cardona-Huerta S, Cheung KL, Philco-Salas MJ, Ruiz-Borrego M, Shao Z, Noguchi S, Rowbottom J, Stuart M, Grinsted LM, Fazal M, Ellis MJ. Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet. 2016 Dec 17;388(10063):2997-3005. Epub 2016 Nov 28. [https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(16)32389-3/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/27908454 PubMed]
# '''BELLE-2:''' Baselga J, Im SA, Iwata H, Cortés J, De Laurentiis M, Jiang Z, Arteaga CL, Jonat W, Clemons M, Ito Y, Awada A, Chia S, Jagiełło-Gruszfeld A, Pistilli B, Tseng LM, Hurvitz S, Masuda N, Takahashi M, Vuylsteke P, Hachemi S, Dharan B, Di Tomaso E, Urban P, Massacesi C, Campone M. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2017 Jul;18(7):904-916. Epub 2017 May 30. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30376-5/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5549667/ link to PMC article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28576675 PubMed]
# '''MONARCH-2:''' Sledge GW Jr, Toi M, Neven P, Sohn J, Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, Koh H, Grischke EM, Frenzel M, Lin Y, Barriga S, Smith IC, Bourayou N, Llombart-Cussac A. MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol. 2017 Sep 1;35(25):2875-2884. Epub 2017 Jun 3. [http://ascopubs.org/doi/full/10.1200/JCO.2017.73.7585 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/28580882 PubMed]
# '''BELLE-3:''' Di Leo A, Johnston S, Lee KS, Ciruelos E, Lønning PE, Janni W, O'Regan R, Mouret-Reynier MA, Kalev D, Egle D, Csőszi T, Bordonaro R, Decker T, Tjan-Heijnen VCG, Blau S, Schirone A, Weber D, El-Hashimy M, Dharan B, Sellami D, Bachelot T. Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2018 Jan;19(1):87-100. Epub 2017 Dec 7. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30688-5/fulltext link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/29223745 PubMed]
# '''MONALEESA-3:''' Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martín M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Pivot X, Vidam G, Wang Y, Rodriguez Lorenc K, Miller M, Taran T, Jerusalem G. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018 Aug 20;36(24):2465-2472. Epub 2018 Jun 3. [http://ascopubs.org/doi/full/10.1200/JCO.2018.78.9909 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29860922 PubMed]

==Fulvestrant & Palbociclib {{#subobject:a59b43|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:f3a761|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://www.nejm.org/doi/full/10.1056/NEJMoa1505270 Turner et al. 2015 (PALOMA-3)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Fulvestrant_monotherapy_2|Fulvestrant]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
====Chemohormonotherapy====
*[[Fulvestrant (Faslodex)]] 500 mg IM once every 2 weeks for 3 doses, then once every 4 weeks
*[[Palbociclib (Ibrance)]] 125 mg PO once per day on days 1 to 21

'''28-day cycles'''

===References===
# '''PALOMA-3:''' Turner NC, Ro J, André F, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Huang Bartlett C, Zhang K, Giorgetti C, Randolph S, Koehler M, Cristofanilli M; PALOMA3 Study Group. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med. 2015 Jul 16;373(3):209-19. Epub 2015 Jun 1. [https://www.nejm.org/doi/full/10.1056/NEJMoa1505270 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/26030518 PubMed]
## '''Update:''' Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Zhang K, Theall KP, Jiang Y, Bartlett CH, Koehler M, Slamon D. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016 Apr;17(4):425-39. Epub 2016 Mar 3. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)00613-0/fulltext link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/26947331 PubMed]
## '''Subgroup analysis:''' Loibl S, Turner NC, Ro J, Cristofanilli M, Iwata H, Im SA, Masuda N, Loi S, André F, Harbeck N, Verma S, Folkerd E, Puyana Theall K, Hoffman J, Zhang K, Bartlett CH, Dowsett M. Palbociclib combined with fulvestrant in premenopausal women with advanced breast cancer and prior progression on endocrine therapy: PALOMA-3 results. Oncologist. 2017 Sep;22(9):1028-1038. Epub 2017 Jun 26. [http://theoncologist.alphamedpress.org/content/22/9/1028.long link to original article] [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5599195/ link to PMC article] [https://www.ncbi.nlm.nih.gov/pubmed/28652278 PubMed]
## '''Update:''' Turner NC, Slamon DJ, Ro J, Bondarenko I, Im SA, Masuda N, Colleoni M, DeMichele A, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, André F, Puyana Theall K, Huang X, Giorgetti C, Huang Bartlett C, Cristofanilli M. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N Engl J Med. 2018 Nov 15;379(20):1926-1936. Epub 2018 Oct 20. [https://www.nejm.org/doi/full/10.1056/NEJMoa1810527 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/30345905 PubMed]

==Fulvestrant & Ribociclib {{#subobject:0c6a05|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:ade594|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2018.78.9909 Slamon et al. 2018 (MONALEESA-3)]
| style="background-color:#1a9851" |Phase III (E)
|[[#Fulvestrant_monotherapy_2|Fulvestrant]]
| style="background-color:#1a9850" |Superior PFS
|-
|}
====Chemohormonotherapy====
*[[Fulvestrant (Faslodex)]] as follows:
**Cycle 1: 500 mg IM once per day on days 1 & 15
**Cycle 2 onwards: 500 mg IM once on day 1
*[[Ribociclib (Kisqali)]] 600 mg PO once per day on days 1 to 21

'''28-day cycles'''

===References===
# '''MONALEESA-3:''' Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martín M, Nusch A, Sonke GS, De la Cruz-Merino L, Beck JT, Pivot X, Vidam G, Wang Y, Rodriguez Lorenc K, Miller M, Taran T, Jerusalem G. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol. 2018 Aug 20;36(24):2465-2472. Epub 2018 Jun 3. [http://ascopubs.org/doi/full/10.1200/JCO.2018.78.9909 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/29860922 PubMed]

==Letrozole monotherapy {{#subobject:230132|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:458647|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|rowspan=2|[http://ascopubs.org/doi/full/10.1200/JCO.2001.19.14.3357 Buzdar et al. 2001]
|rowspan=2 style="background-color:#1a9851"|Phase III (E)
|Letrozole 0.5 mg/d
| style="background-color:#ffffbf" |Seems not superior
|-
|[[Breast_cancer_-_historical#Megestrol_acetate_monotherapy|Megestrol acetate]]
| style="background-color:#ffffbf" |Seems not superior
|-
|}
====Hormonotherapy====
*[[Letrozole (Femara)]] 2.5 mg PO once per day

'''Continued indefinitely'''

===References===
# Buzdar A, Douma J, Davidson N, Elledge R, Morgan M, Smith R, Porter L, Nabholtz J, Xiang X, Brady C. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol. 2001 Jul 15;19(14):3357-66. [http://ascopubs.org/doi/full/10.1200/JCO.2001.19.14.3357 link to original article] '''contains protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/11454883 PubMed]

==Tamoxifen monotherapy {{#subobject:8bc09f|Regimen=1}}==
{| class="wikitable" style="float:right; margin-left: 5px;"
|-
|[[#top|back to top]]
|}
===Regimen {{#subobject:a1e733|Variant=1}}===
{| class="wikitable" style="width: 100%; text-align:center;" 
!style="width: 25%"|Study
!style="width: 25%"|[[Levels_of_Evidence#Evidence|Evidence]]
!style="width: 25%"|Comparator
!style="width: 25%"|[[Levels_of_Evidence#Efficacy|Efficacy]]
|-
|[https://jamanetwork.com/journals/jama/article-abstract/365603 Legha et al. 1979]
| style="background-color:#91cf61" |Phase II
| style="background-color:#d3d3d3" |
| style="background-color:#d3d3d3" |
|-
|[http://annals.org/aim/article-abstract/696249/evaluation-tamoxifen-doses-without-fluoxymesterone-advanced-breast-cancer Tormey et al. 1983]
| style="background-color:#1a9851" |Randomized (C)
|Fluoxymesterone & Tamoxifen
| style="background-color:#d73027" |Inferior TTTF
|-
|[http://ascopubs.org/doi/full/10.1200/JCO.2011.39.0708 Bachelot et al. 2012 (TAMRAD)]
| style="background-color:#1a9851" |Randomized Phase II (C)
|[[#Everolimus_.26_Tamoxifen|Everolimus & Tamoxifen]]
| style="background-color:#d73027" |Inferior OS
|-
|}
''Note: Tormey et al. 1983 specified a wide range of tamoxifen dosing; see paper for details.''
====Hormonotherapy====
*[[Tamoxifen (Nolvadex)]] 20 mg PO once per day

'''Continued indefinitely'''

===References===
# Legha SS, Buzdar AU, Hortobagyi GN, Wiseman C, Benjamin RS, Blumenschein GR. Tamoxifen: use in treatment of metastatic breast cancer refractory to combination chemotherapy. JAMA. 1979 Jul 6;242(1):49-52. [https://jamanetwork.com/journals/jama/article-abstract/365603 link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/448865 PubMed]
# Tormey DC, Lippman ME, Edwards BK, Cassidy JG. Evaluation of tamoxifen doses with and without fluoxymesterone in advanced breast cancer. Ann Intern Med. 1983 Feb;98(2):139-44. [http://annals.org/aim/article-abstract/696249/evaluation-tamoxifen-doses-without-fluoxymesterone-advanced-breast-cancer link to original article] [https://www.ncbi.nlm.nih.gov/pubmed/6824247 PubMed]
<!-- Presented in part at the 33rd Annual San Antonio Breast Cancer Symposium, San Antonio, TX, December 8-12, 2010, and 2011 European Multidisciplinary Cancer Congress, Stockholm, Sweden, September 23-27, 2011. -->
# '''TAMRAD:''' Bachelot T, Bourgier C, Cropet C, Ray-Coquard I, Ferrero JM, Freyer G, Abadie-Lacourtoisie S, Eymard JC, Debled M, Spaëth D, Legouffe E, Allouache D, El Kouri C, Pujade-Lauraine E. Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol. 2012 Aug 1;30(22):2718-24. Epub 2012 May 7. [http://ascopubs.org/doi/full/10.1200/JCO.2011.39.0708 link to original article] '''contains verified protocol''' [https://www.ncbi.nlm.nih.gov/pubmed/22565002 PubMed]

[[Category:Breast cancer regimens]]
[[Category:Biomarker-specific pages]]
[[Category:Breast cancers]]
